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ix. Abstract 
Sepsis is the leading cause of direct maternal mortality in the UK, but also a leading concern 
worldwide. In the USA, severe maternal sepsis rates and the risk of sepsis-related death have doubled 
in the last decade. There appears to be an increased susceptibility to, and severity of, infections during 
pregnancy. However, the mechanisms behind the increased morbidity and mortality are not fully 
understood. Pregnancy is associated with acute physiological changes in most organ systems, in 
particular the cardiovascular and immune systems. In this thesis the haemodynamic response to 
infection and inflammation was investigated. It was hypothesised that there is an altered 
haemodynamic response to infection mediated by inflammatory pathways, and by targeting signalling 
pathways within the immune and cardiovascular systems maternal outcomes could be improved. In 
order to achieve to this, a murine model of endotoxaemia during pregnancy was employed to study 
the effects of inflammation on maternal haemodynamics, utilising a telemetric technique to monitor 
physiologic changes. Firstly, this model was used to demonstrate that inflammation in pregnancy can 
lead to marked hypotension and haemodynamic dysfunction that does not occur in non-pregnant 
controls. Supplementation with additional progesterone, a key hormone of pregnancy, did not 
exacerbate this hypotensive effect. Manipulation of the chemokine receptor CCR2 was able to reverse 
inflammation-induced hypotension in pregnancy, both by genetic knockout and pharmacological 
inhibition. Manipulation via genetic knockout of DDAH1, a component of the nitric oxide signalling 
pathway, whilst conferring an initial hypertension did not significantly impact the gestational 
haemodynamic profile.  The marked fall in blood pressure in response to endotoxin may help to 
explain the greater susceptibility of pregnant women to sepsis. Maternal outcomes may be improved 
by modulating the immune response.  
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Chapter 1: General Introduction 
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1.1 Physiological Adaptations in Healthy Pregnancy 
1.1.1 Cardiovascular Adaptations in Pregnancy 
The physiological adaptations that occur within the maternal cardiovascular system have been studied 
since the late 19
th
 century, where although investigators agreed that cardiac output was increased 
during human pregnancy, the onset, extent and the mechanisms behind this have been the subject of 
dispute [1]. The discrepancy in results was likely due to the lack of repeatability and accuracy of the 
methods of measuring haemodynamic parameters, alongside wide individual variation. Thus, since 
the availability of non-invasive techniques such as echocardiography in the 1960s and 1970s, 
understanding within the field has greatly improved. It is now commonly accepted that cardiac output 
is increased by approximately five weeks of gestation after the last menstrual period and this 
continues to increase until approximately 24 weeks, where it remains at 45% above the baseline level 
[1]. Both stroke volume and heart rate are thought to contribute to this rise; however the increase in 
heart rate begins before stroke volume increases.  
These changes are also accompanied by physiological cardiac hypertrophy which resolves following 
pregnancy. In non-pregnant women, these changes would lead to hypertension, yet in pregnancy mean 
arterial pressure (MAP) usually declines. Systemic vasodilation and transient insensitivity to 
vasoactive substances are suggested gestational hypotensive mechanisms [2]. 
It is the general consensus that the first process to occur is a significant drop in vascular resistance, 
where by eight weeks gestation, peripheral resistance is already 30% lower than pre-conception 
values. This reduction is paralleled in a fall in systemic blood pressure which reaches a nadir at the 
mid-gestational point, not to increase again until after 32 weeks [3, 4]. The mechanisms behind these 
changes are still not fully understood. Likely, these haemodynamic alterations are underpinned by 
hormonal changes, suggesting a role for the actions of progesterone, oestrogen, prostaglandins, 
prolactin and relaxin, or the interplay between them, in haemodynamic control [5, 6].   
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In human pregnancy, a decrease in MAP of 5-15 mmHg during the first and second trimesters is 
considered to be normal due to decreased vascular resistance and vasodilation, secondary to the 
effects of progesterone on smooth muscle. This decrease in MAP is thought to reflect changes in 
diastolic, rather than systolic arterial pressure [7].  
Further, these changes in cardiac output, blood pressure and the reduction in vascular tone result in a 
relative drop in renal perfusion pressure. This in turn stimulates the production of renin, which via the 
formation of angiotensinogen and angiotensin I, leads to an increase in circulating angiotensin II. 
During pregnancy, the pressor responsiveness to angiotensin II is reduced, however its effects on the 
kidney (and also to some extent the liver) lead to a 3-4 fold increase in the adrenal steroid aldosterone 
[8-10]. The result is a significant increase in blood volume from as early as 6 weeks gestation, where 
both sodium and water retention leads to the characteristic hyponatraemic hypervolemia of pregnancy 
[11]. The pivotal role of the renin-angiotensin-aldosterone system in the maintenance of blood 
pressure and salt/water retention is also aided by increased renal sympathetic nerve activity at this 
time [12].  Typically, blood volume increases by approximately 45% during pregnancy (higher in 
multifetal gestations) and at term is estimated to be 100mL/kg [13, 14]. Amongst other reasons, it has 
been postulated that one possibility for this large increase in blood volume is that it may be an 
adaptive mechanism to prepare the mother for inevitable blood loss during labour [14]. 
Integral to these changes, many structural and functional changes occur within the uteroplacental 
vasculature, including structural reorganisation of the uterine and spiral arteries, to accommodate the 
increased circulatory requirements of the growing fetus [15]. This is principally achieved by a 
profound increase in uteroplacental blood flow (approximately 10-fold by term) which constitutes up 
to 25% of cardiac output [16, 17] and a decrease in uterine vascular resistance. In fact, the 
uteroplacental circulation is a low resistance circulation and contributes approximately 20% of the 
total reduction of systemic vascular resistance in the second trimester [18]. Increased blood flow is 
accommodated by the enormous modifications that take place in the spiral arteries, namely a marked 
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increase in luminal diameter and the absence of musculoelastic tissue [17, 19], changes that are 
initiated by trophoblast invasion.      
1.1.2 Hormonal Adaptations in Pregnancy 
 The hormonal changes that occur from conception through to the post-partum period have been well 
defined. In human pregnancy, dramatic changes in progesterone and oestrogen are accompanied by 
changes in the levels of human chorionic gonadotropin (hCG), prolactin, placental lactogen, relaxin, 
oxytocin, corticotropin releasing hormone (CRH) and human growth hormone amongst others. Here, 
the pattern of progesterone and oestrogens are discussed.  
During pregnancy, the plasma levels of progesterone rise from 11ng/mL in the luteal phase of the 
menstrual cycle to 125-200ng/mL in the third trimester [20]. After the initial six weeks gestation, the 
major site of progesterone production is the placental trophoblast, before which it is the corpus luteum 
that maintains progesterone levels [21]. The conceptus is also the source of high levels of oestrogens 
in human pregnancy, both from the placental trophoblast and also the fetal adrenal [21]. The extended 
secretion of progesterone is critical for the initiation and maintenance of a successful pregnancy, as it 
is the functional withdrawal of progesterone that is thought to be the driving factor for the onset of 
labour. Progesterone acts on the uterus to stimulate and maintain uterine functions that are permissive 
to early embryonic development such as implantation, placentation and successful fetal and placental 
development to term [22].  
As well as being important for stimulation of progesterone production in the placenta, oestrogen acts 
to stimulate the correct growth and function of the placenta; which in turn ensures the maintenance 
and control of steroid hormone production. Along with progesterone, oestrogen is necessary for the 
development of fetal organs and promotes maternal breast growth. Similarly to progesterone, 
oestradiol-17β and oestradiol conjugates rise from approximately 1.6ng/mL to 52ng/mL at 5 weeks 
and at 40 weeks of pregnancy, respectively [23]. However, it is oestriol, produced by the placenta, 
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that rises from undetectable levels in non-pregnant women to plasma concentrations of 270ng/mL 
[24]. Low levels of oestriol in the third trimester may be an indication of adverse outcome.   
1.1.3 Hormonal Regulation of Cardiovascular Adaptation in Pregnancy 
Hormonal control of blood pressure during pregnancy and the mechanisms behind this are still 
relatively unclear. As described previously, it is thought that the drop in systemic vascular resistance 
is one of the first cardiovascular adaptations in pregnancy and it is therefore likely that this is 
triggered by the rapid hormonal changes that occur following conception.   
Progesterone plays an important role in the regulation of cardiovascular adaptation from the moment 
that fetal implantation occurs. In a population of Swedish pregnant women, an epidemiological study 
noted that when concentrations of the hormones progesterone and relaxin were highest in early 
pregnancy, this correlated with lower mean systolic blood pressure in later pregnancy suggesting that 
these hormones influence haemodynamic changes. However, the authors note that this observation 
was not able to infer causality [6]. In vitro, progesterone (P4) has been reported to have both 
vasodilatory and vasoconstrictive effects in the vasculature depending on location of the vessel and 
level of exposure [25, 26], yet in hypertensive subjects treatment with P4 was able to reduce blood 
pressure [27]. Earlier work conducted in pregnant ewes was able to show that P4 had a direct 
haemodynamic effects, decreasing resting blood pressure and increasing plasma volume. The 
investigators observed that whilst administration of P4 was able to increase plasma volume, this was 
in absence of a rise in renin and aldosterone concentrations. Furthermore, the addition of oestradiol 
(E2) did not lead to a differential effect on blood pressure or volume from treatment with P4 alone 
thus suggesting the effect is not propagated via oestrogen-induced or -facilitated progesterone 
pathways [5].  
Of course oestrogen plays an important role as well, and research dating back to the 1970s using 
intact and ovariectomised rats suggested that oestrogens may alter vascular compliance by decreasing 
the ratio of arterial collagen to elastin. These data also showed that as well as altering the relative 
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concentrations of these proteins, administered oestrogens affected the rate of collagen and elastin 
accumulation in the aortic wall [28, 29].  Studies in ovariectomised non-pregnant ewes have shown 
that systemic oestradiol infusion increases heart rate (and therefore cardiac output) and decreases 
systemic vascular resistance [30, 31]. Whilst Pencins-Thompson et al., did not find any additional 
effect of E2 upon blood pressure and volume, other research has indicated that 17β-oestradiol 
increases nitric oxide synthase (NOS) expression and therefore increasing concentrations during 
pregnancy add to the powerful vasodilatory action of nitric oxide (NO) [5, 19, 32].  
As well as the effects of progesterone and oestrogen on blood pressure control during pregnancy, 
animal studies have shown that relaxin plays a major role in pregnancy as a vasodilator, both in renal 
vasodilation and osmoregulation [11, 33, 34]. Relaxin is a 6-kDa peptide hormone in the insulin-
relaxin superfamily of hormones. It is produced by the corpus luteum under the stimulation of hCG 
and circulates during pregnancy in humans and other mammalian species [33]. Although secretion of 
relaxin is known to increase throughout pregnancy, its ability to exert a direct vasodilatory effect or to 
decrease vascular sensitivity to angiotensin II has been contested [8, 35]. The vascular refractoriness 
to vasoconstrictors (including angiotensin II and noradrenaline) is known to contribute to vasodilation 
in healthy pregnancy and other suggested reasons include a decrease in angiotensin II receptors or the 
effect of increased progesterone and prostacyclin [30, 36, 37]. Albeit, relaxin has been shown to be an 
important mediator of maternal blood pressure; potentially through its effects on vascular compliance, 
connective tissue composition, regulation of water metabolism and production of NO [38-42]. 
Chronic administration of recombinant human relaxin to non-pregnant animals produced increased 
cardiac output and arterial compliance. More recently, studies designed to understand the mechanism 
behind both the rapid and sustained vasodilatory response to relaxin have observed the critical role of 
the angiogenic factors vascular endothelial growth factor (VEGF) and placental growth factor (PLGF) 
as intermediaries in the relaxin vasodilatory pathway [39].  
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1.1.4 Immunological Adaptations in Pregnancy 
As human pregnancy progresses and hormone levels change dramatically, the interplay between sex 
hormones and the maternal immune system leads to complex and multifactorial immunological 
changes (see Figure 1.1). Receptors for progesterone and/or oestrogen are expressed on the majority 
of cells in both the innate and adaptive immune systems and T cells, B cells, neutrophils, dendritic 
cells, monocytes and natural killer (NK) cells all have been shown to be transcriptionally regulated by 
oestrogen [43, 44]. Several theories have been proposed aiming to explain the immunological changes 
that occur during pregnancy. We know that the maternal immune response to infection is uniquely 
regulated; where the balance between tolerance and suppression has often been referred to as ‘the 
immune paradox of pregnancy’ [45]. This immune adaptation acts to allow for antimicrobial defence 
and tissue repair whilst preventing damage to developing fetal organs via paternal antigen tolerance. 
The classic theory first proposed in 1953 by Peter Medawar viewed the fetus as a semi-allogenic graft 
[46]. The theory proposed that non-specific systemic immunosuppression in pregnancy reduces the 
chances of an antigen-specific response against the immunologically ‘immature’ fetus, aided by the 
‘neutral barrier’ function of the placenta and the immunologically privileged nature of the uterus. 
Although we now know that the fetus does express major histocompatibility molecules and is not in 
that sense allogenically immature, the exact mechanism of fetal tolerance is yet to be elucidated. This 
likely over-simplistic theory has been largely superseded by the pervasive theory of Th2 (T helper 2) 
bias. First published in the early 1990s based upon experimental research investigating antibody 
production at the fetomaternal interface, Lin et al., suggested that the continuous presence of the 
interleukins IL-4, IL-5 and IL-10, and the transient expression of interferon-γ (IFN-γ), supported the 
idea of a Th2-like bias driving the maternal immune response [47]. It is possible however, that whilst 
this is a phenotype strongly characterised at the fetomaternal interface, there is a paucity of evidence 
that supports a systemic Th2 shift [43, 48]. 
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Figure 1.1: Changes in the principal hormone levels and corresponding immune system characteristics 
during pregnancy. As pregnancy advances and progesterone and oestrogen levels rise, T cell activity (T helper 
and cytotoxic T cells), natural killer cell activity, and possibly B-cell activity are reduced, whereas monocyte, 
dendritic cell, and other polymorphonuclear cell activity is increased. The severity of some infections increases 
with advancing pregnancy. Adapted from Kourtis et al., [49]. 
 
To ensure the tolerance of a semiallogenic fetus, it was initially thought that pregnancy confers broad 
immunosuppression. This idea was supported by the observation that during pregnancy, the symptoms 
of autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS) are often 
suppressed.  Klipple et al., hypothesised that the modulation of cell-mediated immunity coupled with 
alterations in immune complex generation during pregnancy may account for the partial or complete 
remission of RA symptoms in 70% of pregnant patients, even when coupled with almost complete 
cessation of medications. Additionally, the group observed that over 90% of patients relapsed by 6-8 
months post-partum [50]. Similarly, in pregnant MS patients the rate of remission declines with 
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advancing gestation, and reverses in the 3 month post-partum period before returning to pre-
pregnancy rates [51]. More evidence for the immunosuppressive hypothesis of pregnancy is found in 
the increased disease severity during pregnancy to some infectious pathogens including Varicella 
zoster, Plasmodium falciparum and Listeria monocytogenes [43]. Of considerable note is the apparent 
increased susceptibility of pregnant women to influenza (see Chapter 1.2.1.1).     
Conversely, there is now a mounting body of evidence that challenges the notion of maternal 
immunosuppression. Data from studies of pregnant mice showing normal T cell development after 
lymphocytic choriomeningitis virus infection and data that indicated fetus-specific cytotoxic T cell 
(Tc cell) responses that could be generated in pregnancy without the occurrence of pregnancy loss; all 
contradict the idea of systemic immunosuppression in pregnancy [49, 52, 53]. Some have even gone 
on to suggest that pregnancy may in fact confer a ‘hypersensitisation’ to infection. For example, due 
to increases in CD14 expression (a cell-surface receptor that recognises endotoxin when a complex is 
formed with lipopolysaccharide-binding protein expression) in the third trimester and increases in the 
cytokine IL-12, there is an enhanced (and often fatal) monocyte cytokine response to endotoxin [54]. 
Furthermore there have been several reports presenting evidence of an adequate response to vaccines 
during pregnancy. Sperling et al., observed that in response to trivalent inactivated influenza vaccine, 
no diminution of immunogenicity was detected in the third trimester, which is a well-accepted time of 
increased clinical vulnerability to influenza [55]. Similar findings were reported for tetanus diphtheria 
and acellular pertussis vaccination [56].  
It is now generally accepted that the view of pregnancy as a state of immunosuppression is outdated 
and probably oversimplified. In several recent review papers on the subject, many authors agree it 
may be better to view pregnancy as a “modulated immunological condition” [43, 49, 57]. This 
definition recognises that there is a change in the ratio and function (rather than a complete 
suppression) of the maternal leukocytes that occurs during pregnancy. 
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1.1.4.1. Innate Immune System Adaptations 
Sacks et al., when discussing the idea that pregnancy is immunosuppressed, proposed a paradigm shift 
suggesting that suppression was confined to the maternal adaptive immune system. In this new 
concept, the authors suggested that the maternal innate immune system compensates for the adaptive, 
leading to monocyte-driven immunological response [58]. Cells of the innate immune system initiate 
a response by processing and presenting antigens to lymphocytes via association with major 
histocompatibility complex (MHC) class I and II molecules, described as ‘signal 1’. The response to 
an immune challenge, such as endotoxin, instigates the production of co-stimulatory molecules and/or 
pro-inflammatory cytokines, described as ‘signal 2’. Both of these mechanisms stimulate naïve T cells 
to become effector Th1 or Th2 cells; however in pregnancy, it is hypothesised that placental 
particulate and soluble products can stimulate cytokine release from macrophages, which occurs in 
the absence of antigen presentation (Figure 1.2) [58]. Furthermore, the hormones progesterone (the 
‘classic hormone of immune suppression’) and oestrogen have been shown to promote Th2 bias [59-
61].  
 
 
 
 
 
 
Figure 1.2: ‘Signal 1’ and ‘signal 2’ in an immune response to infection and how this is altered in 
pregnancy. (A) In an infection, monocytes/macrophages (M1) process and present antigen to T cells – signal 1. 
Monocytes/macrophages that might (M1) or might not (M2) be involved in antigen presentation are also 
activated by adjuvant (e.g. endotoxin) to produce costimulatory surface molecules or pro-inflammatory 
cytokines – signal 2. Signals 1 and 2 stimulate T cells to become effector Th1 or Th2 cells. (B) In pregnancy 
there is a bias to a Th2 response. However, adjuvant (e.g. deported fetal or placental products) activates 
monocytes and hence other innate cells. Adapted from Sacks et al., [58]. 
A B 
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More recently however, two further paradigms have been proposed. The first of these is the idea of a 
complete absence of immune suppression [57, 62]. Two reviews written by Mor et al., outline the 
group’s hypothesis that the maternal immune system is not suppressed, but functional and highly 
active. In pregnancy from the first trimester onwards, there is evidence to suggest that monocytes and 
granulocytes are already systemically activated without an infectious stimulus [63]. Moreover, 
monocytes are increased in number and have an activated phenotype and exhibit increased 
phagocytosis, production of certain cytokines and expression of CD14 [64, 65].  
The second paradigm focusses on the addition of a further layer of complexity to the Th1/Th2 
dichotomy model, where another subset of Th cells, Th17 cells, are introduced. The Th17 subset are a 
relatively recently characterised lineage that play a critical role in the induction and regulation of 
inflammation via the production of distinct cytokines such as the pro-inflammatory IL-17 [66]. 
Interestingly, these cells have been implicated in the pathogenesis of autoimmune disease and 
rejection [67]. In normal pregnancy, Th17 cells have been shown to be slightly decreased in 
peripheral blood, but increased in the uterus [68]. This indicates a role for Th17 cells in immune 
tolerance as a lack of IL-17 (or of Th17 cells) has been associated with neutrophil defects and 
increased incidence and severity of infections with Staphylococcus aureus or fungi [69].  
 1.1.4.2 Adaptive Immune System Adaptations 
Whilst the innate immune response is a nonspecific reaction towards foreign antigens, the adaptive 
system (also known as the specific system) response forms a very specific reaction towards antigens. 
The adaptive immune system is exclusively present in higher multicellular organisms and consists of 
cellular (T and B cells) and humoral (antibodies) components. Although different immune 
components are involved in these systems, much overlap and cross-talk exists between the two [70]. 
In general, it is thought that the adaptive immune system response is decreased during pregnancy, 
especially in later stages [49].   
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Studies in mice have shown that upon presentation of fetal antigens to maternal T cells (which can 
begin as early as conception potentially via seminal fluid), they become aware of these antigens and 
actively protect them during pregnancy [71]. These cells are thought to contribute to the tolerogenic 
environment which allows the survival of the fetus. Regulatory T cells (Tregs) have shown to be 
elevated in normal pregnancy. Outside of pregnancy they are thought to be responsible for the 
maintenance of immunological self-tolerance by actively suppressing T cell proliferations and 
cytokine production [72]. They also play a major role in preventing autoimmunity and tolerating 
allogeneic organ grafts, potentially involving the promoting tolerance of dendritic cells [73, 74]. The 
importance of Tregs in the maintenance of pregnancy is demonstrated in a study by Jasper et al., 
where they propose that pregnancy is associated with reduced expression of the Treg cell transcription 
factor Foxp3 in endometrial tissue [75]. 
In addition to the T cell aspect of the adaptive immune system, B cells are the principal cells involved 
in the production of antigen-specific antibodies to target foreign antigens for phagocytosis; they are 
activated via signal from the Th cells. The role of B cells during pregnancy is not fully understood and 
previous studies have mostly concentrated on the production of antibodies in pathologic pregnancies 
[76]. However, in recent years, several other functions have been attributed to these cells showing that 
B cells can uptake, process and present antigens as well as produce several cytokines that further 
influence immunity [77]. 
1.1.4.3 Adaptations in Cytokine Production 
Cytokines are small pleiotropic regulatory proteins that are released by cells to enable inter-cell 
interaction and communication, in either an endocrine or paracrine manner depending on the cytokine 
and location. The name ‘cytokine’ is a nonspecific term for several sub-groups including the 
interleukins (of which are made by one leukocyte and act on another), and the chemokines (cytokines 
which are chemotactic, that is the primary action involves leukocyte migration) [78, 79]. Cytokines 
are often produced in a cascade fashion, and although they are secreted by many cell types, they are 
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produced predominantly by activated macrophages and Th cells. Largely, cytokines can be thought of 
as belonging to one of three main categories: pro-inflammatory, anti-inflammatory and chemokine. 
Levels of several cytokines are altered in pregnancy. Most notably, most pregnant women exhibit 
increased tumour necrosis factor-alpha (TNF-α), interleukin-10 (IL-10) and granulocyte-colony 
stimulating factor (G-CSF) and decreased IFN-γ and VEGF [43, 80]. More generally, levels of 
inflammatory cytokines are reduced and cytokines that induce macrophage recruitment and activity 
are increased. These alterations in cytokine profile do not follow a clear Th1 or Th2 phenotype [49]. 
These changes are summarised in Figure 1.3. 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Cytokine alterations during pregnancy. Cytokines were measured by multiplex ELISA three 
times during pregnancy and compared to 6th month post-partum. Data were first published by Kraus et al., [80], 
figure adapted from Pazos et al. [43]. 
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Broadly speaking, the Th2 cytokines are released from naïve Th0 cells under the influence of IL-4 and 
produce IL-4, IL-5, IL-13, IL-10 and IL-6. Whilst mainly these are considered to be anti-
inflammatory drivers, IL-6 has pro-inflammatory properties. Additionally, although IL-10 and IL-6 
are frequently associated with the Th2 phenotype, they are both produced by other cell types 
including Th1 cells, fibroblasts, macrophages and B cells [70, 81, 82]. IL-10 then acts to regulate Th1 
differentiation in a negative feedback loop [48]. Th1 cytokines are released from naïve Th0 cells 
under the influence of IFN-γ and produce a broad spectrum of pro-inflammatory cytokines including 
IFN-γ and TNF-α. It is this phenotype that drives phagocyte-mediated host defence which is critical 
for defence against intracellular pathogens [83].  
1.1.5 The Role of the Nitric Oxide Signalling Pathway in Pregnancy 
NO is a physiological messenger, and major regulator within the cardiovascular, nervous and immune 
systems of the body [84]. It is synthesised through the sequential oxidation of L-arginine, catalysed by 
NOS enzymes of which there are three isoforms: neuronal (nNOS), inducible (iNOS) and endothelial 
(eNOS) [85]. In the circulation, NO through the second messenger cyclic guanosine monophosphate 
(cGMP), acts as a potent vasodilator that regulates vascular tone and tissue blood flow; it also inhibits 
platelet aggregation and leukocyte adhesion on the endothelial surface [86]. Further to this, NO also 
acts within the innate arm of the immune system as an antimicrobial and tissue-damaging effector 
molecule and in turn has been shown to strongly affect adaptive immune responses and exert 
cytoprotective effects [87]. 
1.1.5.1 The DDAH/ADMA/NO Pathway 
NOS inhibition is largely achieved by the inhibitory L-arginine analogues N-monomethyl-L-arginine 
(L-NMMA) and N-nitro-L-arginine. They, via a competitive mechanism of inhibition, displace 
L-arginine from the substrate binding site of NOS [88]. Additionally, asymmetric dimethylarginine 
(ADMA) was identified as an endogenous inhibitor of NOS in 1992 [89]; and more recently, ADMA 
(specifically the ratio of ADMA to L-arginine) was observed to determine NOS activity at 
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physiologically occurring concentrations [90]. Both ADMA and L-NMMA are derived from the 
proteolysis of methylated arginine residues, a process which is catalysed by protein-arginine methyl 
transferases (PRMTs) [91]. The free methylarginines released can then be metabolised to L-citrulline 
through the activity of another group of enzymes, dimethylarginine dimethylamino hydrolases 
(DDAHs) [92].  
1.1.5.2 DDAH Isoforms 
DDAH is a predominantly cytoplasmic enzyme expressed as two isoforms: type 1 (DDAH1) and type 
2 (DDAH2) [93]. The discovery of the second DDAH isoform by Leiper et al., followed the 
observation that DDAH activity and protein expression did not always correlate [93, 94]. Initial 
experiments using cDNA cloning and northern blotting techniques as well as DDAH activity assays, 
led investigators to the conclusion that DDAH2 expression made a limited contribution to overall 
DDAH activity. However, this report plus subsequent other studies demonstrated a disparity in the 
organ and cellular distribution of the two isoforms. DDAH1 is principally expressed in the liver and 
kidney, major sites for the metabolism of ADMA [95, 96], as well as displaying strong expression in 
the pancreas and brain [97]. DDAH2 encoding mRNA is expressed in the vascular endothelium and 
immunohistochemical analyses have located DDAH2 in vascular smooth muscle cells, endothelial 
cells and vessel adventitia [98, 99]. Furthermore, DDAH2 is also expressed in heart, placenta, foetal 
tissues, peripheral leukocytes and various immune tissues known to express iNOS [97].   
1.1.5.3 Role of Nitric Oxide in Pregnancy 
NO is thought to contribute to maternal systemic vasodilation during pregnancy. In fact, several 
studies have supported the idea that NO is the principal mediator of arterial vasodilation in pregnancy, 
due to increased levels of NO in vascular beds in the pregnant guinea pig and increased NOS in the 
arteries of pregnant rats [100-102]. However, more recently it has been suggested that it is an 
orchestrated network of vasodilatory systems that control both local and systemic haemodynamic 
adaptations in pregnancy, including NO, prostacyclin, kallikrein, angiotensin-(1–7) and VEGF [103].  
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Other roles for NO during pregnancy include the regulation of uterine and fetal blood flow, and the 
relaxation of the myometrium [104]. One suggested mechanism for the regulation of NO-mediated 
uterine quiescence is the upregulation in DDAH expression levels and activity at mid-gestation 
accompanied by reduced ADMA levels which increase at term [105]. NO is also thought to play a 
central role in the remodelling of the uteroplacental vasculature, and it has been shown that eNOS is 
increased throughout pregnancy, leading to increased synthesis and release of NO from the 
endothelium [106].  
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1.2 Maternal Infection and Inflammation 
1.2.1 Maternal Susceptibility to Infection 
The link between bacterial infections (such as acute pyelonephritis and chorioamnionitis) and adverse 
pregnancy outcomes has been well established [107-109]. Additionally, viral infections such as 
influenza, malaria, human immunodeficiency virus (HIV), hepatitis E virus and herpes simplex virus 
amongst others, as well as bacterial sepsis, are more often fatal in pregnant women, with a positive 
correlation between disease severity and advanced gestation [110]. Furthermore, it is now generally 
accepted that pregnant women exposed to viral and bacterial infection risk potential harm to the fetus; 
even if placental transmission is not achieved, the fetus can be adversely affected by the maternal 
response to infection [57].  
The maternal immune response to infection used to be described as blunted, where apparent increased 
maternal susceptibility to infection as indicated by epidemiological evidence was thought to indicate 
immunosuppression. Nonetheless, it must be considered that the evidence for pregnancy-induced 
increased susceptibility to infection is not clear-cut, as an increase in disease severity in pregnant 
women does not always imply increased susceptibility. Moreover, literature collated in a recent 
review by Sappenfield et al., suggests that the innate response may be boosted during pregnancy [43, 
111, 112]. This led the authors’ to suggest that this may represent a compensatory immune 
mechanism to protect the pregnant mother and the fetus, If this is so it would imply decreased 
susceptibility to infection [110]. 
1.2.1.1 Influenza 
It was originally documented by Harris in 1919, that during the 1918 influenza pandemic, the 
mortality rate in pregnant women was as high as 27% (increasing to 50% when complicated by 
secondary pneumonia), compared to 1% in the general population [113]. Similarly, others observed 
that in the 1957 pandemic, 50% of all influenza deaths in reproductive-aged women occurred in those 
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who were pregnant [110, 114]. More recently during the 2009 H1N1 pandemic, 64.6% of the pregnant 
women diagnosed were hospitalised, and although pregnant women accounted for less than 1% of the 
population they accounted for 5-7% of deaths, hospitalisations and ICU admissions [110]. The highest 
proportion of ICU admissions during this time was in women in the third trimester, although severe 
illness was reported in women in all trimesters, which supports the finding that increased disease 
severity in third trimester pregnancies has been documented in the inter-pandemic periods also [49].  
Interestingly, influenza-linked fatalities in pregnant and post-partum women have been documented in 
the developing world where mortality rates were more than three times higher in pregnant women 
than non-pregnant (25% in pregnant, 8% in non-pregnant) [115]. However, this has not been seen in 
western countries, possibly due to effective timely antiviral therapy and better medical facilities [110, 
116, 117]. That being said, a three-fold greater risk of mortality is often quoted. 
The mechanisms behind this increased morbidity and mortality are not fully understood, however it is 
likely that the immunological adaptations that occur during pregnancy that allow for fetal tolerance 
may affect outcome. Kay et al., were able to show that pregnant women have adequate antibody 
responses to the inactivated influenza vaccination (IIV), as they have increased NK and T cell 
responses after IIV when compared with non-pregnant women [118]. In vitro, NK and T cell mediated 
cytokine and chemokine production in isolated peripheral blood mononuclear cells (PBMCs) were 
also increased in pregnant women in response to influenza virus, indicating that there may be 
excessive immune cell recruitment and potentially a deleterious immune response [118]. This 
excessive innate immune system activation and consequent chemokine production has been shown to 
be a crucial factor in influenza-induced lethality, albeit in a non-pregnant mouse model [119]. To the 
author’s knowledge there have been no direct comparisons of the production of chemokines in 
response to influenza virus between pregnant and non-pregnant animals.      
Another possible mechanism underlying the increased lethality of influenza in pregnancy is that of 
respiratory adaptation and reduced capacity for repair. A recent study by Marcelin et al., showed that 
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increased severity of the pH1N1 virus in pregnant mice was associated with increased pulmonary 
neutrophil and macrophage infiltration [120]. Their observation of disparity in the distribution of 
neutrophil infiltration within different lung tissues, and the alteration in macrophage populations 
driven by the Th2 shift and development of alternatively activated macrophages (AAMs), led to the 
hypothesis that an impairment in lung repair mechanisms is likely to contribute to the enhanced 
severity of H1N1 in pregnancy.  
Despite these experimental and epidemiological data suggesting an increased severity of influenza 
infection in pregnancy, it must be addressed that an increase in susceptibility to infection has not been 
documented. This not only fits in well with the hypothesis of a decreased adaptive immunity in 
pregnancy, but that immune responses that are suppressed are likely to be those involved in recovery 
rather than the prevention of onset of infection [43].  
1.2.1.2. Malaria 
Malaria infection is a mosquito-borne infection transmitted by six species of Plasmodium parasite. It 
has been well documented that the greatest burden of disease is seen in young children and pregnant 
women [121]. The highest incidence is in sub-Saharan Africa, where approximately 25 million 
pregnant women are at risk of Plasmodium falciparum infection every year, and 25% have evidence 
of placental infection at the time of delivery [122]. In the Asia-Pacific region, malaria is the most 
common cause of maternal death during pregnancy, with a maternal mortality rate at 48% between 
2004 and 2006 [123]. Several studies have shown that pregnant women have a 3-fold increase in risk 
of developing severe malaria (which is defined by the WHO as the presence of at least one clinical 
symptom, as opposed to asymptomatic malaria [124]), and analysis of eight studies (n=227) indicated 
that the median mortality rate for women with severe malaria in pregnancy was approximately 39% 
[123]. Furthermore, adverse outcomes including maternal anaemia, stillbirth, pre-term labour (PTL) 
and low birth weight have all been associated with maternal malaria infection [125], where in a meta-
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analysis of 32 independent datasets Eisele et al., estimated that maternal malaria was associated with 
14% of low birth weight infants worldwide and 11% of infant mortality in sub-Saharan Africa [126].  
Similar to influenza virus, the mechanism, or mechanisms, behind the increased mortality rates in 
pregnant women with malaria are not fully understood. Pregnant women are more susceptible to 
malaria in the first pregnancy than any subsequent pregnancies, which led researchers in the Gambia 
to conclude this may be due to the absence of antibodies that can target a subset of malaria-infected 
erythrocytes which can accumulate in the placenta [127, 128]. However, since this research was 
conducted, the idea that pregnant women have suppressed cell-mediated immune responses has been 
largely contradicted.  A study that examined antimalarial T-cell responses in women in their first and 
second pregnancies, as well as postpartum women, found that IL-2 responses were suppressed but 
IL-4 and IFN-γ responses were either not affected or enhanced [129]. To add further complexity, a 
later study by the same group found that parasite type and strain also affected cytokine production 
[130]. The role of innate immune cells has also been examined in the placenta, where it is thought 
macrophages aid in direct parasite elimination as well as by indirectly enhancing the innate response 
through cytokine release [127]. Additionally, infected erythrocytes were observed to adhere to NK 
cells and initiate production of IFN-γ, as well as adhere to dendritic cells via CD36 which led to the 
modulation of dendritic cell function, likely through the parasite-produced pigment hemozoin [131-
133].  
1.2.1.3 Acute Pyelonephritis 
Morphological and physiological changes to the genitourinary tract that occur during pregnancy mean 
that urinary tract infections (UTIs), both symptomatic and asymptomatic, are common [107, 134]. 
Asymptomatic bacteriuria, defined as the presence of actively multiplying bacteria without the 
symptoms of a UTI can be found in both pregnant and non-pregnant women, but the progression to 
symptomatic bacteriuria is enhanced in pregnancy [135]. In pregnancy, symptomatic bacteriuria leads 
to acute pyelonephritis (AP) in 20-50% of cases which in turn can lead to adverse obstetric outcomes 
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such as preterm birth, fetal mortality, and also sepsis and acute respiratory distress if left untreated 
[136, 137]. A retrospective analysis study by Wing et al., conducted in South Carolina found that 
almost 2% of pregnant women with AP developed septicaemia, which amounted to nearly 50 times 
that of women without AP [138].   
One recent explanation put forward for the increased susceptibility of pregnant women to AP is the 
decreased presence of soluble tumour necrosis factor-related apoptosis-inducing ligand (sTRAIL) in 
maternal plasma. Chaemsaithonga et al., found that pregnant women with AP, especially those with 
bacteraemia, had a lower mean plasma concentration of sTRAIL than those with uncomplicated 
pregnancies; albeit pregnant women had lower plasma levels of sTRAIL than non-pregnant women to 
begin with [139]. These findings were consistent with previous studies which concluded that TRAIL 
is a protective cytokine against bacterial infection [140, 141].  
1.2.2. The Effects of Maternal Infection and Inflammation  
1.2.2.1 Maternal Sepsis 
The term “sepsis” includes illnesses that range from minor through to multiple organ dysfunction and 
shock. It is often characterised first by a systemic inflammatory response syndrome (SIRS) followed 
by multiple organ failure and finally by immunosuppression [142]. The most severe form of sepsis, 
septic shock, is demarcated as sepsis with refractory hypotension despite adequate fluid resuscitation. 
The speed of progression from initial bacteraemia (or viraemia) through to SIRS, severe sepsis with 
organ dysfunction and septic shock, is determined by the balance between the virulence of the 
infecting organism and the host response. Co-existing conditions such as pregnancy and increased age 
have a major bearing on the effectiveness of the host response.  Bacteraemia leads to SIRS and 
eventually sepsis via several mechanisms. The best known of which is the activation of the 
CD14/TLR4/MD2 complex by components of the invading organism, such as lipopolysaccharide 
(LPS). Consequently, activated inflammatory cells release cytokines, such as TNF-α, IL-1β and IL-6 
which, amongst other effects, lead to increase capillary leakage, increased production of adhesion 
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molecules on endothelial cells and neutrophils and increased neutrophil-endothelial interaction [143]. 
It is the excessive production of these cytokines that can often be more dangerous than the original 
infection, overreaching the boundaries of normal immune response regulation.  
This, alongside the simultaneous development of consumptive coagulopathy and other metabolic 
dysfunctions, promotes inflammation at the target site and at off-target systemic sites, thus to a lesser 
or greater extent affecting all organ systems (multiorgan failure) [144].  
In the stages leading to multiorgan failure, severe sepsis is associated with depressed myocardial 
function; where approximately 50% of the patients who are diagnosed with sepsis exhibit signs of 
myocardial dysfunction [145]. Furthermore, reports have suggested that patients with sepsis who 
develop myocardial dysfunction have an increased risk of death compared to those without evidence 
of myocardial dysfunction [146, 147]. A critical inducer of this dysfunction is TNF-α, regulated by 
NO and calcium signalling mechanisms, and subsequent induction of the nuclear factor kappa-B 
(NFκ-B) pathway [148-150]. Animal studies have demonstrated that in septic heart models there is a 
decrease in left ventricular (LV) systolic and diastolic performance, and more recently a clinical study 
using echocardiography found that LV performance was altered in 44% of septic patients [145]. 
Cardiac troponins are regulatory proteins of the thin actin filaments of the cardiac muscle which are 
released upon myocardial cell injury. ver Elst et al., were able to demonstrate a positive correlation 
between LV dysfunction and cardiac troponin-I and troponin-T elevation in the first 48 hours of septic 
shock, although continuous electrocardiographic in patients who did not survive demonstrated that 
this elevation was not due to acute ischemia [151]. Both troponin-I and –T are now considered to be 
biomarkers that aid in the diagnosis and prognosis of myocardial dysfunction in severe sepsis [152]. 
Other such biomarkers are the peptide hormones atrial natriuretic peptide (ANP) and brain natriuretic 
peptide (BNP; also known as brain natriuretic factor, BNF) [153-155]. Both are secreted in response 
to atrial or ventricular volume expansion and pressure overload, respectively; however in the presence 
of inflammation, pro-inflammatory cytokines contribute to ANP and BNP release. Witthaut et al., 
 42 
 
found that in septic shock both ANP and BNP plasma levels were increased acutely in the early 
phases of septic shock, however increased BNP was more likely to be indicative of LV dysfunction, 
where elevation in ANP concentrations was more likely to be linked to a rise in IL-6 production 
[153]. In pregnancy, ANP and BNP play important roles in blood volume homeostasis and gradually 
increase throughout pregnancy and the peripartum period [156]. Elevated levels have also been noted 
in pre-eclamptic women where the degree of ANP and BNP increase has been correlated with the 
severity of maternal left ventricular dysfunction [157].  
The cardiovascular consequences of sepsis may also be accompanied by respiratory symptoms, where 
lung infiltration by activated neutrophils increases capillary permeability leading to pulmonary 
oedema [158]. Gill et al., showed that in an in vivo mouse model of sepsis, using pulmonary intravital 
videomicroscopy and histological assessment, pulmonary microvascular barrier dysfunction resulted 
in albumin hyperpermeability which was in turn associated with pulmonary microvascular endothelial 
cell death [159]. Pregnancy may exacerbate this as the oncotic pressure of blood is reduced [160], 
potentially increasing fluid leakage, alveolar collapse and the development of acute respiratory 
distress syndrome (ARDS). ARDS is a feature of many pregnant women who are admitted to ITU 
[161].  
Clinically, pregnant women with sepsis can be more difficult to evaluate as pregnancy is associated 
with faster heart rate, lower blood pressure and altered respiratory capacity, all of which are clinical 
signs of sepsis [13]. Furthermore, the laboratory-based investigations to direct treatment and indicate 
prognoses such as white cells counts, creatinine levels and serum lactate levels are already altered in 
pregnancy [162, 163]. Barton and Sibai suggested that when taken together, there is the potential for 
early signs of overwhelming infection and sepsis to be masked, thus delaying the diagnosis and 
initiation of antibiotic (or other) therapies leading to a worsened outcome [162]. To the author’s 
knowledge, there are no data comparing the outcomes of non-pregnant and pregnant septic patients.   
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In developed countries maternal sepsis is usually the result of urinary tract infections and instigating 
organisms originate from the polymicrobial flora of the genitourinary tract [108]. However, there is a 
plethora of both bacteria and viruses (see Table 1.1) and fungal infections that have been associated 
with maternal sepsis that make a significant contribution to infectious morbidity in pregnancy, 
exacerbated by the altered immune physiology during pregnancy. Other causes of severe sepsis in 
pregnancy include septic abortion, neglected endometritis, pelvic abscess or non-obstetric 
intraperitoneal aetiology such as appendicitis, bowel infarction or necrotising fasciitis [162].   
Table 1.1: Organisms associated with maternal sepsis. Adapted from Morgan and Roberts [108] 
Gram-positive 
cocci 
Gram-negative 
rods 
Gram-positive 
rods 
Anaerobes Viruses 
Pneumococcus Escherichia coli Listeria 
monocytogenes 
Bacteroides spp Herpes and 
varicella 
Streptococcus A 
and B 
Haemophilus 
influenza 
 Prevotella HIV 
Enterococcus 
feacalis 
Klebsiella  Clostridium 
perprfringens 
Influenza A 
and B 
Staphylococcus 
aureus 
Enterobacter spp  Fusobacterium spp  
 Proteus spp  Peptococcus  
 Pseudomona spp  Peptostreptococcus  
 Serratia spp    
 
1.2.2.2 Role of Chemokines in Sepsis 
Chemokines are a category of cytokine that can be classified into four further categories depending on 
the location of conserved cysteine residues: CC chemokines (such as CCL2, CCL5, CCL6) principally 
involved in the chemotaxis of mononuclear cells, CXC chemokines (CXCL1, CXCL2) principally 
involved in the chemotaxis of neutrophils, C chemokines (XCL1, XCL2) principally involved in the 
chemotaxis of T cells, and the CX3C chemokine (CX3CL1, also known as fractalkine or neurotactin) 
which is principally involved in the strong adhesion of leukocytes to endothelial cells where CX3CL1 
is primarily expressed [78]. Chemokines signal through chemokine receptors that largely correspond 
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to their respective ligand, although most are ‘promiscuous’ and bind structurally related chemokines 
but with differing affinity. Indeed, chemokines can bind to several different receptors, while 
chemokine receptors can bind more than one chemokine [164].  Of these families, the first two (CC- 
and CXC-motif) have been extensively studied over the past 20 years in the context of sepsis and 
endotoxaemia. For example, several studies have investigated the putative role of chemokines in 
pulmonary immunosuppression following experimental sepsis, proposing that it is, at least in part, a 
result of the activities of CCL2, CCL17 and CCL6; all of which are induced by IL-4 and IL-13. These 
studies concluded that the pulmonary immune response in septic patients may therefore be 
inappropriately tilted toward the Th2 cytokine pattern [165, 166]. This reflects the changes that are 
already apparent in pregnancy, where pregnancy is considered to shift the balance between Th1 and 
Th2 towards a Th2 phenotype (see Chapter 1.1.4). Specifically, the chemokine CCL2 (also known as 
monocyte chemotactic protein-1; MCP-1) and its receptor CCR2, have been shown to be involved in 
regulating Th1- and Th2-type immunity [167], and have been associated with pregnancy-specific 
responses such  as driving CCR2-dependent monocyte homing to the uterus [168]. 
1.2.2.2a CCL2  
Due to the regulatory effect on pro- and anti-inflammatory responses to infection, several studies have 
explored the potential protective role for CCL2 in sepsis. In mice systemically infected with 
Pseudomonas aeruginosa or Salmonella typhimurium, treatment with recombinant CCL2 increased 
bacterial clearance [169]. Similarly, Gomes et al., have demonstrated a crucial role for CCL2 in the 
clearance of bacteria by a mechanism that utilises increased iNOS expression and NO production via 
the extracellular signal-related kinase (ERK) signalling pathway [170]. Furthermore, in a model of 
peritoneal sepsis anti-CCL2 has been shown to lead to increased lethality and reduced leukocyte 
recruitment and bacterial clearance.  CCL2-deficient mice have been shown to be more susceptible to 
sepsis induced by both LPS and caecal ligation and puncture (CLP), potentially due to the action of 
CCL2 in positively regulating the anti-inflammatory cytokine IL-10 [171]. However, other 
researchers utilising the CLP model of polymicrobial sepsis made the observation that inhibition of 
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CCL2/CCR2 signalling led to mice being significantly more resistant to CLP-induced mortality than 
their wildtype or vehicle-treated counterparts [172]. The explanation for this focussed on the role of 
CCL2/CCR2 signalling in neutrophil recruitment. Although CCR2 is principally expressed in 
monocytes, Toll-like receptor 2 (TLR2) and TLR4 have been shown to upregulate the expression of 
CCR2 in circulating neutrophils during sepsis leading to off-site neutrophil recruitment and systemic 
tissue damage [173]; and whilst increased survival in CCR2-deficient mice could not be attributed to 
improved migration of neutrophils to the target site of inflammation or enhancement of bacterial 
clearance, it could be attributed to a marked reduction of neutrophil infiltration in the lungs, liver, 
kidney and heart [172].  
1.2.2.3 Role of Nitric Oxide in Sepsis  
Since the original work in 1990 conducted by Thiemermann et al., that showed enhanced formation of 
NO contributed to endotoxin-induced hypotension, there has been an ever increasing interest in the 
role of NO in the pathophysiology of sepsis and septic shock [174, 175].  Overproduction of NO is a 
known to occur in sepsis, where iNOS activity is upregulated as part of the host response [176]. When 
this is excessive, high levels of NO induce severe hypotension, partly through loss of vasomotor tone. 
As pregnancy is already associated with lowered vasomotor tone, potentially via increased NO 
production [177], the risk of severe hypotension is aggravated.  
Trials of several non-selective NOS inhibitors have shown increases in MAP, but these were also 
accompanied by decreased cardiac output and increased pulmonary arterial pressure [178]. 
Furthermore, in a study utilising a model of sepsis in rats, pre-treatment with the non-selective 
inhibitor L-NG-nitroarginine methyl ester (L-NAME) improved glutathione concentration in the brain 
(beneficial due the involvement of glutathione in defence against reactive oxygen species) [179]. 
In 2004, a trial of the NOS inhibitor N(G)-methyl-L-arginine hydrochloride (546C88) resulted in 
resolution of shock at 72 hr by 40% and 24% of patients in the drug-treated and placebo cohorts 
respectively [180]. Whilst there was no initial indication that 546C88 had any major adverse effect on 
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pulmonary, hepatic or renal function, when the study entered an international phase III  trial 
recruitment was discontinued due to the emergence of increased mortality in the drug-treated group 
[181]. Nevertheless, the data from this trial supports the idea that NOS-inhibition contributes to the 
improved vascular tone in septic patients which is likely to be the primary cause of the observed 
haemodynamic effects; that is, increased systemic and pulmonary vascular resistance as measured by 
systemic and pulmonary arterial pressure and cardiac output.  
1.2.2.4 Preterm Labour 
Infection and inflammation have been implicated in the aetiology of PTL and association between 
infection and spontaneous PTL is now thought to be responsible for preterm delivery in up to 40% of 
cases [182-184]. Maternal infection is the only process for which a causal relationship has been 
established. Current theories of PTL aetiology include the thought that intrauterine infection arises 
following an ascending intrauterine colonisation, which culminates into an infection of the 
choriodecidua, fetal membranes (chorioamnionitis), amniotic fluid (AF), and ultimately the fetus, 
resulting in activation of the inflammatory cascade and thereby triggering PTL [185]. It is important 
to consider, however, that only a minor proportion of PTL pregnancies exhibit clinical signs of 
chorioamnionitis [186, 187], yet elevated levels of inﬂammatory cytokines such as IL-1, IL-6, IL-8 
and TNF-α in the AF of these women suggested an infectious background even when clinical signs of 
infection were lacking [188]. Elevations in AF levels of certain prostaglandins (PGF2α) have also 
been reported, however most AF eicosanoid concentrations (PGE2 and PGD2) are higher in term than 
in preterm births [189].  
Normal parturition has been shown to involve the activation of a complex inflammatory cascade [190, 
191]; and in both term and preterm labour, the production of pro-inflammatory cytokines induces the 
production of prostaglandins and chemokines which act to promote cervical ripening and allow the 
onset of uterine contractions [192-194]. Therefore, it is the aberrant and premature stimulation of 
these mechanisms, possibly by an intrauterine infection, which can lead to PTL [195]. Indeed, 
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evidence suggests that it is inflammation, rather than the infectious bacteria itself that leads to the 
onset of PTL [196, 197]. 
This may have bearing on the clinical strategies presently employed to combat PTL, as recent reviews 
of antibiotic therapies found no benefit and administration of currently available tocolytics has not 
been associated with an improvement in neonatal outcome [198]; therefore currently, 
immunomodulatory targets are being sought [195, 199] 
1.2.2.5 Neonatal Sepsis 
Whilst infections such as chorioamnionitis have been associated with the aetiology of preterm labour, 
maternal sepsis and preterm labour are also both risk factors for neonatal sepsis. In 30% of cases, 
bacteria responsible for maternal intra-amniotic infection can be detected in the fetal circulation 
leading to fetal inflammatory response syndrome (FIRS) [200, 201]. FIRS presents with systemic 
activation of the fetal immune system and eventually progresses to multi-organ failure where these 
neonates are at risk of developing chronic lung disease and cerebral palsy [202-204].   
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1.3 Animal Models 
There are relatively few experimental models of bacteraemia and sepsis in pregnancy. One reason for 
this is that sepsis is notoriously difficult to model in animals. The models that have been developed 
follow one of three strategies: administration of endogenous toxins such as LPS; administration of 
viable pathogens such as bacteria; and alteration of the endogenous protective barrier of the animal 
[142].   
1.3.1 The Endotoxaemic Model 
LPS (which is also known as endotoxin) is an important structural cell wall component of Gram-
negative bacteria. It is one of the best studied immunostimulatory components of bacteria and is 
known to induce systemic inflammation (which can lead to sepsis if the signals are great enough). The 
structure of LPS can be thought of in three parts: lipid A, a core oligosaccharide, and an O side chain 
[205]. It is the lipid A that is the key pathogen-associated molecular pattern (PAMP), considered by 
most to be the prototypical PAMP. 
The principal mechanism by which LPS signals is via the TLR4/MD2 complex. LPS is sensed via the 
formation of a complex with LPS-binding protein (LBP) and the co-receptor CD14 [206]. LBP acts as 
a shuttle protein which directly binds and facilitates the association of LPS and CD14, and CD14 acts 
to facilitate the transfer of LPS to the TLR4/MD2 receptor complex and modulates LPS recognition. 
Upon binding, intracellular signalling relies on a signalling cascade involving the intracellular TLR 
domain (called Toll IL-1 receptor homology domain, or TIR) binding to IL-1 receptor-associated 
kinase (IRAK) which is facilitated by the adapter proteins myeloid differentiation protein 88 (MyD88) 
and TIR domain-containing adapter protein (TIRAP) [205, 207]. This pathway is outlined in Figure 
1.4. The MyD88-dependant initiation of pro-inflammatory cytokines can be facilitated by the 
activation of NF-κB. This protein complex transcription factor is known to be activated in response to 
pro-inflammatory stimuli, but also regulates the transcription of inflammatory genes [208, 209]. 
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Figure 1.4: An overview of the LPS signalling pathway.  LPS recognition is facilitated by LBP and CD14, 
and is mediated by the TLR4/MD2 receptor complex. Upon binding, the MyD88-dependent pathway mediates 
the activation of pro-inflammatory cytokines. This process can be intermediated by NF-κB driven transcription 
of pro-inflammatory genes. Adapted from Lu et al., [205]. 
 
Due to the key involvement of this cell wall component in the pathogenesis of sepsis, the effects of 
LPS have been extensively characterised over the past 50 years and it is widely used in inflammation, 
infection and sepsis research. The reason it is often preferred as an experimental tool is because of its 
stability and the ease of storage in its lyophilised form. Furthermore, it can be measured precisely and 
given to test animals as bolus or infusion [210]. For most sepsis models, LPS is administered via the 
intraperitoneal (i.p.), intratracheal or intravenous (i.v.) route, all of which result in increased 
concentrations of pro-inflammatory cytokines in the serum. However, i.p. injection of LPS has been 
shown to lead to a hyperdynamic cardiovascular response which does not occur if injected via the i.v. 
route [211, 212]. This is thought to more closely mimic the initial rise in cardiac output that occurs in 
human sepsis. Whilst the LPS model leads to increased serum cytokines that are clear markers of 
disease severity, the cytokine profile evoked in rodents shows several differences compared to 
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humans. The peaks of cytokine release can appear much earlier in LPS-challenged animals compared 
to other models of sepsis or in human sepsis [213-215]. Additionally, the dose of LPS used in most 
published in vivo sepsis studies in mice ranges from 1-80mg/kg which leads to a mortality rate of  up 
to 50% [216]. This dose is between 10
3
-10
4
 times the dose required to induce septic shock in humans 
and 10
6
 times the dose used in healthy volunteers to elicit pyrexia and elevated serum cytokines [217, 
218]. 
Whilst the use of LPS challenge to model inflammation, infection and sepsis in non-pregnant animals 
is abundant, the vast majority of studies utilising LPS in pregnant animals do so to model PTL. 
Despite the lack of studies previously using this model to investigate sepsis during pregnancy, it is 
evident that LPS induces an inflammatory cascade which most consider to play a role in the onset of 
PTL.   
1.3.2 Bacterial Inoculation Models  
Following the strategy of administration of pathogens, some previous experiments have shown that 
pregnant mice (E14.5) inoculated with heat-killed Escherichia coli (E. coli) into the uterine horn or 
kidney delivered within 48 hours in a dose-dependent manner, equating to preterm birth [219, 220].  
The literature describing animal models utilising live bacteria have demonstrated that there is an 
extremely variable phenotype depending on the type of bacteria used. For example, Ureaplasma 
parvum, a microorganism frequently associated with preterm birth and found in women presenting 
with chorioamnionitis, was found not to cause preterm delivery nor maternal mortality when injected 
via the intra-amniotic route in E13.5 CD1 mice [221]. Conversely, Fusobacterium nucleatum (gram-
negative bacteria found in the oral cavity) injected intravenously into pregnant CD1 mice at E16 
resulted in premature delivery, stillbirths and non-sustained live births. Interestingly, the F. nucleatum 
bacteria did not spread systemically, but were restricted to the uterus [222].  
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1.3.3 Models of Polymicrobial Sepsis 
LPS endotoxaemia represents only one specific aspect of the immune response (signalling via TLR4) 
and not the complex interactions of multiple signalling pathways that occur during the progression of 
sepsis. Equally, both endotoxin injection and bacterial inoculum are followed by rapid elevations in 
cytokines which are much higher than observed in human sepsis [223]. Therefore, there is a need for a 
polymicrobial animal model of sepsis. The current gold standard animal model of polymicrobial 
sepsis is known as ‘caecal ligation and puncture’ (CLP) and is an example of a model that disturbs the 
endogenous intestinal barrier. In this model, the caecum of rodents is ligated and punctured with a 
needle, resulting in spillage of the intestinal contents into the peritoneum and the development of 
secondary bacterial peritonitis [216]. This model is one of the most stringent sepsis models in rodents 
and is considered to be crucial in preclinical testing of new therapies for sepsis in humans.  
Despite the keywords ‘caecal ligation puncture’ bringing up over 2400 publications in NCBI PubMed, 
there have been no studies employing this procedure to study the effects of polymicrobial sepsis in 
pregnancy. This is surprising as one of the advantages of CLP is that it can recreate human sepsis 
progression with similar haemodynamic and metabolic phases, including both hyper- and hypo-
inflammatory phases; also recreating the prolonged and lower elevation of cytokine release as in 
humans [142]. A mouse model of CLP in combination with radiotelemetry during pregnancy could be 
an ideal way to monitor and compare the normal cardiovascular adaptations that occur during 
pregnancy with the effects of polymicrobial sepsis. This method may also provide an opportunity to 
assess the potential adverse effects of new tocolytic and/or immunosuppressant therapies on the 
maternal ability to fight infection. However, it must be recognised, CLP does not exactly reproduce 
the clinical course of sepsis in humans. 
Another model of polymicrobial sepsis was introduced in the late 1990s by Zantl et al., termed ‘colon 
ascendens stent peritonitis’ (CASP) [224]. The model involved the insertion of a small stent into the 
ascending colon of mice or rats leading to a continuous leaking of intestinal bacteria into the 
peritoneal cavity, resulting in peritonitis and systemic bacteraemia. The severity of the model can be 
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regulated by adjusting the diameter of the stent [225]. The CASP model is thought to be a 
reproducible model to enable investigations of peritoneal enterobacterial infection and sepsis 
progression. It has also been suggested that CASP is more representative of clinical sepsis, as opposed 
to a peritoneal abscess formation which is the main criticism of the CLP model. Although the 
prevalence of the CASP model in sepsis studies has only recently increased, the number of studies 
utilising the CLP sepsis model far exceed those using CASP [226].  
There are several limitations of both CLP and CASP, including the large inter-study variations due to 
differences in protocols used between investigators (for example, the number of caecal punctures and 
sizes of needles or stents used to perforate the bowels) and inter-animal variability including 
differences in the amount of faecal content in the caecum at the time of surgery, the size of caecum of 
each animal, and bacterial flora in different animals. Most importantly however, there is no current 
animal model that can directly resemble complex human sepsis.  
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1.4 Clinical Relevance and Justification of Study 
1.4.1 Sepsis in Pregnancy 
Sepsis is now the leading cause of direct maternal mortality in the UK [227, 228]. Similarly, in 
developing countries, sepsis is one of the most important causes of maternal death [229, 230]. In the 
UK it is fortunately relatively rare with the rate of septic shock being 1.13 per 100,000 deliveries from 
2006 to 2008 [231], however reports from Nigeria state that mortality related to maternal sepsis 
account for more than three times that number [229]. Furthermore, there is a higher incidence of 
pregnant women who suffer serious acute maternal morbidity (SAMM) as a result of sepsis, and 
although data are scarce, the reported incidence of SAMM in the western world is between 0.1 and 
0.6 per 1000 deliveries [232, 233]. In 2011-2012, this equated to approximately 50 women for every 
maternal sepsis death in the UK [234].  
A similar incidence of maternal sepsis has been reported in the USA, and worryingly, recent work has 
suggested an approximate doubling of the rate of severe maternal sepsis (since the period 1991-2003) 
and an increased risk of sepsis-related death [235, 236]. In 2014, Oud et al. found that in a population 
study in Texas, the rank of pregnancy-associated severe sepsis reported among hospital deaths had 
increased from sixth in 2001 to first (reported in up to 32.4% of cases) since 2008 [237]. These 
increases are expected to continue to increase in the future, and are thought to possibly be attributable 
to increasing maternal age that brings with it an increase in several co-morbidities [162]. These 
patients are more likely to require invasive diagnostic and therapeutic procedures that have been 
associated with an increased risk of septic complications [162, 238, 239]. It can be concluded 
therefore that maternal sepsis can be viewed as an infrequent but lethal complication of pregnancy 
that affects pregnant women on a global scale. 
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1.4.2 Maternal Infection and Preterm Labour 
Premature delivery is one of the most important problems in obstetrics causing over 70% of neonatal 
death and handicap, where globally an estimated 15 million babies are born before 37 weeks of 
gestation annually [240, 241]. This translates to affecting between 5 and 18% of all pregnancies.  
PTL is the leading cause and is often driven by maternal infection/inflammation. There is a 
correlation between gestational age and perinatal morbidity. Thus, whilst approximately 10% of all 
births are preterm, death and serious illness is most common in the 1-2% of infants delivered at less 
than 32 weeks of gestation [242]; furthermore, preterm pregnancies that are complicated by maternal 
infection are at greatest risk of cerebral palsy [243]. Infection and inflammation are now thought to 
account for PTL in over 40% of cases [182], and even subclinical infections can lead to severe 
neonatal morbidity and mortality [244-246].  
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1.5 Novel Hypotheses 
It has been established that pregnancy is associated with an altered response to infection. Yet 
remarkably, there is little known about the effect of infection and sepsis in pregnancy on 
cardiovascular function, especially the adaptation and regulation of the peripheral vascular system that 
leads to the hypotension associated with severe sepsis.  
In this thesis, the two main hypotheses are as follows:  
 The haemodynamic response to infection and inflammation is altered in pregnancy. 
 Agents targeting the chemokine and NO signaling pathways given in pregnancy could alter 
the maternal response to infection and inflammation. 
1.5.1 Aims and Objectives 
To explore these hypotheses, a telemetric method of measuring haemodynamic parameters during 
murine pregnancy in conscious mice need first be established, in which to investigate the 
cardiovascular response to inflammation in pregnancy. Further to this, the role of progesterone on 
inflammation-induced haemodynamic and immune alterations in pregnancy using progesterone 
supplementation will be determined. To try and understand the involvement of chemokines in these 
modulated responses, the role of chemokines (specifically CCL2/CCR2 signalling) in the 
inflammation-induced haemodynamic and immune responses in pregnancy using both CCR2-
deficient mice and the pharmacological inhibition of CCR2 will be investigated. Finally, to try and 
understand the contribution of NO signalling to the altered responses in pregnancy to inflammation, 
focussing on the role played by the upstream endogenous ADMA inhibitor DDAH.  
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2. Materials and Methods 
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2.1 Materials 
2.1.1 Reagents and Buffers 
2.1.1.1 Chemicals and Solvents 
Absolute Ethanol    VWR, Lutterworth, UK 
Acetonitrile     Sigma-Aldrich, Poole, UK 
ADMA      Merck Millipore, Billerica, MA, USA 
Agarose (Iberose)    Web Scientific, Crewe, UK  
D7-ADMA     Cambridge Isotope Laboratories, Cambridge, UK 
Dithiothreitol      Sigma-Aldrich, Poole, UK 
Ethidium bromide    Sigma-Aldrich, Poole, UK 
Formic acid     Sigma-Aldrich, Poole, UK 
Isopropanol     Sigma-Aldrich, Poole, UK 
Methanol     VWR, Lutterworth, UK 
Non-fat dried milk powder   Calbiochem, Millipore, Billerica, MA, USA 
SYBR safe DNA gel stain   Life Technologies, Paisley, UK 
Tween-20      Applichem, Darmstadt, Germany 
Vanadium (II) chloride    Sigma-Aldrich, Poole, UK 
2.1.1.2 Buffers 
All chemicals used to make the following buffer recipes were purchased from Sigma-Aldrich, Poole, 
UK. 
FACS Wash Buffer (FWB): 2% fetal calf serum (FCS), 0.1% NaN3, 2mM EDTA 
High Potassium Physiological Salt Solution (KPSS): 125mM KCl, 1.2mM MgSO4, 1.2mM KH2PO4, 
24.9mM NaHCO3, 2.5mM CaCl2, 11.1mM glucose. pH 7.4 when solution gassed with 95% O2/ 5% 
CO2 mixture. 
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NaOH Solution: 25mM NaOH, 0.2mM EDTA. pH 12.0. 
Permeablizing Wash Buffer (PWB): 0.2% saponin, 0.5% bovine serum albumin (BSA), 0.1% NaN3 
Phosphate Buffered Saline (PBS): 140mM NaCl, 2.5mM KCl, 1.5mM KH2PO4, 10mM Na2HPO4. pH 
7.2. 
Physiological Salt Solution (PSS): 118.4mM NaCl, 4.8mM KCl, 1.2mM MgSO4, 1.2mM KH2PO4, 
24.9mM NaHCO3, 2.5mM CaCl2, 11.1mM glucose, 0.023mM EDTA. pH 7.4 when solution gassed 
with 95% O2/ 5% CO2 mixture. 
Proteinase K Buffer: 1M Tris-HCl, pH8.5, 1M MgCl2, 3M KCl, 1% Gelatine solution from porcine 
skin, Nonidet P-40, 0.45% Tween-20. 
Tris-Buffered Saline with Tween-20 (TBS-T): 50mM Tris-HCl, 150mM NaCl, 0.01% (v/v) Tween-
20. pH 7.5. 
Tris-EDTA Buffer (TBE): 10mM Tris-HCl, 1mM EDTA. pH 8.0 
Tris-HCl Buffer: 40mM Tris-HCl. pH 5.0. 
2.1.1.3 PCR Reagents and Buffers 
10mM dNTPs     Applied Biosciences, Foster City, CA, USA 
10x NH4 Reaction Buffer   Bioline, London, UK 
20U/μL RNase Inhibitor   Applied Biosciences, Foster City, CA, USA 
25mM MgCl2     Applied Biosciences, Foster City, CA, USA 
2mM dNTPs     Bioline, London, UK 
50mM MgCl2     Bioline, London, UK 
5nmoles Oligo d(T)    Applied Biosciences, Foster City, CA, USA 
5U/μL Taq     Bioline, London, UK 
Hyperladder I     Bioline, London, UK 
Hyperladder III     Bioline, London, UK 
Hyperladder V     Bioline, London, UK 
MuLV 50U/ μL reverse transcriptase  Applied Biosciences, Foster City, CA, USA 
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PCR 0.1mL strip tubes    Qiagen, Crawley, UK 
PCR Buffer     Applied Biosciences, Foster City, CA, USA 
Power SYBR Green    Applied Biosystems, Warrington, UK 
QiaShredder spin columns   Qiagen, Crawley, UK 
Readymix Taq PCR reaction mix  Abgene, Thermo Scientific, MA, USA 
RLT Lysis Buffer    Qiagen, Crawley, UK   
TrackIt™     Invitrogen, Life Technologies, Paisley, UK 
2.1.1.4 Protein Extraction and Western Blotting Reagents 
DC Protein Assay Reagent A   Bio-Rad, Hemel Hempstead, UK 
DC Protein Assay Reagent B   Bio-Rad, Hemel Hempstead, UK 
DC Protein Assay Reagent S          Bio-Rad, Hemel Hempstead, UK 
ECL-2 Plus     Pierce, Thermo Scientific, MA, USA 
Halt Protease Inhibitor Cocktail   Thermo Scientific, MA, USA 
Mini-PROTEAN TGX gels   Bio-Rad, Hemel Hempstead, UK  
NuPAGE LDS sample buffer   Invitrogen, Life Technologies, Paisley, UK 
Precision Plus™ Dual Colour Standard  Bio-Rad, Hemel Hempstead, UK 
RIPA Buffer     Sigma-Aldrich, Poole, UK 
SuperSignal Chemiluminescent Substrate  Pierce, Thermo Scientific, MA, USA 
Trans-Blot Turbo™ PVDF membrane  Bio-Rad, Hemel Hempstead, UK  
2.1.1.5 FACS Equipment and Reagents 
40μM nylon cell strainer   BD, Falcon, Oxford, UK 
AccuCheck counting beads   Invitrogen, Life Technologies, Paisley, UK 
FACS lysing solution    BD, Falcon, Oxford, UK 
gentleMACS M tubes    Miltenyi Biotex Ltd, Surrey, UK 
IC fixation buffer    eBioscience, Hatfield, UK 
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Saponin     Sigma-Aldrich, Poole, UK 
Sodium azide     Sigma-Aldrich, Poole, UK 
2.1.1.6 Kits 
Milliplex MAP Mouse Cytokine/Chemokine Magnetic Bead Panel  
Merck Millipore, Billerica, MA, USA 
Milliplex MAP Mouse Angiogenesis/Growth Factor Magnetic Bead Panel 
Merck Millipore, Billerica, MA, USA 
Mouse cGMP ELISA     Enzo Life Sciences, Farmingdale, NY, USA 
Mouse PLGF2 ELISA    R&D Systems, Abingdon, UK 
QIAgen RNeasy Mini Kit    Qiagen, Crawley, UK 
QIAquick Gel Extraction Kit    Qiagen, Crawley, UK 
2.1.2 Mice, Surgical Consumables and Drugs 
25G 2.5cm needle    BD, Medisave, Weymouth, UK 
4-0 Mersilk     MidMeds, Waltham Abbey, UK  
Acetylcholine      Sigma-Aldrich, Poole, UK 
Bovine serum albumin    Sigma-Aldrich, Poole, UK 
Buprenorphine     Alstoe Animal Health, York, UK 
CD1 mice     Charles River, Margate, UK 
CD1 timed-mated mice    Harlan Laboratories, Bicester, UK 
Dimethyl sulphoxide (DMSO)   Sigma-Aldrich, Poole, UK 
Enrofloxacin     Bayer Animal Health, Newbury, UK 
Evans Blue     Sigma-Aldrich, Poole, UK 
Isoflurane     Abbot Laboratories, Maidenhead, UK 
Lipopolysaccharide (O111:B4)   Sigma-Aldrich, Poole, UK 
Microhaematocrit tubes    Sarstedt, Leicester, UK 
 61 
 
Noradrenaline     Sigma-Aldrich, Poole, UK 
PA-C10 Telemetry Device   Data Science International, Netherlands 
Peanut Oil      Sigma-Aldrich, Poole, UK 
Phenylephrine     Sigma-Aldrich, Poole, UK 
Progesterone (P4)    Sigma-Aldrich, Poole, UK 
RS504393     Tocris Bioscience, Bristol, UK 
Sodium nitroprusside    Sigma-Aldrich, Poole, UK 
2.1.3 Equipment 
Agilent 6400 series LC-MS/MS   Agilent Technologies, Stockport, UK  
AVerDiGi HYBRID Surveillance Platform RF Concepts, Dundonald, UK 
FACS CyAn ADP flow cytometer  Beckman Coulter, High Wycombe, UK  
ND-1000 UV-Vis Spectrophotometer  NanoDrop Technologies, Labtech, UK 
OPTImax tunable microplate reader  Molecular Devices, Wokingham, UK 
RotorGene Sequence Detector   Corbett Research, Mortlake, Sydney, Australia 
Sievers Nitric Oxide Analyser    GE Analytical Instruments, Manchester, UK  
Tissue Tearor     BioSpec Products Inc, Bartlesville, OK, USA 
Trans-Blot Turbo™ Transfer System  Bio-Rad, Hemel Hempstead, UK 
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2.1.4 Primer Sequences 
Table 2.1: Mouse primer sequences for use in PCR/ RT-PCR. *Primers used for genotyping. 
#
Sequence was 
provided by Jackson Laboratories. 
##
Sequence obtain from Leiper laboratory. †Sequence obtained from 
Villanari et al (2013), [247]. 
Gene Forward 
 
Reverse 
 
Ref Seq 
(NCBI/GenBank) 
α-MHC gaggaccaggccaatgagta gctgggtgtaggagagcttg NM010856   
ANP aacctgctagaccacctgga tctctgaggtgggttgacct AF460238 
β-actin aggctgtgctgtccctgtat gctgtggtggtgaagctgta NM007393      
β-MHC atgccaggattgaggatgag ccagcctctcactgatctcc NM080728 
Bad aggatcgctgtgtcccttta gcagtccagaacaggagagg NM_007522.2 
Bax tgcagaggatgattgctgac gatcagctcgggcactttag NM_007527.3 
Bcl-2 yaatggaggagtcggtttgc gctgctgctgcttcttcttt NM_009741.3 
BNF cagctcttgaaggaccaagg tccgatccggtctatcttgt NM008726 
CCR2 (WT)* ccacagaatcaaaggaaatgg ccaatgtgatagagccctgtg 
# 
CCR2 (KO)* cttgggtggagaggctattc aggtgagatgacaggagatc 
# 
COX-2 tgcagaattgaaagccctct gctcggcttccagtattgag NM_011198.3 
Cre* gcctgcattaccggtcgatgca gtggcacatggcgcggaac 
## 
DDAH1 (floxed)* cctcccattgctaatgaaacgg tcagttggagtgtgagtgac 
## 
cTroponin-I gaagcaggagatggaacgag ttaaacttgccacggaggtc NM_009406.3 
CXCL1 gcctatcgccaatgagctg aagggagcttcagggtcaag NM_008176.3 
CXCL2 agtgaactgcgctgtcaatg ttcagggtcaaggcaaactt NM_009140.2 
CXCR1 gggtgaagccacaacagatt tagggcagacaacagagcaa NM_178241.4 
CXCR2 atcttcgctgtcgtccttgt agccaagaatctccgtagca NM_009909.3 
eNOS aagacaaggcagcggtgg gcaggggacaggaaatagtt NM_008713.4 
Endothelin-1 tcgtgactttccaaggagct ccaggtggcagaagtagaca NM_010104.3 
FasL catcacaaccactcccactg gttctgccagttccttctgc NM_010177.4 
GAPDH actccactcacggcaaattc tctccatggtggtgaagaca NM001001303 
Hsp70 atgaaggagatcgctgag tgagagtcgttgaagtagg † 
IL-1β gctgcttccaaacctttgac tgtcctcatcctggaaggtc NM_008361 
IL-4 tgacggcacagagctattga ggtgttcttcgttgctgtga M25892.1 
IL-6 ccggagaggagacttcacag ttctgcaagtgcatcatcgt NM_031168 
IL-10 ccaagccttatcggaaatga gctccactgccttgctctta NM_010548.2 
iNOS cagctgggctgtacaaacctt atgtgatgtttgcttcggaca NM_010927.3 
NKAα1 ttcccttcaactccaccaac cgtccttcagctcttcatcc NM_144900.2 
NKAα3 ccaagtgcgactgtgtgtct cacgagagccatatgagcaa NM_144921.1 
NKx2.5 gctacaagtgcaagcgacag gggtaggcgttgtagccata NM_008700.2 
PLN tcgcctccttacctccacta agcttcagcgtcacgtttct NM_001141927.1 
RP-L19 ggtgacctggatgagaagga ttcagcttgtggatgtgctc NM_009078.2 
RP-S18 tgtggtgttgaggaaagcag tcccatccttcacatccttc NM_011296.2 
SERCA aagctatgggagtggtggtg gcaatgcaaatgagggagat NM009722 
TNF-α tggcagaagaggcactcc gaggccatttgggaacttct NM_013693 
VEGF-A atggcatgctttgtggatcc taccaggcctcttcttccac AF317892.1 
VEGF-B tggtgccatggatagacgtt tgcattcggacttggtgttg NM_011697.3 
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2.1.5 Antibodies 
Table 2.2: Antibodies used for FACS 
Antibody Source 
Ly6C (HK1.4) BioLegend, Cambridge, UK 
Gr1 (RB6-8C5) BioLegend, Cambridge, UK 
NK1.1 (PK136) BioLegend, Cambridge, UK 
F4/80 (Cl:A3-1) BioLegend, Cambridge, UK 
CD45 (30-F11) BioLegend, Cambridge, UK 
CD86 (B7-2) eBioscience, Hatfield, UK 
CD11b (M1/70) eBioscience, Hatfield, UK 
MHCII (AMS-32.1) eBioscience, Hatfield, UK 
F4/80 (BM8) eBioscience, Hatfield, UK 
COX-2 (M19) Santa Cruz Biotechnology, Santa Cruz, CA, USA 
 
Table 2.3: Antibodies for use in Western Blotting. *Antibodies were purified from goat serum in-house.  
Antibody Concentration Source 
Caspase-3 (ABIN125614) 1:500 Antibodies-online.com 
DDAH1 1:4000 * 
DDAH2 1:2000 * 
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2.2 In Vivo Methods 
2.2.1 Animals 
All animal procedures were carried out in accordance with the Home Office Animals (Scientific 
Procedures) Act, 1986, under project licenses 70/7372 (Imperial College) or 70/6096 (availability at 
UCL) and were previously approved by the Animal Welfare and Ethical Review Board (AWERB) at 
Imperial College London. All mice were housed in individually ventilated cages with access to 
normal rodent chow and water ad libitum, and maintained on a 12:12 light-dark cycle.   
Unless otherwise specified, experiments were performed using female CD1 mice aged 7-9 weeks. 
Mice were purchased from Charles River (Margate, UK) aged 6-8 weeks and acclimatised for at least 
1 week. CD1 stud males were used for timed mating with CD1 as well as CCR2
-/- 
and DDAH1
-/-
 
female mice.  
Mice lacking CCR2 (CCR2
-/-
), originally from Jackson Laboratories [248], were maintained on an 
outbred CD1 background and bred in house using homozygous knockout breeding pairs. 
Experimental females were used aged 7-9 weeks. Wild-type (WT) controls were female CD1 mice 
purchased from Charles River (Margate, UK). 
DDAH1 heterozygous floxed mice were generated by Genoway (Lyon, France) and mated to generate 
homozygous progeny. DDAH1 knockouts (DDAH1
-/-
) were maintained on a mixed C57BL/6 
background. Initial attempts to breed a DDAH1 knockout mouse were embryonic lethal [249], 
however deletion of exon one using the cre/lox-P system produced viable offspring. Cre was 
expressed under the control of α-actin which is expressed globally. DDAH1 heterozygous (DDAH-/+ 
with cre negative female, cre positive male) matings produced experimental females. Litters therefore 
contained an approximate 1:1 ratio of DDAH1 cre positive and cre negative mice. Both homozygous 
DDAH1
-/-
 and WT littermates were used aged 12-16 weeks. 
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For myography experiments, timed-mated female CD1 mice were purchased from Harlan 
Laboratories (Bicester, UK) so that mice would be of known gestation (E16) on consecutive working 
days. 
2.2.2 Genotyping 
Mice were weaned at 3-4 weeks and ear notched where necessary for identification. Tail clippings 
were taken for genotyping.  
2.2.2.1 CCR2
-/-
 Colony 
To extract genomic DNA from CCR2 colony mice, tissue was submerged in 75μL NaOH solution and 
thoroughly vortexed. Samples were heated to 95
o
C for 10 minutes before cooling to 4
o
C by quickly 
plunging into ice. 75μL of Tris-HCl, pH 5.0 was then added to each sample before mixing by vortex 
and centrifugation. Polymerase chain reaction (PCR) was performed using heat stable DNA 
polymerase, Taq. Per reaction, 2μL 10x NH4 reaction buffer, 2μL 2mM dNTPs, 0.6μL 50mM MgCl2, 
0.1μL 5U/μL Taq (all from Bioline, London, UK), 1μL forward primer, 1μL reverse primer, 4μL 
DNA and 9.3μL dH20 was used. Thermocycler conditions were as follows: hold for 5 minutes at 
95
o
C, 35 cycles of 30s at 95
o
C, 60s at 65
o
C, 120s at 72
o
C, then a final extension for 10 minutes at 
72
o
C. Primer sequences are shown in Table 2.1. PCR products were separated by agarose gel (1.5%, 
containing 1x SYBR safe (Life Technologies, Paisley, UK)) and visualised under ultraviolet (UV) 
light using TrackIt™ (Invitrogen, Life Technologies, Paisley UK) loading buffer (Figure 2.1). Product 
sizes were confirmed through the use of the appropriate DNA ladder (Hyperladder; Bioline, London, 
UK) (Figure 2.1). 
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Figure 2.1: Genotyping gels of CCR2 expression. CCR2 genotype was identified due to either a single band at 
424 base pairs (WT), a single band at 280 base pairs (homozygous knockout, KO), or the presence of both bands 
(heterozygote) (bp, base pairs). 
2.2.2.2 DDAH1
-/-
 Colony 
This work was done by Mr. Matthew Delahaye (NOS Signalling Group). 
To extract genomic DNA from DDAH1 colony mice, tail clippings were digested overnight at 53-
55
o
C in a digestive Proteinase K Buffer. After digestion the proteinase K was deactivated at 94
o
C for 
10 minutes. PCR was performed using 1x Readymix Taq PCR reaction mix which contained 
polymerase, dNTPs and loading dye (Abgene, Thermo Scientific, MA). Both DDAH1 floxed and Cre 
primer protocols utilised a hold of 2 minutes at 94
o
C, then 20s at 94
o
C, 40s at 60
o
C and 60s at 72
o
C 
for 40 cycles, before a final extension of 5 minutes at 72
o
C. Primer sequences are shown in Table 2.1. 
PCR products were separated by agarose gel (1.5%, containing 0.01% ethidium bromide; EtBr) and 
EtBr-stained DNA bands were visualised under UV light (Figure 2.2).  
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Figure 2.2: Genotyping gels of DDAH1 floxed alleles and cre expression. DDAH1 genotype was identified 
due to either a single band at 427 base pairs (WT), a single band at 568 base pairs (homozygous knockout), or 
the presence of both bands (heterozygote). Cre recombinase expression was verified through the presence of a 
single band at 720 base pairs. 
2.2.3 Telemetry  
Telemetry is a technology that allows the remote measurement of physiological and bioelectrical 
variables in freely-moving conscious animals. The absence of tethering, handling and restraint during 
measurement has provided the unique opportunity to study laboratory animals with reduced distress, 
discomfort and physiological disturbance over long periods of time in their normal housing. Long-
term telemetric measurement of cardiovascular parameters such as blood pressure and heart rate in 
awake pregnant mice was a technique optimised by Butz and Davisson to study cardiovascular 
regulation during pregnancy [250], demonstrating the feasibility of radiotelemetric monitoring 
throughout pregnancy in mice. The advantages of this method include that it can reduce the numbers 
of animals used in each experiment. This is achieved by decreasing any variation due to stress and by 
enabling each animal to act as its own control.  
2.2.3.1 Telemetry Device Implantation 
Before surgery, mice received a subcutaneous injection of 5% enrofloxacin and 0.3mg/mL 
buprenorphine. Female CD1 mice were anaesthetised with isoflurane (5% induction, 2% maintenance, 
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2L/min O2 flow rate) and the neck and chest were shaved and swabbed with povidone iodine. Animals 
were placed supine on the dorsal side on a heated mat, with the nose just inside a modified smaller 
sized coaxial Bain circuit nosecone for anaesthetic delivery. Forelimbs were loosely secured using 
tape and the nose held inside the anaesthetic tube by a loop of mersilk around the upper incisors and 
anchored to the surface. Surgical anaesthesia level was confirmed by a lack of pedal pinch reflex 
response. A ventral midline incision was made and the submandibular glands were gently separated 
before isolation of the left common carotid artery.  The artery was tied off at the distal end to the 
aorta; temporarily occluded at the proximal end, and punctured with iris scissors or an adapted angled 
25G needle (BD, Medisave, Weymouth, UK). The catheter tip of the transmitter was then advanced to 
the aortic arch and secured with two sutures (anterior and posterior) (Figure 2.3A). The transmitter 
body was then advanced subcutaneously to lie over the right flank (Figure 2.3B) before the incision 
was closed (4-0 Mersilk, MidMeds, Waltham Abbey, UK). Mice were then placed into a heated 
recovery chamber (30ᵒC). All mice were individually housed after implantation of the device.  
Animal weights, surgical wound healing, general health and any signs of morbidity were observed 
daily for 5-7 days post-operatively to ensure good recovery. Over the course of this study, over 95% 
of mice survived surgery, with a further 90% surviving the post-operative recovery period. At the end 
of these experiments, mice were terminally anaesthetised before device removal. Device sterilisation 
was achieved using enzymatic detergent and cold sterilant. 
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Figure 2.3: Telemetry transmitter placement. (A) Surgical procedure diagram for implantation of the 
telemetry device in the thoracic aorta via the left common carotid artery. Insets 1 and 2 are enlargements 
illustrating the catheter insertion site and tip placement (in the thoracic aorta). In Inset 1, A and B refer to the 
anterior and posterior ligatures, respectively. Adapted from Butz and Davisson [250]. (B) Subcutaneous 
placement of the transmitter body on the right flank. (C) DSI PA-C10 telemetry device before implantation 
(adapted from www.nc3rs.org.uk).  
2.2.3.2 Telemetry Recording, Acquisition and Analysis 
On day 8 after surgery, continuous 24 hour recording (data collection) began using the Dataquest 
ART Acquisition System (Data Sciences International, v4.1) for at least 48 hours to collect data in 
non-pregnant animals (non-pregnant baseline). These data allowed animals to act as their own 
controls. Radiotelemeters were magnetically activated and deactivated. Whilst recording, animals 
were kept in their home cages with access to food and water ad libitum; however these cages were 
placed in a separate room for recording. This environment was chosen to cause fewer disturbances 
from other facility users and staff. 
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For longitudinal studies which required recording throughout the course of gestation, data collection 
was resumed after evidence of a copulatory plug had been observed (E0) and continued up until 3 
days post-partum; no data were collected during mating. For all other studies, data was collected 
during the following time points: E8-E9 (48hrs), E15-postpartum (48-120hrs). 
Collected parameters included mean arterial pressure (MAP), systolic arterial pressure (SAP), 
diastolic arterial pressure (DAP), heart rate (HR), and activity. Haemodynamic data were collected for 
10 seconds every 30 seconds. Labour time and litter sizes were also recorded. Accurate labour time 
was enabled by the use of infrared IP cameras in conjunction with the AVerDiGi (NV3000 Series) 
HYBRID Surveillance Platform (RF Concepts, Dundonald, UK). 
2.2.4 PTL Model (Systemic Endotoxaemia) and Pharmacological Intervention 
2.2.4.1 PTL Model (Systemic Endotoxaemia) 
The administration of E. coli lipopolysaccharide (LPS) to rodents is a widely accepted technique 
which aims to model bacterial infection-induced PTL. However, the method of administration and 
dose of LPS previously used has been diverse [251]. Elovitz et al., reported a reproducible model 
using intrauterine administration of LPS that resulted in 100% PTL with no maternal mortality [252]. 
An adapted version of this model using 10μg LPS administered via the intrauterine route was 
subsequently established within our group; however the laparotomy required for intrauterine 
administration of LPS and the telemetry implantation surgery was not possible under the current 
Procedure Project Licence (PPL). Therefore we aimed to establish a systemic endotoxaemic model 
using the intraperitoneal (i.p.) route.  
LPS endotoxin (serotype O111:B4; Sigma-Aldrich, Poole, UK) or sterile vehicle control (PBS) were 
administered systemically (i.p.). The dose of LPS was firstly determined using a dose-response study 
in CD1 females on E16 using a range of doses indicated by the intrauterine work in our group and 
current literature. A single injection of 10μg LPS per dam (in 100μL PBS) resulted in no maternal 
mortality and gave the most consistent outcomes in latency to labour and pup survival. All pregnant 
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mice were anaesthetised under isoflurane for i.p. injection to minimise potential harm to fetuses and 
were carried out between 8am and 10am.  
2.2.4.2 Progesterone Treatment 
In those experiments examining the role of progesterone, P4 (Sigma-Aldrich, Poole, UK) was 
dissolved in peanut oil (Sigma-Aldrich, Poole, UK) at a stock concentration of 250mg/mL. After 
initial dose-finding experiments, a final concentration of 10mg per mouse (in 40μL peanut oil) was 
injected subcutaneously (s/c) into the right flank. P4 or vehicle (peanut oil) injections were carried out 
once a day from E14 to E16 between 8am-10am.  
2.2.4.3 CCR2 Antagonism 
In those experiments using pharmacological inhibition of CCR2, the CCR2 antagonist RS504393 
(Tocris Bioscience, Bristol, UK) was used at a final concentration of 2mg/kg per mouse. RS504393 
was dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich, Poole, UK) at a stock concentration of 
4mg/mL and stored at -20
o
C. One hour prior to use, stock solutions were thawed, diluted in sterile 
PBS and thoroughly vortexed so that the final DMSO concentration was 5%. RS504393 or vehicle 
(5% DMSO in PBS) was injected s/c into the right and left flank (half dose in each side) 30 minutes 
before LPS (on E16) and then every 12 hours until labour. Initial toxicity studies indicated that 
RS504393 alone did not confer any morbidity or alter labour times (n=3). 
2.2.5 Tissue Collection  
To record accurate haemodynamic data it is imperative to keep disturbances to a minimum. Therefore, 
blood, serum and other tissues were taken from separate groups of animals at two time points, 6 hours 
and 12 hours post i.p injection.  
Mice were terminally anaesthetised using isoflurane (5% induction, 3% maintenance, 2L/min O2 flow 
rate) and a cardiac puncture was performed to collect plasma or serum samples. Subsequent to 
schedule 1 culling, lung, heart, left ventricle, myometrium and placenta were collected and snap 
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frozen on dry ice. These samples were then stored at -80ᵒC until needed for RNA and protein 
extraction.  
For myography studies, thoracic aorta and uterine artery were dissected from a separate group of 
animals (see section 2.2.6). 
Strips from left and right horn myometrium, lung, liver (sections from each lobe), placenta and blood 
(mixed with 5mM EDTA) were also temporarily stored (for up to 6h) in PBS for subsequent FACS 
analysis (see section 2.2.8).  
In addition, Dr Bronwen Herbert gifted serum samples taken at extended time points (NP, E6, E11, 
E16, E18 and 36 hours post-partum) to be used to examine PLGF levels over the course of gestation.  
2.2.6 Wire Myography 
This work was done in collaboration with Anna Slaviero DVM (MRC Whole Animal Physiology 
team). 
Vessel function and sensitivity to vasoactive substances was assessed by wire myography.  Both aorta 
and uterine vessels were dissected from pregnant (E16) or non-pregnant CD1 mice. Animals received 
either vehicle (PBS) or 10μg LPS injected i.p. 12 hours before culling using schedule 1 procedure. 
2.2.6.1 Preparation of Vessels 
The thoracic aorta was dissected, extraneous connective tissue removed, and immediately placed in 
cold (4
o
C) physiological salt solution (PSS). The uterus was then dissected from below the ovaries to 
the upper cervix and the uterine artery identified and carefully dissected. Aortic sections (2mm), taken 
from the centre of the vessel, were mounted in parallel on the DMT vessel myograph (DMT, Aarchus, 
Denmark) using the pin mounting system. Vessels were gradually warmed to 37
o
C in PSS aerated 
with 95% O2, 5% CO2 for 30-60 minutes. Uterine vessels were mounted onto much thinner 20μm 
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tungsten wires. These were connected to an isometric force transducer which was then calibrated to 
zero.  
2.2.6.2 Normalisation and Viability of Tissues 
Once the myograph was at zero, tension was applied to the mounted vessels such that the force 
display was adjusted to 70 mmHg for aorta, and 45 mmHg for uterine artery. The vessels were then 
left to equilibrate for approximately 20 minutes before buffer was refreshed and the force adjusted to 
10mN. Force was again adjusted to 10mN after two further 20 minute equilibrations; buffer was 
changed after every 20 minute period.  
Viability of tissues was confirmed using a standard ‘wake up’ protocol. To obtain optimal data from 
vessels, it is important to ascertain that functional response is not compromised by the dissection, 
isolation and mounting of the vessels [253]. This was performed by testing contractile ability using 
the response to high potassium depolarisation and a standard vasoconstrictor, noradrenaline (NA). 
Briefly, vessels were stimulated with potassium physiological salt solution (KPSS) with 10μM 
noradrenaline (Sigma-Aldrich, Poole, UK) for 3 minutes (when contraction reaches plateau) before 4x 
washes with PSS. This was repeated twice more before stimulating with KPSS alone for 3 minutes 
twice. If vessels failed to contract to KPSS with NA, or KPSS alone they were excluded from the 
study.  
2.2.6.3 Concentration Response Curves 
Cumulative concentration response curves were performed for phenylephrine (PE; from 10⁻⁶ M to 
10⁻² M), acetylcholine (ACh; from 10⁻⁶M to 10⁻²M), and sodium nitroprusside (SNP; from 10⁻⁷ M to 
10⁻³ M); all drugs were procured from Sigma-Aldrich, Poole, UK. After each dose, time was given 
for the response to reach a plateau before continuing with the next dose. After the final concentration 
had been added, vessels were washed 4 times with PSS and left for 5 minutes to rest. In order to allow 
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for a relaxation response, before ACh or SNP were added, a dose of PE corresponding to 80% of the 
maximum concentration obtained was added to contract each vessel. 
2.2.7 Plasma Volume Determination 
To determine any plasma volume differences between pregnant (E16) and non-pregnant mice, an 
Evans Blue dilution method was used, as previously described by Sena et al., [254]. A 0.08% (w/v) of 
Evans Blue dye (Sigma-Aldrich, Poole, UK) solution was made up in sterile PBS. 100μL was then 
injected intravenously (i.v.) into the tail vein of CD1 mice that had been placed in a warming chamber 
at 34
o
C for up to 10 minutes prior to the procedure. At 10 and 30 minutes post-injection venous blood 
was collected in microhaematocrit tubes (Sarstedt, Leicester, UK) to measure disappearance kinetics. 
After centrifugation at 13,000 rpm, plasma was diluted 1:15 in water before samples were added in 
duplicate onto a 96-well plate. Evans blue concentration in the plasma was measured as optical 
density on a spectrophotometer (OPTImax tunable microplate reader; Molecular Devices, 
Wokingham, UK) at λ=620nm.  
Concentrations were determined using a standard curve constructed using known amounts of Evans 
Blue made up in a bovine serum albumin (BSA, Sigma-Aldrich, Poole, UK) solution (Figure 2.4A). 
Data were analysed using a least-square line fitted to the data at 10 and 30 minutes from each 
individual mouse. Extrapolation of the regression line back to x=0 meant plasma volume could be 
calculated as the total quantity injected, divided by the y intercept (Figure 2.4B). 
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Figure 2.4: Calculation of plasma volume using Evans Blue dilution method. (A) Standard curve showing 
known amounts of Evans Blue against absorbance as determined by optical density at λ=620nm. (B) 
Extrapolation of the regression line back to x=0 determines the Evans Blue concentration as diluted by plasma 
volume. NP- non-pregnant, E16- pregnant.  
2.2.8 Flow Cytometry 
This work was performed in collaboration with Ms. Lydia Edey (Imperial Parturition Group).  
Fluorescence-activated cell sorting (FACS) technique was employed to assess leukocyte cell densities 
in maternal blood and tissues. Lung and liver were homogenised using gentleMACS M tubes 
(Miltenyi Biotex Ltd, Surrey, UK) containing 1mL of IC fixation buffer (eBioscience, Hatfield UK) 
for 1 minute. After filtering through a 40μm nylon cell strainer (BD Falcon, Oxford UK), cell 
suspensions were centrifuged twice at 1450 rpm for 5 minutes to extract leukocytes. After the first 
centrifugation, cells were re-suspended in FACS wash buffer (FWB). After the final centrifugation 
cells were re-suspended in permeablizing wash buffer (PWB). The exact volume of the cell 
suspension was assessed and recorded. EDTA was added to blood samples at a 1:10 ratio and 
incubated at RT. 
All cell samples were then incubated with the appropriate antibodies for 30 minutes at 4
o
C. 
Fluorophore-conjugated rat anti-mouse monoclonal antibodies were used for staining (outlined in 
Table 2.2). Following the incubation, samples were re-suspended in 4mL PWB for tissue, and 4mL 
FWB for blood. All samples were then centrifuged at 2000 rpm for 5 minutes at 4
 o
C. Following this, 
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tissue samples were re-suspended in 400μL PWB. FACS lysing solution (BD, Falcon, Oxford UK) 
was used to lyse erythrocytes in blood samples before a final centrifugation and re-suspension in 
400μL FWB.  
Cell counts were determined using AccuCheck counting beads (Invitrogen, Life Technologies, Paisley 
UK). Samples were run using a CyAn ADP Beckman Coulter flow cytometer in conjunction with Cell 
Quest 3.3 software. Data were analysed using FlowJo version 7.6.5. 
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2.3 In Vitro Methods 
2.3.1 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) 
2.3.1.1 mRNA Extraction 
mRNA was extracted from mouse tissue using the QIAgen RNeasy Mini Kit (Qiagen, Manchester, 
UK) according to manufacturer’s instructions. Homogenisation was achieved using a RLT lysis buffer 
(Qiagen, Crawley, UK) with 2M DTT (Sigma-Aldrich, Poole, UK) added before mechanical 
homogenisation (Tissue Tearor, BioSpec Products Inc, Bartlesville, OK). The tissue lysate was put 
through QIAshredder columns (Qiagen, Crawley, UK) to eliminate DNA contamination prior to 
addition to the RNeasy spin columns. RNA yield was quantified using a ND-1000 UV-Vis 
spectrophotometer (NanoDrop Technologies, Labtech International, UK). RNA sample purity was 
assessed using A260/280 ratio of approximately 2.0. Resulting RNA samples were stored at -80
o
C. 
2.3.1.2 cDNA Synthesis 
Reverse transcription of RNA for cDNA synthesis was performed using 2μg RNA heated at 70C for 
5 minutes before incubation with 4μL PCR Buffer II (2x) (Applied Biosciences (AB) Foster City, 
CA), 8μL 25mM MgCl2 (AB) 8μL 10mM dNTP (AB), 1μL 20U/μL RNase Inhibitor (AB), 1μL 
5nmoles Oligo d(T) (AB), and 1μL MuLV 50U/μL reverse transcriptase (AB) at 42C for 60 minutes, 
followed by 5 minutes at 95C. Samples were then quickly chilled to 4C, and the resulting cDNA 
stored at -20C.  
2.3.1.3 Primer design and Production of Standards 
Paired oligonucleotide primers for amplification of genes of interest were designed using Primer 3 
software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) against the sequences 
downloaded from GenBank (Table 2.1). Standards were constructed using PCR (2uL mouse cDNA, 
10uL Power SYBR Green (Life Technologies, Paisley, UK), 7uL water, 1uL primer F/R) where the 
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reaction conditions were 10min at 95C followed by up to 60 cycles of 95C for 20s, 60C for 20s and 
72C for 20s followed by an extension at 72C for 15s. Gel extraction of the PCR product was then 
performed using agarose gel electrophoresis (agarose gels were prepared using 1.5% agarose in 1x 
TBE buffer, plus SYBR safe (Life Technologies, Paisley, UK)) followed by extraction using 
QIAquick gel extraction kit (Qiagen, Crawley, UK) according to manufacturer’s instructions. PCR 
product size was confirmed through the use of the appropriate DNA ladder (Hyperladder; Bioline, 
London, UK). Standards were prepared using 1:10 serial dilutions in distilled water. In subsequent 
reverse transcriptase PCR (RT-PCR) assays, standards 3-9 were used alongside a water blank (no-
template control). 
2.3.1.4 RT-PCR 
2μL cDNA templates were combined with the 1uL of primer (mixed forward and reverse), 10μL 
Power SYBR Green (Applied Biosystems, Warrington, UK) and 7μL distilled water in PCR 0.1mL 
strip tubes (Qiagen, Crawley, UK). Amplicon yield was monitored during cycling in a RotorGene 
Sequence Detector (Corbett Research Ltd., Mortlake, Sydney, Australia). Pre-PCR cycle was 10min 
at 95
o
C followed by up to 65 cycles of 95
o
C for 20s, 60
o
C for 20s and 72
o
C for 20s followed by an 
extension at 72
o
C for 15s. To determine amplicon purity, a melt curve was constructed over the 
temperature range of 72-99
o
C rising by 1 degree steps with a wait for 15s on the first step followed by 
a wait of 5s for each subsequent step. One single peak alluded to a pure product without dimer 
contamination. The cycle at which the fluorescence reached a pre-set threshold (cycle threshold) was 
used for semi-quantitative analyses. The cycle threshold in each assay was set at a level where the 
exponential increase in amplicon abundance was approximately parallel between all samples.  
By use of the comparison to standards, relative concentrations could be determined. These were then 
normalised to a housekeeping (or reference) gene. Four housekeeping genes, selected for their 
stability across all treatment groups, were used in this study: Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), β-actin, ribosomal protein s18 (s18) and ribosomal protein L19 (L19) 
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[255]. In heart and left ventricular tissue, s18 was found to be the most consistently expressed, and in 
placenta GAPDH was found to be most consistently expressed and so these comparisons are shown in 
subsequent analyses. 
2.3.2 Protein Expression Analysis 
2.3.2.1 Protein Extraction 
Protein was extracted from mouse tissue using mechanical homogenisation (Tissue Tearor, BioSpec 
Products Inc, Bartlesville, OK) in RIPA buffer (Sigma-Aldrich, Poole, UK) with added protease 
inhibitor (Halt Protease Inhibitor Cocktail, Thermo Scientific) and phosphatase inhibitor (Halt 
Phosphatase Inhibitor Cocktail, Thermo Scientific, MA) at 4
o
C. Lysates were centrifuged at 4
o
C at 
13,300 rpm for 20 minutes and the supernatant aliquoted. Concentration of protein in each sample was 
determined by protein assay.  
2.3.2.2 Protein Assay 
To quantify protein concentrations in tissue homogenates, a DC protein assay (Bio-Rad, Hemel 
Hempstead, UK) was performed according to manufacturer’s instructions. These reagents allow for 
concentration determination following detergent solubilisation, similar to the well-documented Lowry 
assay [256]. Briefly, in a 96-well plate 7 dilutions of BSA (Sigma-Aldrich, Poole, UK) in duplicate 
were used to construct a standard curve, made up in the appropriate buffer. 5μL of each sample were 
added in duplicate to the plate, previously diluted in the appropriate buffer 1:3 or 1:5. Reagent S was 
combined 1:50 with Reagent A (an alkaline copper tartrate solution) before added 25μL to each well. 
200μL of Reagent B (a dilute Folin reagent) was then added to each well and the plate was gently 
mixed for 30s on a plate shaker. The plate was incubated at room temperature for 10-20 minutes 
before reading optical density on a spectrophotometer (OPTImax tunable microplate reader; 
Molecular Devices, Wokingham, UK) at  λ=595nm.  
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2.3.2.3 SDS-PAGE and Western Blot 
Electrophoresis was carried out on aliquots of protein samples that were denatured by adding 
NuPAGE LDS sample buffer (Invitrogen, Life Technologies, Paisley, UK) and DTT (Sigma-Aldrich, 
Poole, UK) at a final concentration of 20mM and heating for 10min at 70-80
oC. 40μg of protein 
sample was loaded into each well on pre-cast 15 well 4-15% Mini-protean TGX gels (Bio-Rad, 
Hemel Hempstead, UK). Proteins were separated by electrophoresis in 1x SDS running buffer for 40-
60 minutes at 80-120V.  
Western blotting was performed following a 7-minute electrophoretic transfer onto Trans-Blot 
Turbo™ PVDF membrane (Bio-Rad, Hemel Hempstead, UK) using the Trans-Blot Turbo™ Transfer 
System (Bio-Rad, Hemel Hempstead, UK). Membranes were blocked in blocking buffer (5% milk in 
1x TBS-T) for 1 hour at room temperature, washed in 1×TBST and hybridized with the primary 
antibody over night at 4
o
C in 1% milk. Antibody details are outlined in Table 2.3. Membranes were 
washed again and then incubated with secondary antibody at a dilution of 1:2000 in 1% milk for 2 
hours at room temperature. SuperSignal West Pico Chemiluminescent Substrate (Pierce, Thermo 
Scientific, MA) or ECL-2 Plus (Pierce, Thermo Scientific, MA) was used for detection. Protein band 
size was determined using Precision Plus Protein™ Dual Colour Standard (Bio-Rad, Hemel 
Hempstead, UK).  
DDAH1 and DDAH2 western blots were completed by MSc project student, Miss Stephanie Dowle. 
2.3.2.4 Multiplex Assay  
Tissue homogenates were prepared as described in section 2.3.2.2. Serum or tissue samples were 
prepared for analysis in a 96-well plate using a bespoke 9-, 7-, 5-, or 3-plex mouse 
cytokine/chemokine or angiogenesis/growth factor magnetic bead panel (Merck Millipore, Billerica 
MA, USA) according to manufacturer’s protocol. Analytes were quantified using a Luminex 
MAGPIX instrument with xPonent 4.2 software (Luminex Corp., Austin TX, USA) or Bioplex 
Manager MP (Bio-Rad, Hemel Hempstead, UK).   
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Briefly, colour-coded microspheres were provided where each distinctly coloured bead set was coated 
with a specific capture antibody. Analytes in each test sample were then captured by the bead before a 
biotinylated detection antibody was introduced. This was followed by the addition of Streptavdidin-
phyocoerythrin conjugate, which attaches as a reporter molecule. The microspheres were then passed 
rapidly through a laser in the MAGPIX instrument which excites the internal dyes denoting the 
specific bead set, whilst a second laser excites phyocoerythrin. Individual microspheres were 
identified from images captured on a cooled CCD camera and quantified by Milliplex Analyst 
Software (Merck Millipore, Billerica MA) or Bioplex Manager 6.1 (Bio-Rad, Hemel Hempstead, 
UK). In this way, multiple analytes within each test sample could be measured simultaneously. The 
concentrations of analytes were calculated by comparison to standard curves. Two company-provided 
quality controls, low level and high level, were run with each assay.  
2.3.2.5 Placental Growth Factor (PLGF2) Enzyme-linked Immunosorbent Assay (ELISA) 
This work was done in collaboration with Dr. Julia Zöllner. 
Quantitative sandwich enzyme immunoassay ELISAs for mouse placental growth factor (PLGF2) was 
performed to investigate the circulating levels of PLGF occurring during normal CD1 mouse 
gestation.  In humans, four isoforms of PLGF have been identified, PlGF1-4. However, only the 
PlGF2 transcript can be detected in mouse tissues [257, 258].  
ELISA assay procedure was followed according to manufacturer’s instructions (R&D Systems, 
Abingdon, UK). Serum samples were diluted 1:2 in Calibrator Diluent RD5-17 and mixed well. 
Calculation of concentrations was performed using standard concentrations for comparison fit with a 
4-parameter logistic curve.  
2.3.2.6 Cyclic Guanosine Monophosphate (cGMP) ELISA 
This work was done in collaboration with Dr. Julia Zöllner.  
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NO is known to activate guanylate cyclase (GC) to stimulate cGMP synthesis; where in vivo  
evidence has suggested that cGMP plays a primary role in the mediation of the response to NO [259]. 
The contribution of cGMP to the vasodilator response is thought to be through a Ca
2+
-dependent 
mechanism [260]. To quantify cGMP levels in the circulation and in a representative vascular tissue, 
serum and heart tissue were examined respectively. Frozen heart tissue was ground into a fine powder 
under liquid nitrogen and homogenised in 10 volumes of 0.1M HCl. Samples were then centrifuged at 
13,000 rpm and the supernatant reserved for analysis.  
ELISA assay procedure was followed according to manufacturer’s instructions (Enzo Life Sciences, 
Farmingdale, NY). The acetylated format of the assay was run to increase sensitivity. Serum samples 
were diluted 1:10 in Assay Buffer 2. Calculation of concentrations was performed using standard 
concentrations for comparison fit with a 4-parameter logistic curve. 
2.3.2.7 Soluble Fms-like Tyrosine Kinase-1 (sFlt-1) ELISA  
This work was done by MSc project student, Miss Stephanie Dowle. 
Quantitative sandwich enzyme immunoassay ELISAs for sFlt-1 were performed on placental 
homogenate according to manufacturer’s instructions (R & D systems, Minneapolis, USA). 1μg of 
protein was loaded onto the pre-coated 96 well plate containing a specific sVEGFR1 monoclonal 
antibody. Correlation between sample dilutions and known measured sVEGFR1 were linear 
(R
2
>0.99). 
2.3.3 Nitric Oxide Analysis 
NO production was determined from the concentrations of both nitrite and nitrate combined (NOx). 
The Sievers nitric oxide analyser (NOA, GE Analytical Equipment) was used to measure total NOx 
concentration in mouse serum and tissue homogenates [261]. The NOA is capable of detecting NOx 
within very small volumes of samples (down to 5μL with a lower limit of detection of 0.2μM). 
Samples were prepared by protein precipitation with four volumes of methanol and centrifugation at 
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16,000 rpm for 30 minutes.  The supernatant was then used for analysis. Nitrates and nitrites in each 
sample were reduced back to NO through a reaction with VCl2 (Sigma-Aldrich, Poole, UK) in 1M 
HCl (Sigma-Aldrich, Poole, UK) at 90
o
C before passing into the system to react with ozone (O3). This 
produced a chemiluminescent signal that was quantified by a photo-multiplier system. The 
concentration of NOx was calculated by comparison to a calibration curve of known nitrate samples. 
2.3.4 Methylarginine Measurement 
ADMA was identified and quantified by Liquid Chromatography-Mass Spectrometry (LC-MS/MS). 
Tissue samples were prepared as described in section 2.3.2.2. 2μL of 25μg/mL D7-ADMA 
(Cambridge Isotope Laboratories, Cambridge, UK) was added to 50μL of tissue homogenate, or 30μL 
of serum, as an internal standard. 5 volumes of 100% methanol were used to precipitate out protein. 
Samples were centrifuged at 13,000 rpm at room temperature for 20 minutes. The supernatant was 
removed and incubated at 95
o
C to evaporate excess methanol. 100μL of 0.1% formic acid (mobile 
phase; Sigma-Aldrich, Poole, UK) was then added to each sample and thoroughly mixed before 
loading onto a 96-well plate. Standards were generated using a starting concentration of 100μM of 
ADMA (Merck Millipore, Billerica, MA) and 1:2 serial dilutions were made thereafter to a final 
concentration of 5.96 x 10
-6
 M. To later calculate extraction efficiency of ADMA, 2μL of D7-ADMA 
was added to 100μL of 0.1% formic acid (spiked sample).  
Samples were then analysed by LC-MS/MS. The high pressure liquid chromatography (HPLC) 
system (Agilent, Stockport, UK) separates sample components based on their binding affinity to a 
silica-based column. 10μL of samples were injected onto the column and eluted using 1% formic acid, 
1% acetonitrile (Sigma-Aldrich, Poole, UK), rising to 50% acetonitrile over 10 minutes, taking 15 
minutes per sample.  The column was washed clean in between each sample using 1% formic acid, 
50% acetonitrile. After elution, samples were vaporised and ionised in the Agilent 6400 series triple 
quadrupole LC-MS/MS (Agilent Technologies, Stockport, UK). ADMA was detected using mass to 
charge ratio (m/z) 203.3 to 46.0 and d7-ADMA 210.0 to 46.0.    
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After extraction of chromatograms using the multiple reactions monitoring (MRM) method, analyses 
of ADMA values were performed by determination of the total ion count within the relevant peak. 
Concentrations were then calculated based on comparison to the standard curve accounting for 
extraction efficiency and normalised to the amount of protein in each sample where appropriate.    
2.3.5 Data Handling and Statistical Analysis 
In the longitudinal study using CD1 mice looking at haemodynamic parameters over the course of 
gestation, parameters were plotted as mean values ± standard error of mean (SEM) for each 12 hour 
light/dark period and as mean values ± SEM for each 24 hour period; or as change (Δ) from baseline. 
Longitudinal data collected using DDAH1
-/-
 mice over the course of gestation were plotted as mean 
values +/- SEM for each 24 hour period as a change (Δ) from baseline.  Data collected in the 24hr 
period after intraperitoneal injections were plotted as 1 hour averages ± SEM as a change (Δ) from 
baseline alongside area under the curve (AUC) analysis, maximum increase and maximum decrease 
(where appropriate).  
Differences in the cardiovascular parameters at different time points throughout pregnancy were 
analysed by repeated measures ANOVA followed by Bonferroni correction for multiple comparisons 
between the means.  
Multiple effects modelling (performed by Dr Fabiana Gordon, Imperial Statistical Advisory Service) 
was used to compare the response to LPS in pregnant and non-pregnant animals (Appendix 1). In all 
further haemodynamic data to assess the impact of progesterone or CCR2 deficiency, treatment 
groups were compared using a 2-way ANOVA followed by Bonferroni correction. Student’s t-tests or 
Mann Whitney U tests (as appropriate) were used to compare haemodynamic data after AUC analysis 
and for comparisons of maximum increase and decrease. 
Two-way ANOVA followed by Bonferroni correction was used to make comparisons between 
concentration-response curves (wire myography). All FACS data, multiplex data, RT-PCR data, NOx 
analysis, ADMA analysis, ELISA analysis and western blot densitometry, were statistically analysed 
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using pairwise analyses using t-tests or Mann Whitney U tests (as appropriate) unless indicated 
otherwise in the text.  
Student’s t-test was used to compare litter sizes, latency to labour, plasma volume and P4 dose 
response. Where data were found to be not normally distributed as determined by Kolmogorov-
Smirnoff tests, non-parametric equivalent tests such as or Mann-Whitney U were employed.  
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Chapter 3: Longitudinal Telemetric Recording of Haemodynamic 
Parameters and Activity in Murine Pregnancy 
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3.1 Introduction 
As previously discussed in greater detail, the cardiovascular changes that occur in normal pregnancy 
are well defined: where cardiac output, heart rate and blood volume are increased, vascular resistance 
and arterial pressure are decreased [2, 41]. The drop in vascular resistance is a consequence of 
peripheral vasodilation, which is reflected in a fall in systemic blood pressure (predominantly driven 
by diastolic pressure) [3, 4]. Accordingly, cardiac contractility and heart rate, and therefore cardiac 
output, are increased. Furthermore, blood volume increases during pregnancy by approximately 45-
50% [14, 262]. Alongside the fall in vascular tone, increases in blood volume in early pregnancy 
trigger a decrease in preload to the heart which initiates the compensatory increase in heart rate [263]. 
These changes allow for implantation to occur. 
In non-pregnant women the haemodynamic changes described above would lead to hypertension, yet 
in uncomplicated pregnancies MAP is maintained, or declines. Suggested hypotensive mechanisms 
behind these changes include systemic hormone-driven vasodilation and transient insensitivity to 
vasoactive substances [264, 265].  
To measure long-term haemodynamic changes in a murine model, radiotelemetric monitoring was 
used throughout normal mouse pregnancy. This method provides several advantages over other 
techniques that can be employed to measure arterial pressures in the mouse, such as tail cuff 
plethysmography, or exteriorised implanted fluid filled catheters. Although a non-invasive technique, 
tail cuff systems require extensive animal handling and restraint. This can lead to inflated systolic 
pressure measurements and may affect accuracy and reproducibility. Vasoconstriction of the tail 
artery due to environmental temperature, increased sympathetic tone, hypotension or the action of 
vasoactive substances could further affect the accuracy of measurements taken using the tail cuff 
method [266]. Fluid filled catheter systems require that mice are tethered throughout the monitoring 
period, thus restricting movement and activity adding to stress. Additionally, the frequency of catheter 
obstructions could hinder long-term measurements. By using small radiotelemetric devices to 
chronically implant mice, the absence of tethering, handling and restraint allows for more accurate 
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long-term haemodynamic measurements. The initial surgical technique developed using these devices 
involved catheter placement into the abdominal aorta, which would obstruct blood flow to the lower 
extremities in mice weighing <30g, thus potentially compromising uterine blood flow [267]. Since 
this would not be feasible for the study of pregnant mice, the surgical procedure was subsequently 
adapted to a carotid placement of the catheter tip [250, 268], which is now by far the most widely 
used approach [269]. Butz and Davisson went on to show that haemodynamic and cardiovascular 
parameters could be monitored throughout gestation, and that the device did not interfere with 
conception, delivery or postnatal care of pups.    
3.1.1 Aims and Objectives 
To be able to further dissect the underlying impact of inflammation on the cardiovascular system 
during pregnancy, it was important to understand the haemodynamic changes that occur normally. 
Therefore, haemodynamic parameters and activity levels were studied using telemetry method in an 
outbred CD1 mouse strain over the course of normal gestation.  
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3.2 Results 
3.2.1 The Haemodynamic Profile of Pregnancy in CD1 Mice 
Continuous data collection across the gestational and post-partum period in the CD1 strain of mice 
enabled the composition of a haemodynamic and activity profile that included detection of subtle 
haemodynamic changes. All mice that were used in this experiment were recorded for at least 48 
hours before mating and subsequent pregnancy (termed Baseline) which enabled the use of each 
individual mouse as their own control. Labour occurred at term (overnight between E18 and the 
morning of E19) in all mice. 
We observed a gradual decline in MAP from 109.4 ± 1.86 mmHg at baseline to a mid-gestation nadir 
of 100.75 ± 1.3 mmHg at E8 (p<0.01; Figure 3.1). Pressure then gradually increased and returned to 
baseline levels by E14. Post-partum pressure did not differ significantly from baseline (Figure 3.1). 
Similar trends were observed in systolic arterial pressures (SAP; Figure 3.2) where SAP fell to a mid-
gestational nadir on E8 from 121.25 ± 1.23 mmHg to 109.88 ± 1.03 mmHg (p<0.001). However, the 
significant reduction in systolic pressure during mid-gestation occurred for a longer period of time 
(E7-E11). Furthermore, there was an additional drop in systolic pressure during the post-partum 
period. DAP was also reduced to a mid-gestational nadir of 88.17 ± 1.66 mmHg from baseline levels 
of 94.48 ± 2.8 mmHg (E8, p<0.01); however, when normalised to baseline this reduction was not 
significant (Figure 3.3).  There was no change in diastolic pressure during the post-partum period. 
There was no observed change in HR (Figure 3.4). There was an initial trend seen at E0 towards 
increased heart rate but this returned to baseline levels without reaching significance. This is likely to 
be due to the large variability seen between animals. Pulse pressure remained constant throughout the 
course of gestation (data not shown). 
 90 
 
Figure 3.1: Continuous measurement of mean arterial pressure (MAP) throughout pregnancy. (A) MAP 
in CD1 mice whilst not pregnant (Baseline), throughout gestation, and for 3 days post-partum (1DPP-3DPP) 
shown as 24-hour, light-phase and dark-phase averages. **p<0.01, 1-way repeated measures ANOVA, 
Bonferroni post-test (n=7) compared to baseline for 24h average. (B) ΔMAP from baseline. *p<0.05, 1-way 
repeated measures ANOVA, Bonferroni post-test (n=7) compared to baseline.  
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Figure 3.2: Continuous measurement of systolic arterial pressure (SAP) throughout pregnancy. (A) SAP 
in CD1 mice whilst not pregnant (Baseline), throughout gestation, and for 3 days post-partum (1DPP-3DPP) 
shown as 24-hour, light-phase and dark-phase averages. *p<0.05, **p<0.01, ***p<0.001, 1-way repeated 
measures ANOVA, Bonferroni post-test (n=7) compared to baseline for 24h average. (B) ΔSAP from baseline. 
*p<0.05, **p<0.01, 1-way repeated measures ANOVA, Bonferroni post-test (n=7) compared to baseline.   
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Figure 3.3: Continuous measurement of diastolic arterial pressure (DAP) throughout pregnancy. (A) DAP 
in CD1 mice whilst not pregnant (Baseline), throughout gestation, and for 3 days post-partum (1DPP-3DPP) 
shown as 24-hour, light-phase and dark-phase averages. **p<0.01, 1-way repeated measures ANOVA, 
Bonferroni post-test (n=7) compared to baseline for 24h average. (B) ΔDAP from baseline (n=7). 
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Figure 3.4: Continuous measurement of heart rate (HR) throughout pregnancy. (A) HR in CD1 mice 
whilst not pregnant (Baseline), throughout gestation, and for 3 days post-partum (1DPP-3DPP) shown as 24-
hour, light-phase and dark-phase averages (n=7). (B) ΔHR from baseline (n=7). 
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3.2.2 Activity during Pregnancy in CD1 Mice 
As well as measuring haemodynamic parameters, the telemetry system also produces an activity 
‘count’ that represents an index of the animal’s locomotor activity. These data show that the 
percentage of time spent inactive (%TSI) increased gradually over the course of gestation (Figure 3.5) 
with mice generally spending more time inactive during the light phase. The change in %TSI from 
baseline was significantly greater at E17 and E18; increasing to 85.15 ± 1.18% and 84.34 ± 1.19% 
respectively from baseline levels of 77.5 ± 1.69%. 
Intensity of activity was shown to decrease towards labour, particularly during the generally more 
active dark phase (Figure 3.6). This decrease in activity was significantly reduced from baseline 
during labour and the post-partum period (p<0.05), likely to birthing and weaning behaviours. As 
expected, due to the nocturnal nature of mice, activity was generally observed to be greater during the 
dark-period than the light period at all time points until labour. Across the 24hr averages taken, 
activity remained relatively constant until E8, and then from E9 onwards until 3DPP there was a 
decline in activity to a nadir at E18. When eliminating inactive time points, mean activity >0 did not 
differ as much between light and dark periods (Figure 3.7A). Similar to overall activity, there was a 
gradual decrease in activity from E8 until 3DPP. This general decrease over the period of gestation 
was likely to result from the large size of the animal towards the end of pregnancy, and then weaning 
during 1DPP-3DPP.  
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Figure 3.5: Continuous measurement of the percentage of time spent inactive (%TSI) throughout 
pregnancy. (A) %TSI in CD1 mice whilst not pregnant (Baseline), throughout gestation, and for 3 days post-
partum (1DPP-3DPP) shown as 24-hour, light-phase and dark-phase averages (n=7). (B) Δ%TSI from baseline. 
*p<0.05, 1-way repeated measures ANOVA, Bonferroni post-test (n=7) compared to baseline. 
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Figure 3.6: Continuous measurement of activity throughout pregnancy. (A) Activity (in arbitrary units) in 
CD1 mice whilst not pregnant (Baseline), throughout gestation, and for 3 days post-partum (1DPP-3DPP) 
shown as 24-hour, light-phase and dark-phase averages. *p<0.05, 1-way repeated measures ANOVA, 
Bonferroni post-test (n=7) compared to baseline. (B) Δ Activity from baseline. *p<0.05, 1-way repeated 
measures ANOVA, Bonferroni post-test (n=7) compared to baseline.  
 97 
 
Figure 3.7: Continuous measurement of activity >0 throughout pregnancy. (A) Activity >0 (in arbitrary 
units) in CD1 mice whilst not pregnant (Baseline), throughout gestation, and for 3 days post-partum (1DPP-
3DPP) shown as 24-hour, light-phase and dark-phase averages. *p<0.05, ***p<0.001 1-way repeated measures 
ANOVA, Bonferroni post-test (n=7) compared to baseline. (B) Δ Activity>0 from baseline. *p<0.05, **p<0.01, 
***p<0.001 1-way repeated measures ANOVA, Bonferroni post-test (n=7) compared to baseline.  
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3.3. Summary and Discussion 
MAP in CD1 mice decreased to mid-gestational nadir at E8 before rising back to baseline levels. This 
seems to be mainly driven by systolic rather than diastolic pressure. Heart rate did not change 
significantly over the course of gestation; however there was a trend to increase in the first days of 
pregnancy only to decline as the drop in blood pressure was reversed. Activity levels decreased 
gradually towards labour and the post-partum period where they remained low. 
This first study demonstrates the feasibility of remote monitoring of cardiovascular parameters in 
conscious freely moving pregnant mice. Additionally, these mice were able to successfully conceive 
and carry a normal-sized litter to term (approximately 12 pups per litter [270]). The implants 
remained relatively undisturbed and fully functional over the course of the experiment.   
The haemodynamic profile observed in CD1 mice was comparable to that observed by Burke et al., in 
other mouse strains (BALB/c and B6) [2].  The general trend reported was that MAP remained 
constant until E5 and then declined, reaching a nadir at E9. Pressure then returned to non-pregnant 
baseline levels by E12 and remained stable until the peri-partum period. The authors identified a 
distinct pattern of arterial pressure which corresponded with gestational milestones such as 
implantation (E5), pre-placental conceptus development (E5-E9), placental growth and the opening of 
placental circulation (E9-E14), the fetal growth phase (E14-E18) and the peri-partum interval.   
The decrease in MAP observed in CD1 mice, with a nadir approximately halfway through gestation, 
is comparable to the decline in blood pressure seen in human pregnancy where MAP reaches a nadir 
at approximately halfway through gestation at  16-20 weeks [271, 272]. However, whilst in human 
pregnancy the decline in blood pressure is thought to be predominantly due to a fall in DAP [3, 4, 
273], in CD1 mice the decline in SAP was more pronounced and appeared to be the drive behind the 
decrease in MAP, rather than DAP. This difference may contribute to the limitations of using the 
mouse to model pregnancy-related haemodynamics. Due to the many differences in human and 
murine uterine anatomy, placental morphogenesis and endocrine function, the structural enlargement 
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of the uterine vascular tree which contributes to the initial drop in vascular resistance is likely to be 
different in the mouse. Greater numbers of uteroplacental implantation sites and developing placentae 
in the mouse may confer a larger drop in systolic arterial pressure [15, 274].   
It has been proposed that the observed haemodynamic changes over the course of gestation are 
primarily due to systemic vascular resistance. Endogenous mediators of vasodilation, principally NO 
and its second messenger cGMP, have been shown to be increased in both human and animal 
pregnancy [275-277]. Other suggested key mediators include oestrogens, prostaglandins (particularly 
prostacyclin) and relaxin [33, 34, 278, 279]. Additionally, progesterone has also been implicated in 
the regulation of vascular tone, via locally produced NO [280]. 
Oestrogen is thought to exert protective effects on the vasculature through vasorelaxation; largely 
mediated by the generation of NO via modulation of eNOS through both genomic and non-genomic 
pathways [281], and by stimulation of hydrogen sulphide which induces vasodilation through the 
activation of protein kinase G (PKG) [282]. However, oestrogen may play a more important role in 
specific vascular relaxation and function in reproductive tissues [31, 283, 284]. Rosenfeld and Roy 
saw that exogenous oestradiol-17β led to a 79% decrease in ovine uterine vascular resistance and a 3-
fold increase in uterine blood flow which did not result in a change in MAP [284]; although this may 
have been due to the compensatory increase in HR.   
Furthermore, as haemodynamic changes in pregnancy are temporally defined, it has been suggested 
that because peripheral vasodilation occurs before placentation is complete this may be responsible 
for the fall in MAP. Chapman et al., proposed that maternal factors, possibly related to changes in 
ovarian function or extended function of the corpora lutea, are responsible for the initial peripheral 
vasodilation found in human pregnancy [265]. Studies in rodents have also shown that haemodynamic 
changes in pregnancy occur early without the contribution of the fetus or placenta, and this can be 
mimicked in pseudopregnancy [285].   
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Interestingly, decreased activity did not correlate with a decrease in HR. This is likely to be due to the 
overriding effects of maternal cardiovascular adaptation and changes in peripheral resistance. 
Moreover, in human pregnancy, maternal HR measured during physical activity was found to be 
lower than in post-partum controls [286]. This finding supports the concept that HR during pregnancy 
is less likely to be affected by activity level and more so by prevailing changes to vascular resistance 
and blood volume. 
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Chapter 4: The Response to Lipopolysaccharide-Induced 
Inflammation in Non-Pregnant and Pregnant Mice  
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4.1 Introduction 
Once the normal haemodynamic profile of CD1 mouse throughout gestation was established, the next 
step was to evaluate the haemodynamic response to LPS-induced inflammation in pregnancy. It is 
well established that LPS administration in rodents causes marked hypotension. Yamashita et al., 
showed that 80mg/kg i.p. LPS, a dose shown to cause >90% mortality in WT (C57bl/6) male mice, 
triggered a severe and progressive drop in MAP, where blood pressure fell to ~60 mmHg equalling a 
40% reduction from pre-treatment values [287]. Lower doses of LPS have also induced marked 
hypotension in WT mice over 6-12 hours using 40mg/kg, 10mg/kg and 3mg/kg i.p. respectively [288-
290]. This effect has also been demonstrated in rats where a 5mg/kg intravenous dose of LPS led to a 
significant and sustained drop in MAP as early as 90 minutes post-administration [291, 292]. These 
haemodynamic responses were also associated with increased iNOS expression in the lung, as well as 
increased plasma levels of nitrates and pro-inflammatory cytokines.  
Similar effects have also been seen in humans, where LPS induces a hypotensive response, associated 
with an increase in circulating cytokines. Interestingly, humans are more sensitive to the effects of 
LPS, requiring much smaller doses to achieve similar cytokine responses when compared to studies in 
rodents [293, 294]. There appears to be a dimorphism in the response to LPS with several studies 
showing that females are more resistant [295-297]. However, this is not consistent across all studies, 
as work by Van Eijk et al., showed that females had a greater pro-inflammatory response to LPS in 
terms of a higher rise in C-reactive protein, more leukocyte sequestration and a more pronounced drop 
in blood pressure [298].  
Although sex-steroid dependent modulation of the immune function in mammals is widely accepted, 
very few experiments have assessed the differences between the male and female murine response to 
systemic LPS. Female mice appear to be more resistant to LPS-induced inflammation as shown by the 
resistance to intra-tracheal administration of LPS in females, when the same dose in male mice results 
in increased albumin leakage, increased IL-1β and TNF-α levels in bronchoalveolar lavage (BAL) 
fluid, and airway hyperresponsiveness [299, 300]. These findings were independent of strain. 
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Additionally, several groups have demonstrated that oestrogen administration in animal models of 
trauma-haemorrhage can restore altered immune function and rescue adverse outcomes via prevention 
of androgen-induced immunosuppression [301, 302].  
The administration of LPS has also been widely used in pregnant mice to model PTL [303]. 
Intraperitoneal administration of LPS provokes preterm delivery in pregnant females, often with 
marked maternal morbidity and even mortality [304-307]. However, more recent models have moved 
towards using the intrauterine route of administration to more closely approximate localised 
inflammation in order to allow for the investigation of specific PTL signal transduction pathways 
[252]. Furthermore, due to maternal morbidity, the i.p. route is thought to more closely resemble 
systemic maternal sepsis, including pyelonephritis or overwhelming pneumonia. Therefore, although 
the effects of pre-natal LPS on fetal cerebral hypoxia, brain injury and offspring haemodynamics have 
been previously investigated in both ovine and rodent models [308-311]; the effects of LPS-induced 
inflammation on maternal haemodynamics are not well understood. 
In summary, being female appears to be protective in the context of inflammation and the response to 
LPS. However, it appears that pregnancy may reverse this and potentially exacerbate the response to 
LPS.  
4.1.1 Aims and Objectives 
The following studies were undertaken to test the hypotheses that infection and inflammation in 
pregnancy have a more marked effect on haemodynamic parameters than in non-pregnant animals, 
and that pregnancy is associated with an altered inflammatory response to LPS. Therefore, using 
telemetry, maternal haemodynamics were studied in both non-pregnant and pregnant populations after 
systemic administration of LPS. This novel application of telemetry in pregnant mice combined with 
the systemic LPS model of PTL aimed to optimise the information gained and reduce the numbers of 
animals needed, thus refining current models. Additionally, the inflammatory response was 
investigated by examining cytokine profiles of non-pregnant and pregnant mice after LPS exposure.   
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4.2 Results 
4.2.1 Maternal Systemic LPS Administration  
To enable an investigation into the changes in maternal haemodynamics in response to inflammation, 
an alternative to PTL model previously set up in our group which used LPS given via the intrauterine 
route, needed to be established. The intraperitoneal route was chosen as it was less invasive than 
intrauterine administration, could be used subsequent to telemetry probe implantation surgery and is 
thought to be a more representative model of systemic maternal sepsis.  
A dose response curve was constructed to examine the effects of intraperitoneal administration of LPS 
(serotype O111:B4, Sigma) injected on E16, where measured outcomes were maternal morbidity and 
mortality, latency to labour and pup survival (Figure 4.1, Table 4.1). Pup survival was reported as the 
mean percentage survival for each litter. All mice injected with phosphate buffered saline (PBS) i.p. 
(vehicle control) carried their pregnancies to term and delivered 57.2 ± 6.6 hours post injection. Over 
90% of these control litters survived to 3 days post-partum (3DPP), the chosen endpoint to assess 
survival. In subsequent experiments, 100% of litters born to PBS-treated dams survived labour. After 
the i.p. administration of 5µg LPS, latency to labour was reduced to 29.9 ± 2.6 hours (p>0.05). The 
i.p. administration of 10μg LPS led to a significant reduction in latency to labour to 23.07 ± 2.07 
hours (p<0.01) accompanied by 18.8 ± 16.43% pup survival. At 15μg and 20μg LPS, both latency to 
labour and pup survival were highly variable. Maternal mortality was observed in a least one mouse 
when doses of 20μg LPS or higher were used (Table 4.1); for this reason, fewer animals were subject 
to high doses of LPS. 
Due to consistent effects on (i) the interval to preterm delivery (significantly reduced latency to labour 
after injection), (ii) pup survival and (iii) maternal mortality, 10μg per dam LPS was chosen as the 
appropriate dose for all subsequent experiments.  
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Figure 4.1: Dose response to intraperitoneal administration of LPS in CD1 mice. Intraperitoneal LPS or 
PBS (100µL) used as a vehicle control were administered on E16 of gestation between 8-10am. Both labour 
time (left y axis) and pup survival (right y axis) are reported. **p<0.01 compared to PBS control, Kruskal-
Wallis followed by Dunn’s multiple comparison test. Data shown as mean ± SEM (n=1-7; see Table 4.1).  
 
 
Table 4.1: Summary of LPS dose response outcomes. Table describing mean labour times (hours), pup 
survival (% litter that survived labour) and number of animals that received each LPS dose. *Maternal mortality 
was observed in at least one mouse that received doses of 20µg LPS or higher.  
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 4.2.2 The Haemodynamic Response to LPS-induced Inflammation in Non-Pregnant and Pregnant 
Mice 
4.2.2.1 The Effect of LPS-induced Inflammation on Labour Time and Pup Survival 
In the subsequent study of maternal haemodynamics, latency to labour was recorded in telemetered 
animals after systemic 10μg LPS or PBS (vehicle control) administration. In these mice, 10μg LPS 
reliably and significantly reduced latency to labour from 48.63 ± 6.1 hours to 19.31 ± 1.3 hours 
(p<0.01; Figure 4.2A). In a separate experiment, where tissue was taken at intermediate time points (6 
and 12 hours post-LPS/PBS) and at the time of labour in telemetered animals, pup survival was 
recorded. In PBS-treated dams, there was 100% pup survival at 6 hours and 12 hours post-i.p., and at 
the time of labour (Figure 4.2B). Pups that were born to telemetered dams who laboured survived for 
at least 3 days until schedule 1. At 6 hours post-LPS, 70.4 ± 18.1% of pups survived which then 
decreased to 39.1 ± 16%, although this was not significant. Unlike the pup survival recorded in the 
dose-response (Figure 4.1), there was no pup survival at the time of labour. 
Figure 4.2: Latency to labour and pup survival in CD1 mice administered 10µg LPS or vehicle. (A) 
Latency to labour (time from LPS/PBS until labour) was observed in telemetered animals. *p<0.01 student’s t-
test (n=4). (B) Pup survival was recorded in those animals used for tissue collection at 6 and 12 hour time points 
or in telemetered animals (labour) after LPS/PBS (Labour, n=4; 6HR, 12HR, n=7).   
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4.2.2.2 The Effect of LPS-induced Inflammation on Maternal Haemodynamics 
The haemodynamic response of pregnant mice to LPS administration was observed to be significantly 
different to the haemodynamic response in non-pregnant controls (p<0.05; Figure 4.3). After i.p. 
administration of 10µg LPS in non-pregnant mice, MAP remained stable for approximately 15 hours 
before peaking at ∆30.9 ± 5.8 mmHg at 21 hours post-LPS when compared to PBS-treated controls 
(Figure 4.3). Conversely, in pregnant mice MAP gradually declined after LPS administration before 
reaching a plateau at approximately 12 hours post-LPS. This resulted in a nadir of ∆-38.3 ± 12.67 
compared to PBS-treated controls at 18 hours post-LPS. To compare the overall response between 
non-pregnant and pregnant mice to LPS, the trajectory of haemodynamic change was compared over 
the 24 hour period using mixed models statistics for longitudinal data. The overall difference in the 
response to LPS in MAP between non-pregnant and pregnant mice, allowing for any baseline 
differences, was significant (p<0.05). These statistical analyses are summarised in Table 4.2.  
The maximum increase in ∆MAP was also significantly lower in pregnancy, ∆35.26 ±5.3 mmHg in 
non-pregnant mice vs. ∆-4.67 ± 15.4 mmHg in pregnant mice (p<0.05, Figure 4.3B). There was a 
drop from a maximum decrease in ∆MAP from ∆-19.24 ± 5.3 mmHg in non-pregnant mice to ∆-41.84 
± 11.9 mmHg in pregnant mice, but this did not reach statistical significance. 
The same trend was also observed in the SAP and DAP recorded in non-pregnant and pregnant mice 
after LPS administration, although the overall ∆SAP and ∆DAP did not reach statistical significance. 
However, the maximum increase in ∆SAP and ∆DAP were significantly lower in pregnancy (p<0.05 
and p<0.01 respectively; Figure 4.4B, 4.4D).  
In both pregnant and non-pregnant mice, heart rate remained stable over the 24 hour period after LPS 
administration and did not significantly differ from HR in PBS-treated mice (data not shown). 
Furthermore, there were no significant differences in maximum change in HR between PBS- and LPS 
treated mice (Figure 4.4E). 
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Figure 4.3: The haemodynamic response to LPS-induced inflammation in pregnant CD1 mice. The 
haemodynamic response was recorded in pregnant and non-pregnant female CD1 mice for 24 hours following 
LPS administration (on E16 in pregnant mice). (A) ΔMAP in LPS-treated mice compared to PBS controls. Data 
are expressed as a mean change from pre-LPS baseline (pre) compared to PBS controls ± SEM (n=4-5). (B) 
Maximum increase in MAP and (C) maximum decrease in MAP, observed during the 24 hours period. *P<0.05 
student’s t-test. Data are expressed as mean ± SEM (Pregnant, n=4; Non-pregnant, n=5).  
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Figure 4.4: The haemodynamic response to LPS-induced inflammation in pregnant CD1 mice as assessed 
by maximum decrease and maximum increase. The haemodynamic response in pregnant and non-pregnant 
CD1 mice recorded during the period 24-hours after LPS administration. Maximum decrease was calculated for 
SAP (A), DAP (C) and HR (E). Maximum increase was calculated for SAP (B), DAP (D) and HR (F). *p<0.05, 
**p<0.01, student’s t-test. Data are expressed as mean ± SEM (Pregnant, n=4; Non-pregnant, n=5). 
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Table 4.2: Treatment group comparisons between pregnant and non-pregnant haemodynamic responses to LPS. The overall trajectory of haemodynamic 
responses recorded over the 24 hour period after LPS (or PBS control) was compared between pregnant and non-pregnant CD1 mice (overall). Comparisons at 1 
hour, 12 hours and 24 hours were also made. The p-values are shown in this table. NP PBS- non-pregnant PBS-treated, NP LPS – non-pregnant LPS-treated, 
E16 PBS- pregnant PBS-treated, E16 LPS- pregnant LPS-treated, ns- not significant. 
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4.2.2.3 The Effect of LPS-induced Inflammation on Maternal Activity 
There were no statistically significant changes in the overall trajectory of ∆%TSI, ∆Activity or 
∆Activity>0 between LPS-treated pregnant mice when compared to non-pregnant controls (Figure 
4.5; Table 4.3).  
In non-pregnant animals, compared to PBS-treated controls, LPS caused a significant increase in 
∆%TSI (p<0.001) accompanied by a significant decrease in ∆Activity (p<0.001) and ∆Activity>0 
(p<0.001). Conversely, in pregnant animals LPS did not cause any significant changes in activity 
parameters compared to PBS-treated controls (Table 4.3). As administration of 10µg LPS led to 
preterm birth in pregnant mice, it could be that in preparation for this event nesting behaviours 
prevented the LPS-treated mice from remaining sedentary. All statistical analyses are summarised in 
Table 4.3. 
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Figure 4.5: Activity in pregnant and non-pregnant CD1 mice after LPS administration. Activity levels in 
pregnant and non-pregnant mice were recorded for 24-hours following LPS administration (on E16 in pregnant 
mice). (A) Δ%TSI (B) ΔActivity (C) ΔActivity>0. Data are expressed as a mean change from pre-LPS baseline 
(pre) compared to PBS controls ± SEM (Pregnant, n=4; Non-pregnant, n=5).   
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Table 4.3: Treatment group comparisons between pregnant and non-pregnant activity in response to LPS. The overall trajectory of activity was recorded 
over the 24 hour period after LPS (or PBS control) was compared between pregnant and non-pregnant CD1 mice (overall). Comparisons at 1 hour, 12 hours and 24 
hours were also made. The p-values are shown in this table. NP PBS- non-pregnant PBS-treated, NP LPS – non-pregnant LPS-treated, E16 PBS- pregnant PBS-
treated, E16 LPS- pregnant LPS-treated, ns- not significant. 
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4.2.3 LPS-induced Cytokine and Chemokine Production in Non-Pregnant and Pregnant Mice 
Absolute concentrations of cytokines and chemokines in serum from pregnant and non-pregnant mice 
6 and 12 hours after LPS/PBS were measured using the Millipore MAGpix multiplex assay system to 
evaluate the systemic inflammatory response. The 12 hour time point was chosen as the plateau in 
MAP was reached at a 12 hours post-LPS injection, and consequently 6 hours was chosen as an 
intermediary time point. 
There was a marked increase in the concentrations of all of the pro-inflammatory cytokines examined 
in those mice treated with LPS compared to the corresponding time point PBS control (Figure 4.6). 
IL-1β and IL-6 and TNF-α increases were sustained over both 6 and 12 hours (Figure 4.6B, 4.6C and 
4.6D). None of the pro-inflammatory cytokines were observed to be different in response to LPS in 
pregnant mice compared to non-pregnant mice.   
There were also increases observed in the circulating levels of the anti-inflammatory cytokines IL-4 
and IL-10 after stimulation with LPS (Figure 4.7). IL-4 was only significantly increased in pregnant 
mice, 12 hours post-LPS (p<0.05, Figure 4.7A). However, IL-10 was increased at both 6 and 12 hours 
following LPS administration in both non-pregnant and pregnant mice (Figure 4.7B).  
The levels of several chemokines were also examined in serum from non-pregnant and pregnant mice 
(Figure 4.8). CCL2 (Figure 4.8A), CCL5 (Figure 4.8C), CXCL1 (Figure 4.8D) and CXCL2 (Figure 
4.8E) were all significantly increased following LPS. CCL3 (Figure 4.8B) was significantly elevated 
6 hours after LPS in non-pregnant mice from 75.01 ± 2.04 pg/mL to 286.2 ± 108.2 pg/mL (p<0.01). 
Interestingly though, CCL3 did not increase above basal levels (PBS-treatment) in the pregnant mice 
after LPS. Consequently, at 6 hours there was less CCL3 in LPS-treated pregnant mice than in non-
pregnant controls (p<0.001).  
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Figure 4.6: Circulating concentrations of pro-inflammatory cytokines in serum of non-pregnant and 
pregnant mice treated with LPS or vehicle. (A) IL-1α (B) IL-1β (C) IL-6 (D) TNF-α. *p<0.05, **p<0.01, 
***p<0.001 compared to vehicle control, pairwise t-test comparisons or Mann Whitney U tests were used where 
appropriate. Data shown as mean ± SEM (LPS groups, n=6; PBS groups, n=4). NP- non-pregnant; E16-
pregnant. 
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Figure 4.7: Circulating concentrations of anti-inflammatory cytokines in serum of non-pregnant and 
pregnant mice treated with LPS or vehicle. (A) IL-4 (B) IL-10. *p<0.05, **p<0.01 compared to vehicle 
control unless otherwise indicated, pairwise t-test comparisons or Mann Whitney U tests were used where 
appropriate. Data shown as mean ± SEM (LPS groups, n=6; PBS groups, n=4). NP- non-pregnant; E16-
pregnant. 
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Figure 4.8: Circulating concentrations of chemokines in serum of non-pregnant and pregnant mice 
treated with LPS or vehicle. (A) CCL2 (B) CCL3 (C) CCL5 (D) CXCL1 (E) CXCL2. *p<0.05, **p<0.01, 
***p<0.001 compared to vehicle control unless otherwise indicated, pairwise t-test comparisons or Mann 
Whitney U tests were used where appropriate. Data shown as mean ± SEM (LPS groups, n=6; PBS groups, 
n=4). NP- non-pregnant; E16-pregnant.  
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4.2.4 Circulating and Cardiac Expression of Vasoactive Factors in Response to LPS in Non-Pregnant 
and Pregnant Mice 
NO, cGMP and ADMA concentrations in serum from pregnant and non-pregnant mice 6 and 12 hours 
after LPS/PBS were determined using the Sievers nitric oxide analyser, ELISA and mass 
spectrometry respectively. Absolute concentrations of vasoactive factors in serum from pregnant and 
non-pregnant mice 6 and 12 hours after LPS/PBS were measured using the Millipore MAGpix 
multiplex assay system to evaluate the systemic response. In addition, these factors were also 
analysed in whole heart homogenate to determine the local response. As the heart is an extremely 
vascular tissue, it was suggested that the presence or dysregulation of vasoactive factors here may 
indicate the response in systemic vascular beds.  
At E16, circulating NO concentrations were not significantly different from non-pregnant controls 
(Figure 4.9A; 55.84 ± 12.43 μM and 54.2 ± 7.86 μM respectively at 6 hours). At 6 and 12 hours after 
LPS administration, NO was significantly increased in both non-pregnant and pregnant mice (p<0.05). 
However, at 6 hours post-LPS this effect was significantly attenuated in pregnant animals compared 
to non-pregnant (108.1 ± 13.51 μM and 191.1 ± 33.42 μM respectively, p<0.05). This result was 
surprising, and whilst initial thoughts were that NO concentrations may have been diluted due to an 
increased plasma volume in pregnant mice, when results were normalised to plasma volume (135% of 
non-pregnant mice; data not shown), NO levels in pregnant mice after LPS remained significantly 
reduced. These results could reflect increased sensitivity of pregnant mice to NO. 
As many actions of NO are mediated by the downstream signalling molecule cGMP, we hypothesised 
that cGMP levels could be altered in pregnancy. cGMP was not found to be significantly increased in 
any of the groups treated with LPS. However, cGMP levels in pregnant mice 6 hours after vehicle 
(PBS) injection were increased compared to non-pregnant controls (p<0.05). This effect was not seen 
at 12 hours (Figure 4.9B). The endogenous inhibitor of NO, ADMA, was found to be increased in 
non-pregnant LPS treated animals at 6 hours (p<0.05), but no increase was observed in pregnant 
animals (Figure 4.9C).   
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Figure 4.9: Nitric oxide, cGMP and ADMA measurements in serum of non-pregnant and pregnant mice 
treated with LPS or vehicle. (A) Concentration of total nitrates and nitrites (NOx) in serum samples taken 6 or 
12 hours after LPS or PBS treatment in non-pregnant or pregnant mice. Values were adjusted to account for 
plasma volume. *p<0.05 pairwise analysis using student’s t-test when compared to PBS control unless 
otherwise indicated. Data are shown as mean ± SEM (LPS groups, n=6; PBS groups, n=4). (B) cGMP levels in 
serum samples taken 6 or 12 hours after LPS or PBS treatment in NP or E16 mice. *p<0.05 pairwise analysis 
using student’s t-test (LPS groups, n=8; PBS groups, n=4). (C) ADMA concentrations in serum samples taken 6 
or 12 hours after LPS or PBS treatment in NP or E16 mice. *p<0.05 Mann-Whitney U test (LPS groups, n=8; 
PBS groups, n=4). NP- non-pregnant; E16-pregnant. 
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Circulating concentrations of VEGF-A (VEGF) were significantly increased at both 6 and 12 hours 
post-LPS in non-pregnant mice: 134.2 ± 51.82 pg/mL and 118.9 ± 31.3 pg/mL at 6 and 12 hours 
respectively up from 13.04 ± 1.04 pg/mL and 14.03 ± 2.7 pg/mL (p<0.05); this effect was almost 
completely abolished in pregnant mice (p<0.05; Figure 4.10A). Thus, in pregnant mice, LPS did not 
cause any increase in VEGF. 
PLGF, a member of the VEGF family, is classically recognised as a pregnancy-related vasoactive 
factor due to its main site of production being the placental trophoblast [312]. However, there has 
been recent interest around its potential role in sepsis in non-pregnant animals [313, 314].  PLGF2 
was increased in non-pregnant mice after LPS, significantly at 12 hours (p<0.001; Figure 4.10B). In 
pregnant mice, LPS did not cause any increase in PLGF2 and at 12 hours the response was very 
significantly attenuated compared to non-pregnant controls (p<0.001). The functional counterpart of 
NO in vascular function, endothelin-1 (ET-1) was found to be significantly decreased in pregnant 
mouse serum compared to non-pregnant, in both PBS and LPS-treated mice, although this was only 
statistically significant at the 6 hour time point (p<0.05 and p<0.01 respectively; Figure 4.10C). LPS 
did not cause any significant changes in ET-1 concentrations in non-pregnant mice, when compared to 
PBS-treated controls.  
To further explore the PLGF response in view of the finding that PLGF levels were increased 
following LPS in the serum of non-pregnant mice compared to pregnant, serum taken from mice at 
gestational time points was examined using a PLGF2 ELISA to determine the normal PLGF profile 
throughout CD1 mouse pregnancy (Figure 4.11). Concentrations of PLGF2 were seen to rise through 
early pregnancy to reach a peak at approximately E11 (333.5 ± 35.79 pg/mL) before dropping again 
by E16 (101.1 ± 26.54 pg/mL) to levels similar to those seen in non-pregnant mice (95.06 ± 17.3 
pg/mL). At E18, there was a large variability in PLGF2 levels (Figure 4.11A). This may possibly be 
due to the proximity of the progression of labour which may have fallen either on late E18 or early 
E19. Recent evidence has suggested that PLGF could play a role in the mediation of pro-
inflammatory and pro-labour actions in mouse uterus [315], human cervix and placenta [316, 317]. 
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PLGF2 levels then consistently fell to below non-pregnant levels in lactating post-partum mice (1.02 
± 1 pg/mL). This may be due to the anti-angiogenic effects of prolactin [318-320]. Circulating 
concentrations as determined by MAGpix multiplex assay and PLGF2 ELISA in untreated and PBS-
treated CD1 mice at E16 were comparable (107.2 ± 16.97 pg/mL and 101.1 ± 26.54 pg/mL 
respectively). 
  
Figure 4.10: Circulating concentrations of vasoactive factors in serum of non-pregnant and pregnant 
mice treated with LPS or vehicle. (A) VEGF (B) PLGF2 (C) Endothelin-1. *p<0.05, **p<0.01, ***p<0.001 
compared to vehicle control unless otherwise indicated, pairwise t-test comparisons or Mann Whitney U tests 
were used where appropriate. Data shown as mean ± SEM (LPS groups, n=8; PBS groups, n=4). NP- non-
pregnant; E16-pregnant. 
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Figure 4.11: Concentrations of circulating PLGF2 measured at gestational time points in CD1 mice. 
PLGF2 as measured by ELISA at gestational time points in CD1 mice shown using data plotted as individual 
animals (A) and as a PLGF2 profile during pregnancy, data shown as mean ± SEM and LOWESS curve (B) 
(NP, n=3; E6, n=6; E11, n=5; E16, n=4; E18, n=7; 36h PP, n=4). NP – non-pregnant; E6 – gestational day 6; 
E11 – gestational day 11; E16 – gestational day 16; E18 – gestational day 18; 36h PP – 36 hours post-partum. 
 
In whole heart homogenate, PLGF2 was increased in both non-pregnant and pregnant groups treated 
with LPS (p<0.01; Figure 4.12B). Concentrations of ET-1 remain unchanged between non-pregnant 
and pregnant, and between PBS- and LPS-treated mice (Figure 4.12C). Overall ET-1 concentrations 
in the heart were greater than those observed in the serum.  
There was a trend observed where VEGF was decreased in PBS-treated mice 12 hours following 
injection compared to 6 hours in both non-pregnant and pregnant mice (Figure 4.12A), however this 
did not reach significance. This may indicate that the intraperitoneal injection itself may trigger 
increases in VEGF in the heart, but this speculation would need to be addressed by examining VEGF 
levels in naïve mice. Due to lower concentrations of VEGF in PBS-treated non-pregnant mice at 6 
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hours, this resulted in a significant increase after LPS at this time point alone. Absolute VEGF 
concentrations in the heart were also greater in PBS control mice than those observed in the serum.  
To further investigate the serum VEGF response disparity in non-pregnant and pregnant mice, several 
VEGF isoforms were measured in serum and heart. It was found that VEGF-C was not significantly 
increased in any treatment group following LPS in the serum (Figure 4.13A). Although, pregnant 
mice had significantly lower VEGF-C concentrations at 12 hours after LPS than non-pregnant mice 
12 hours after LPS (p<0.05), this was not significantly reduced from PBS control. VEGF-C in the 
heart and VEGF-D in both serum and the heart remained at consistent levels in all treatment groups 
(Figure 4.13B, Figure 4.13C, Figure 4.13D).        
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Figure 4.12: Local concentrations of vasoactive factors in hearts taken from non-pregnant and pregnant 
mice treated with LPS or vehicle. (A) VEGF (B) PLGF2 (C) Endothelin-1. **p<0.01 compared to vehicle 
control unless otherwise indicated, pairwise t-test comparisons or Mann Whitney U tests were used where 
appropriate. Data shown as mean ± SEM (LPS groups, n=6; PBS groups, n=4). NP- non-pregnant; E16-
pregnant. 
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Figure 4.13: Circulating and localised concentrations of VEGF isoforms in serum and hearts taken from 
non-pregnant and pregnant mice treated with LPS or vehicle. (A) VEGF-C in serum (B) VEGF-D in serum 
(C) VEGF-C in heart (D) VEGF-D in heart. *p<0.05, pairwise t-test comparisons or Mann Whitney U tests were 
used where appropriate. Data shown as mean ± SEM (LPS groups, n=6; PBS groups, n=4). NP- non-pregnant; 
E16-pregnant. 
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4.2.5 LPS-induced Changes in Vascular Function in Non-Pregnant and Pregnant Mice 
Despite the observed decline in MAP in pregnant mice in response to LPS, concentrations of 
circulating NO and VEGF were found to be attenuated in comparison to non-pregnant mice. It was 
hypothesised that this may be due to an increased sensitivity of the pregnant vasculature to the 
vasodilator action of NO. To further investigate this, vascular reactivity and vessel relaxation were 
examined using wire myography in both aorta (Figure 4.14) and uterine artery (Figure 4.15).  
4.2.5.1 Aorta  
Isolated aortic vessel sections were exposed to increasing doses of phenylephrine (PE) and the 
contractile response was recorded (Figure 4.14A, 4.14B). LogEC50 values for PE were -3.84 M in 
non-pregnant and -3.19 M in pregnant mice (p<0.01). Vessel responses were significantly different at 
log[PE] -4 M and log[PE] -3.5 M as determined by Bonferroni post-tests. After LPS treatment, 
logEC50 values for PE were -3.8 M for non-pregnant and -3.6 M for pregnant (p<0.05). The maximal 
contractions elicited by PE were the same in all treatment groups.      
To test endothelial cell responsiveness to acetylcholine (ACh), vessels were first sub-maximally 
contracted with PE where the EC80 was used to yield an 80% contraction. There was no differential 
response to ACh in pregnant animals compared to non-pregnant (Figure 4.14C). When the response to 
ACh in PBS- and LPS-treated non-pregnant groups was compared, LPS was shown to significantly 
reduce vessel sensitivity (p<0.001, data not shown). However, when non-pregnant and pregnant 
groups after LPS administration were compared, the response in pregnant aorta was significantly 
decreased (p<0.01; Figure 4.14D). Because the data collected in response to ACh could not define a 
top and bottom plateau, EC50 values could not be calculated.  
To investigate whether smooth muscle NO signalling is altered in pregnancy, an NO donor sodium 
nitroprusside (SNP) was used to relax vessels after initial pre-constriction with PE (EC80). In both 
PBS- and LPS-treated groups, vessels from pregnant mice were significantly less responsive to SNP 
(p<0.05 and p<0.001 respectively; Figure 4.14E, 4.14F).   
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Figure 4.14: Ex–vivo measurement of aortic endothelial responses in non-pregnant and pregnant mice 
treated with LPS or vehicle. Responses to (A,B) phenylephrine (PE), (C,D) acetylcholine (ACh), and (E,F) 
sodium nitroprusside (SNP) in aorta from non-pregnant (closed symbols) or pregnant (open symbols) exposed to 
PBS (vehicle; square symbols) or 10μg LPS (circular symbols) for 12 hours. **p<0.01, ***p<0.001, 2-way 
ANOVA with Bonferroni post-hoc test at specific concentrations; overall comparisons were made using a 2-way 
ANOVA with Bonferroni post-hoc test, a p<0.05, c p<0.001. Data are presented at mean ± SEM (NP PBS, n=7; 
NP LPS, n=8; E16 PBS, n=8; E16 LPS, n=7[n=5 for SNP]). NP- non-pregnant; E16-pregnant. 
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Figure 4.15: Ex–vivo measurement of uterine artery endothelial responses in non-pregnant and pregnant 
mice treated with LPS or vehicle. Responses to (A,B) phenylephrine (PE), (C,D) acetylcholine (ACh), and 
(E,F) sodium nitroprusside (SNP) in uterine artery from non-pregnant (NP; closed symbols) or pregnant (E16; 
open symbols) exposed to PBS (vehicle; square symbols) or 10μg LPS (circle symbols) for 12 hours. Overall 
comparisons were made using a 2-way ANOVA with Bonferroni post-hoc test, a p<0.05, c p<0.001. Data are 
presented at mean ± SEM (NP PBS, n=7; NP LPS, n=7; E16 PBS, n=8 [n=5 for ACh]; E16 LPS, n=8[n=5 for 
ACh and SNP]). NP-non-pregnant; E16-pregnant. 
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4.2.5.1 Uterine Artery  
To more closely examine the altered uterine vasculature in pregnancy, uterine artery vessel sections 
were exposed to increasing doses of PE and the contractile response was recorded (Figure 4.15A, 
4.15B). LogEC50 values for PE were -3.19 M in non-pregnant and -3.75 M in pregnant mice 
(p<0.001). After LPS treatment, logEC50 values for PE were -3.37 M for non-pregnant and -3.75 M 
for pregnant mice (p<0.05). The maximal contractions elicited by PE were the same in all treatment 
groups.      
After pre-constriction with PE (EC80) responses to ACh in the uterine artery were recorded. Unlike in 
the aorta, the uterine artery in pregnant animals was significantly more sensitive to ACh (p<0.001; 
Figure 4.15C). Interestingly, this effect was reversed in LPS-treated animals (p<0.05; Figure 4.15D). 
Again, after initial pre-constriction with PE (EC80) responses to SNP in the uterine artery were not 
altered in pregnancy (Figure 4.15E), and after treatment with LPS, pregnant animals had significantly 
decreased sensitivity (p<0.001; Figure 4.15F).  
Comparisons between treatment groups of both aorta and uterine artery responses to PE, ACh, and 
SNP have been summarised in Table 4.4. Analyses include comparisons between PBS- and LPS- 
treated responses in non-pregnant as well as pregnant mice.  
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Table 4.4: Summary of changes in vascular function and sensitivity to vasoactive substances. Comparisons 
were made between pregnant and non-pregnant mice in uterine artery and aorta from mice exposed to LPS or 
vehicle (PBS). P values were obtained from 2-way ANOVA analyses. NP- non-pregnant; E16-pregnant. 
 
 
 
 
 
 Aorta Uterine Artery 
E16 compared to NP 
Decreased sensitivity to PE (P<0.001) Increased sensitivity to PE (P<0.001) 
No difference in response to ACh Increased sensitivity to ACh (P<0.001) 
Decreased sensitivity to SNP (P<0.05) No difference in response to SNP  
  
E16-LPS, compared to NP-LPS 
Decreased sensitivity to PE (P<0.05) Increased sensitivity to PE (P<0.05) 
Decreased sensitivity to ACh (P<0.01) Decreased sensitivity to ACh (P<0.05) 
Decreased sensitivity to SNP (P<0.001) Decreased sensitivity to SNP (P<0.001) 
  
E16-PBS, compared to E16-LPS 
Increased sensitivity to PE (P<0.01) No difference in response to PE  
Decreased sensitivity to ACh (P<0.001) Decreased sensitivity to ACh (P<0.01) 
No difference in response to SNP  No difference in response to SNP 
  
NP-PBS, compared to NP-LPS 
No difference in response to PE No difference in response to PE 
Decreased sensitivity to ACh (P<0.001) Increased sensitivity to ACh (P<0.001) 
Increased sensitivity to SNP (P<0.01) Increased sensitivity to SNP (P<0.001) 
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4.2.6 Expression of Markers of Inflammation, Cardiac Dysfunction and Apoptosis in Non-Pregnant 
and Pregnant Mice 
To assess the extent of cardiac sensitivity, the relative expression of various markers of inflammation, 
apoptosis and cardiac dysfunction were assessed in maternal heart tissue using RT-PCR and western 
blot.   
In whole heart homogenate, IL-6 mRNA was significantly increased 6 hours after LPS treatment in 
non-pregnant mice (p<0.05), but there was no significant increase observed at 12 hours (Figure 
4.16B). The same trend was observed in pregnant mice but levels were attenuated and significance 
was not reached. TNF-α mRNA was significantly increased 6 hours after LPS treatment in both 
pregnant and non-pregnant mice (p<0.05; Figure 4.16C). Cox-2 expression was significantly 
decreased in pregnant animals 12 hours after i.p. in both LPS and PBS groups (p<0.05). There were 
no observed changes between the treatment groups for IL-1β or IL-10 (Figure 4.16A, 4.16D). 
There were no observed changes in markers of cardiac dysfunction in heart tissue after LPS treatment 
or between pregnant and non-pregnant mice (Figure 4.17). There was a trend towards increased BNF 
in pregnant mice treated with LPS at 6 hours, which was not seen at 12 hours, where comparatively in 
non-pregnant animals no increase was seen. However this observation did not reach statistical 
significance.    
B-cell Lymphoma-2 (Bcl-2) family members and other apoptotic markers were examined to assess the 
extent of apoptosis in maternal heart, compared to those of non-pregnant animals. The anti-apoptotic 
Bcl-2 mRNA remained consistently expressed over all treatment groups, however the pro-apoptotic 
marker Bcl-2 associated X protein (Bax) mRNA was shown to be increased after LPS treatment in 
non-pregnant mice (significantly increased by 12hours, p<0.05) but not in pregnant animals (Figure 
4.18B). Bcl-2 associated death promoter (Bad) and Fas ligand (FasL) were also unchanged after LPS 
and did not differ between heart tissue from pregnant and non-pregnant mice hearts (Figure 4.18C, 
4.18D).  
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Figure 4.16: mRNA expression of pro- and anti-inflammatory cytokines and inflammatory regulators in 
heart tissue taken from non-pregnant or pregnant mice treated with LPS or vehicle. (A) IL-1β, (B) IL-6, 
(C) TNF-α, (D) IL-10, and (E) Cox-2. *p<0.05 compared to PBS control unless otherwise indicated, pairwise t-
test comparisons or Mann Whitney U tests were used where appropriate. Data shown as mean ± SEM (LPS 
groups, n=6; PBS groups, n=4). NP- non-pregnant; E16-pregnant.  
A B C 
D E 
 133 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17: mRNA expression of markers of cardiac dysfunction in heart tissue taken from non-
pregnant or pregnant mice treated with LPS or vehicle.(A) Inducible nitric oxide synthase (iNOS), (B) atrial 
natriuretic peptide (ANP), (C) brain natriuretic factor (BNF), (D) α-myosin heavy chain (α-MHC), (E) β-myosin 
heavy chain (β-MHC), (F) sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), (G) phospholamban (PLN), 
(H) cardiac troponin-I and (I) homeobox gene Nkx2.5. Pairwise t-test comparisons or Mann Whitney U tests 
were used where appropriate, no statistical significance was detected. Data shown as mean ± SEM (LPS groups, 
n=6; PBS groups, n=4). NP- non-pregnant; E16-pregnant.  
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Figure 4.18: mRNA expression of pro- and anti-apoptotic markers in heart tissue taken from non-
pregnant or pregnant mice treated with LPS or vehicle. (A) Bcl-2, (B) Bax, (C) Bad and (D) Fas ligand 
(FasL). *p<0.05 compared to PBS control, pairwise t-test comparisons were performed. Data shown as mean ± 
SEM (LPS groups, n=6; PBS groups, n=4). NP- non-pregnant; E16-pregnant. 
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To further examine the effects of LPS during pregnancy on apoptotic pathways, a series of western 
blots were performed to assess the abundance of caspase-3 protein (Figure 4.19A). As caspases are 
post-transcriptionally modified it was imperative to assess caspase activity at the protein level. 
Caspase-3 is formed from pro-caspase (approximately 32kDa) that cleaves into a 17kDa subunit (p17) 
and a smaller 12/14kDa subunit (p12/14) [321, 322]. It was shown by densitometry analysis in 
maternal heart samples that there were no significant changes in expression levels of either subunit in 
pregnant or non-pregnant mice 6 hours after LPS (Figure 4.19B) or 12 hours after LPS (Figure 
4.19C). 
Due to the somewhat dampened increase in pro-inflammatory cytokines observed in response to LPS, 
it was postulated that any systemic effect may have been masked by using whole heart homogenate. 
Therefore inflammatory markers, markers of cardiac dysfunction and makers of apoptosis were also 
assessed in isolated left ventricular tissue. 
In left ventricular tissue, mRNA expression of IL-1β (Figure 4.20A), IL-6 (Figure 4.20B) and TNF-α 
(Figure 4.20C) were significantly upregulated 6 hours after LPS administration in both non-pregnant 
and pregnant mice (p<0.01). Expression levels of all pro-inflammatory cytokines were diminished by 
12 hours. IL-10 expression was significantly increased 6 hours after LPS administration, but only in 
non-pregnant mice (p<0.01; Figure 4.20D). There were no observed changes in mRNA expression of 
Cox-2 (Figure 4.20E). 
Similarly to mRNA expression levels in whole heart tissue, in left ventricular tissue there were few 
changes in markers of cardiac dysfunction. Of note, ANP was significantly decreased at 6 and 12 
hours after LPS administration in both non-pregnant and pregnant mice (p<0.01; Figure 4.21B) and 
BNF was significantly increased 6 hours after LPS administration, but only in pregnant mice 
(p<0.05); however this increase was not significantly greater than expression 6 hours after LPS in 
non-pregnant mice. Further to this, unlike in whole heart tissue there were decreases in c-Troponin-I 
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and Nkx2.5 after LPS administration (Figure 4.21H, 4.21I). These decreases became significant in 
pregnant animals (p<0.05).   
 
Figure 4.19: Expression of caspase-3 in heart tissue taken from non-pregnant or pregnant mice treated 
with LPS or vehicle. A representative western blot (A; n=6) showing p17 and p12/14 caspase-3 subunits for 
non-pregnant and pregnant heart tissue 6 hours after LPS/PBS treatment. Densitometry analysis was performed 
with ImageQuant software using GAPDH as loading control for heart tissue 6 hours after PBS/LPS (n=6) (B) 
and at 12 hours after PBS/LPS (n=6) (C). NP- non-pregnant; E16-pregnant. 
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Figure 4.20: mRNA expression of pro- and anti-inflammatory cytokines and inflammatory regulators in 
the left ventricle of non-pregnant or pregnant mice treated with LPS or vehicle. (A) IL-1β, (B) IL-6, (C) 
TNF-α, (D) IL-10 and (E) Cox-2. **p<0.01 compared to PBS control unless otherwise indicated pairwise t-test 
comparisons or Mann Whitney U tests were used where appropriate. Data shown as mean ± SEM (LPS groups, 
n=6; PBS groups, n=5). NP- non-pregnant; E16-pregnant.  
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Figure 4.21: mRNA expression of markers of cardiac dysfunction in the left ventricle of non-pregnant or 
pregnant mice treated with LPS or vehicle. (A) Inducible nitric oxide synthase (iNOS), (B) atrial naturetic 
peptide (ANP), (C) brain naturetic factor (BNF), (D) α-myosin heavy chain (α-MHC), (E) β-MHC, (F) 
sarco/endoplasmic reticulum Ca
2+
-ATPase (SERCA), (G) phospholamban (PLN), (H) cardiac troponin-I, and (I) 
homeobox gene Nkx2.5. *p<0.05, **p<0.01 compared to PBS control unless otherwise indicated, pairwise t-test 
comparisons or Mann Whitney U tests were used where appropriate. Data shown as mean ± SEM (LPS groups, 
n=6; PBS groups, n=4). NP-non-pregnant; E16-pregnant. 
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In contrast to the findings in whole heart tissue, Bcl-2 mRNA expression was significantly decreased 
in all mice treated with LPS, both at 6 and 12 hours in non-pregnant and pregnant mice (p<0.01 and 
p<0.05; Figure 4.22A). Furthermore, there were no changes observed in Bax or FasL levels (Figure 
4.22B, 4.22D), but Bad was decreased after LPS (p<0.05; Figure 4.22C). Bad was downregulated in 
both non-pregnant and pregnant mouse left ventricular tissues after LPS, but only after 12 hours in 
non-pregnant mice; however the lack of significance at 6 hours may be reflected in the wider 
variability seen in the non-pregnant 6 hour PBS control.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22: mRNA expression of pro- and anti-apoptotic markers in the left ventricle of non-pregnant or 
pregnant mice treated with LPS or vehicle. (A) Bcl-2, (B) Bax, (C) Bad, and (D) Fas ligand (FasL). *p<0.05, 
**p<0.01 compared to PBS control, pairwise t-tests comparisons or Mann Whitney U test were used where 
appropriate. Data shown as mean ± SEM (LPS groups, n=6; PBS groups, n=4). NP-non-pregnant; E16-pregnant.  
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4.2.7 LPS-induced Monocyte and Neutrophil Infiltration in Non-Pregnant and Pregnant Mice  
It is known that there is an increase in systemic inflammation in pregnancy with a rise in numbers of 
circulating monocytes, granulocytes and NK cells from the first trimester onwards [58]. Here, data 
was collected using fluorescence-activated cell sorting (FACS) flow cytometry to investigate 
leukocyte infiltration in the blood, lung and liver of non-pregnant and pregnant mice exposed to LPS 
or vehicle (PBS), specifically focussing on monocyte and neutrophil populations.  
There were significant changes in the acute response to LPS in pregnant animals compared to non-
pregnant animals (Figure 4.23). The overall trend of monocyte presence in the blood was decreased 6 
hours following LPS (compared to PBS) and then increased by 12 hours in both non-pregnant and 
pregnant mice. This likely represents the infiltration of monocytes from the blood into key tissues as 
an initial response to LPS. 
There were significantly increased numbers of monocytes in lung tissue at 6 hours in pregnant mice 
compared to non-pregnant (p<0.05; Figure 4.23C), however these changes were attenuated by 12 
hours. Accompanying this there was a decreased number neutrophils in lung in pregnant mice 
(p<0.05; Figure 4.23D). There were no changes in monocyte populations in the liver in response to 
LPS, but neutrophil infiltration was significantly reduced in pregnant mice compared to non-pregnant 
mice at 6 hours post-LPS (p<0.05; Figure 4.23F).  
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Figure 4.23: Changes in infiltrating leukocytes in response to LPS in non-pregnant and pregnant mice. 
The change in (Δ) cell counts after LPS treatment compared with vehicle controls (PBS) of both monocytes 
(MC; A, C, E) and neutrophils (PMN; B, D, E) in blood (A, B), lung (C, D) and liver (E, F) of non-pregnant or 
pregnant mice. *p<0.05, 2-way ANOVA, Bonferroni post-hoc test. Data shown as mean ± SEM (n=6). NP-non-
pregnant; E16-pregnant. 
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4.3. Summary and Discussion 
There was a marked hypotensive response to LPS in pregnant as compared to non-pregnant mice. 
Contrary to our hypothesis this was accompanied by a very similar systemic cytokine reaction, 
suggesting that the response of the innate immune system is not different in pregnancy. Further, the 
changes in levels of circulating vasoactive factors and the response of large vessels to the same 
vasoactive factors in vitro were similar in the two groups. Similarly, markers of cardiac dysfunction, 
cardiac apoptosis and cytokine levels were very similar. The most marked difference between the two 
groups was in the infiltration of the lungs, where pregnant animals had fewer neutrophils and more 
monocytes. If greater monocytic infiltration can lead to impaired arteriolar function as a result of an 
increase in inflammation and release of locally active vasoactive factors, this may contribute to the 
marked hypotension observed in pregnant animals. Taken together, these data suggest that during 
pregnancy, the cardiovascular system is more sensitive to inflammation and less able to maintain 
blood pressure in the face of an inflammatory stimulus. 
Here we have shown that 10µg LPS led to a significant hypotensive effect which reaches a nadir at 
close to 12 hours, but had no effect on the haemodynamics of non-pregnant mice. Although systemic 
administration of LPS has been show to stimulate maternal systemic inflammation with an increase in 
pro-inflammatory cytokine production in maternal serum and cardiac tissue, the systemic response 
evoked does not appear substantial enough at this early time point to account for fetal demise. A 
recent study by Girsh et al., showed that an i.p. injection of a prostaglandin (PG)-F2α analogue at E16 
caused uteroplacental vasoconstriction and placental hypoxia in pregnant rats, mediated at least in part 
by elevated placental expression of the ET-1 gene and its receptor endothelin type A receptor [323]. 
Placental hypoxia as a result of increased LPS-induced prostaglandin and cytokine production may 
therefore lead to pup death as early as 6 hours post i.p. injection in the LPS model. However 
preliminary findings in the group (experiments conducted by MSc project student Miss Stephanie 
Dowle) have shown that LPS did not evoke any significant changes in the placental gene expression 
of several markers of hypoxia including peroxisome proliferator-activated receptor-γ (PPAR-γ), 
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peroxisome proliferator-activated receptor-γ coactivator-1-α (PGC1-α), glucose transporter 1 
(GLUT1), or heat shock protein 70 (Hsp70), or in the expression of ET-1, eNOS or VEGF. There 
were also no significant differences in placental NO and ADMA after LPS i.p. [324]. These results 
imply that the fetal demise observed after LPS is not likely to be due to placental hypoxia and 
insufficiency; however this observation may be dependent on the timing of the investigation. Another 
explanation proposed by Silver et al, is that pup death could be caused by a LPS-induced maternal 
inflammatory response rather than a direct fetal one [305, 325]. They showed that a high dose of 1mg 
LPS led to no pup death in hypo-responsive dams (C3H/HeJ strain which are LPS resistant, thought to 
be primarily conferred by an LPS-specific impairment in TNF-α transcription and translation), and 
that co-administration of TNF-α could restore abortifacient activity and resulted in 65% fetal death; 
thus demonstrating a causal role for TNF-α possibly via the elaboration of prostaglandins (as 
demonstrated in vitro by Casey et al.,) or an ischemia and haemorrhagic necrosis in the decidua and 
trophoblast [325, 326]. 
In a recent study by Cotechini et al., low dose LPS was administered to pregnant rats on E13.5 
followed by four high doses of LPS daily until E16.5 which resulted in increased MAP compared to 
vehicle controls. Non-pregnant rats given LPS on four separate occasions also demonstrated elevated 
MAP, but only after the second LPS injection. It was also noted that the LPS-induced increase in 
MAP was of a lower magnitude in non-pregnant rats. The authors postulate that the increases in MAP 
after LPS were the result of an inflammatory response triggered by LPS, namely an exaggerated 
TNF-α response as a consequence of an inadequately perfused placenta. This suggestion was 
supported by the observation that LPS did not cause an exaggerated inflammatory response in non-
pregnant rats [327]. This seems contradictory to our results, as LPS administration in pregnant CD1 
mice resulted in a marked hypotensive effect. However, as Cotechini et al., delivered LPS to pregnant 
rats at an earlier time point in their pregnancy, and measured the response to LPS until 7 days post-
partum, the pregnancy-related haemodynamic adaptations that would occur in normal pregnancy may 
have obscured the acute response to LPS. Thus, the immediate effect seen in the 24 hour period after 
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the initial dose of LPS in these rats was a decrease in MAP. Furthermore, as discussed above it seems 
unlikely that the results observed here are directly due to placental insufficiency and under-perfusion, 
however additional studies would be necessary to investigate this further.  
In addition to an LPS-induced hypotension, pregnancy also conferred changes in activity after LPS 
administration. When compared to vehicle controls, non-pregnant animals treated with LPS spent 
more time inactive than pregnant animals treated with LPS. This may seem counter-intuitive when the 
LPS-treated pregnant animals were seen to have a greater hypotensive response to LPS indicating an 
increased sensitivity. However, as LPS administration led to PTL in the pregnant animals, the 
instinctive nature of these mice to create an environment for their offspring meant that nesting 
behaviours may have overridden the effects of LPS.   
When the inflammatory response to LPS was investigated with the aim to determine any differences 
between the response in non-pregnant and pregnant mice after LPS exposure, it was observed that the 
circulating levels of pro- and anti-inflammatory cytokines and chemokines were increased in both 
groups after LPS with the exception of CCL3 and IL-4. CCL3 was found to be increased 6 hours after 
LPS administration in non-pregnant mice where IL-4 was higher in pregnant mice. This contrasts to 
the only other study to compare the response to LPS in non-pregnant and pregnant mice, where 
increases were observed for IL-6, IFN-γ and a reduction was observed in IL-10 in pregnant mice. 
These changes were associated with a greater mortality in pregnant mice and consequently the authors 
concluded that the greater cytokine response to LPS might explain the increased severity of some 
maternal diseases, including septic shock [328]. It must be considered that one explanation for the 
discrepancy may lie in that the dose of LPS used by Vizi et al., was much greater than used here, 
1.6mg, compared with 10µg, and the serotype was not stated, meaning that it is difficult to make 
comparisons between the responses in the two studies. However, it seems likely that the potency of 
the LPS used was much greater, as they experienced a 75% maternal mortality [328]. 
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In the current study, the circulating levels of ET-1 were not affected by LPS, consequently although 
they were higher in non-pregnant mice it is unlikely that ET-1 is solely responsible for the lower 
blood pressure observed in the pregnant animals. This conclusion is supported by a study by Iskit et 
al., that showed in a mouse model of sepsis using CLP, the endothelin antagonist, bosentan, improved 
the outcome [329], suggesting that endothelin may play an active role in the outcome of sepsis.  
Following the observation that LPS administration led to hypotension in pregnant mice, it was 
hypothesised that this hypotension may be caused by a greater release of NO, as a critical role for NO 
has been demonstrated in septic shock [330, 331] and pregnancy is associated with higher NO levels 
[332]. Intriguingly, although LPS administration in this study was associated with a marked increase 
in NO, the increase was actually reduced in pregnant mice. Similarly, the levels of VEGF increased in 
the non-pregnant mice and were greater than those in the pregnant mice at both time points. The 
changes in NO and VEGF would be expected to result in a greater fall in blood pressure in the non-
pregnant mice, again in contrast to the observations presented in this chapter. 
One explanation may be that the vasodilation occurring during LPS-induced hypotension may lead to 
the increased oxygenation of tissues in pregnant mice, and thus in turn lead to a decrease in VEGF 
expression levels as part of a negative feedback loop. However, a decrease in VEGF in the maternal 
circulation was not paralleled in maternal heart tissue, where expression levels were similar to those 
in non-pregnant mice.  
To investigate the hypothesis that pregnancy confers an increased vascular sensitivity to NO, we 
observed the responses of both non-pregnant and pregnant vessels to PE, ACh and SNP after 
treatment with LPS or vehicle. As pregnancy is associated with substantial increases in blood flow in 
the uterine artery, both aorta and uterine artery were used. The main findings from this particular 
experiment were that pregnancy conferred greater sensitivity to ACh in uterine arteries, albeit not in 
aorta. After LPS administration, the response to ACh was inverted leading to decreased sensitivity in 
both uterine artery and aorta.  
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Previous studies have demonstrated that in uterine and mesenteric vessels, pregnancy confers vascular 
adaptations that mediate enhanced NOS- and Cox-1-dependent vasodilation [333]. Moreover, studies 
have shown that in pregnant rats, uterine arteries display attenuated vascular smooth muscle 
relaxation in response to SNP [334], and that reduced vasoconstrictor sensitivity in the mesenteric bed 
of pregnant rats was associated with a greater inhibitory effect of nitric oxide [335]. However, a study 
conducted in rabbits showed that SNP could elicit similar responses in arterioles taken from non-
pregnant and pregnant females, but administration of ACh led to greater dilation in pregnant 
arterioles. The authors concluded that this enhancement was primarily driven by enhanced release of 
NO, rather than from prostaglandins, as the NO inhibitor L-NAME was able to substantially reduce 
the ACh-induced dilation and eliminated the difference in response between non-pregnant and 
pregnant vessels [336]. It has been suggested that this may be due to altered endothelial signal 
transduction in pregnancy, where the sensitivity of eNOS to Ca
2+
 is associated with changes in 
ERK1/2 signalling [337].    
Another study investigated venous adaptations in pregnancy and found that endothelium-dependent 
vasodilation markedly increased and smooth muscle response to NO decreased (primarily related to 
cGMP production) [338]. These results indicated a pro-vasodilatory state in the systemic venous 
system, thought to facilitate the accommodation to plasma volume expansion requisite for normal 
pregnancy. It could therefore be suggested that both venous and arterial vessel adaptations in 
pregnancy lead to a modified sensitivity to NO via altered signal transduction pathways in endothelial 
cells.    
To understand whether cardiac dysfunction was responsible for the hypotension observed in this 
study, we assessed the mRNA expression of markers of impaired cardiac function, including ANP, 
BNF and cardiac troponin-I, in left ventricular tissue. ANP mRNA expression was consistently higher 
in the non-pregnant mice in all conditions, while the expression of LPS-induced BNF was higher in 
the pregnant mice at 6 hours only. Cardiac troponin-I was significantly decreased in pregnant mice at 
both 6 and 12 hours.  
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Circulating BNF and troponin have been reported to markedly elevated in patients with sepsis and 
septic shock [339], and to related to the prognosis. Circulating troponins have been related to cardiac 
dysfunction in sepsis [340], but in the case of BNF, levels have been found to be elevated in presence 
[341] and absence of cardiac dysfunction [342], suggesting that other factors may influence BNF 
circulating levels. Given that the expression of BNF mRNA was elevated, it seems plausible that 
some cardiac dysfunction was present in the pregnant mice in this study and may therefore contribute 
to the hypotension observed. Indeed, MAP observed in LPS-treated pregnant mice was normal at 6 
hours and only started to decline at around 8 hours, consistent with the normal expression of BNF at 6 
hours and an increase at 12 hours. Further work to determine BNF and troponin protein levels may 
help to better determine the role of these factors. 
Sepsis-induced cardiac dysfunction may be caused by the local release of cardiac cytokines [343], but 
although the local levels of cytokines were greater in the mice treated with LPS, the levels in pregnant 
mice tended to be lower rather than higher compared to the non-pregnant mice. Intriguingly, the 
expression of both pro- and anti-apoptotic factors was lower in mice receiving LPS. This is counter to 
the existing literature, which is generally based on much higher doses of variable types of LPS 
administered to male rodents, from 250µg (in rats of  unspecified sex) [344], to 3mg (male rats) [345]. 
Data from the mouse are equally variable, however one paper has reported increased Bax and reduced 
Bcl-2 expression in cardiac tissue from non-pregnant mice (sex not specified) after the injection of 
30µg of LPS [346]. The findings presented here contrast to the existing data, but these data are 
derived predominantly from male rats and using higher doses of variable types of LPS; however, the 
reduction in apoptotic proteins may offer an explanation for the better outcome from sepsis observed 
in females [347]. Overall, the data suggest that cardiac function may be compromised in pregnant 
mice, but the aetiology is unclear, as there is little evidence of greater local cytokine levels or of 
increased apoptosis. 
It is recognised that circulating monocytes, granulocytes and NK cells increase from the first trimester 
onwards in human pregnancy [58]. In response to LPS, there was no difference in the behaviour of the 
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circulating monocytes and neutrophils, yet in contrast to this monocyte infiltration into the lungs was 
higher and of neutrophils lower in pregnant mice. Lung inflammatory cell infiltration has been 
described in several mouse models of sepsis, but none have compared the impact of LPS in pregnant 
and non-pregnant animals. It was expected that both monocytes and neutrophils might show a greater 
lung infiltration, consistent with the greater mortality seen in pregnant women with flu epidemics 
[348], however, this was not the case. Lung cytokine levels were not assessed in this study; however 
future work in this area may help the understanding of the impact of the differential infiltration.  
These data demonstrate that pregnant mice exhibit a marked hypotensive response to LPS and that 
this is associated with evidence of some cardiac compromise. The marked fall in blood pressure in 
response to LPS may help to explain the greater susceptibility of pregnant women to sepsis [349]. 
Understanding the mechanisms responsible will allow the development of a specifically targeted 
therapeutic response and an improvement in the management of severe infection in pregnant women. 
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Chapter 5: The Effect of Progesterone Supplementation on 
Maternal Haemodynamics 
  
 150 
 
5.1 Introduction 
Currently, the hormonal control of blood pressure during pregnancy is relatively poorly understood. 
During pregnancy, the primary role of progesterone is to inhibit uterine contractions and hence keep 
the uterus quiescent until term [350-352]. This is achieved both through a direct action on the 
myometrium and through the prevention of prostaglandin production in the uterus [353-356]. It is well 
known that gonadal steroids can regulate blood vessel functions and oestrogens, through binding to 
oestrogen receptor-α (ERα), are thought to play a role in the production of vasodilating agents such as 
NO, prostacyclin and PGE2 [281, 357, 358].  
During pregnancy, progesterone has also been shown to directly influence the shift in immunity to 
Th2-type responses at the maternal-fetal interface by suppression of T-cell differentiation into Th1 
cells, thus contributing to the development of maternal immune tolerance of the fetoplacental 
unit [359]. Further experimental evidence suggests that progesterone exerts anti-inflammatory 
properties in LPS-treated human amniotic epithelium, likely via the reduction of LPS-induced TLR4 
expression [360]. Furthermore, Anbe et al., demonstrated that LPS-induced IL-6 production, but not 
NO or PGE2, in the pregnant murine myometrium was attenuated by progesterone, thus suggesting 
progesterone mediates an NO-independent anti-inflammatory effect via suppression of interleukin 
production [361].   
However, progesterone also exerts effects on the cardiovascular system. In vitro, progesterone has 
been reported to have both vasodilatory and vasoconstrictive effects depending on the tissue and the 
level of exposure [25, 26, 362]. Furthermore, in hypertensive subjects, oral progesterone treatment 
reduces blood pressure [27]. Work done by Barbagallo et al., demonstrated that intravenous 
progesterone blunted MAP responsiveness to noradrenaline infusion in anaesthetised rats and blunted 
the pressor effects of noradrenaline in both in rat aorta and tail artery strips; a result of direct vascular 
action modulating calcium channel activity [363]. However, all these studies were conducted in non-
pregnant animals/subjects, and it is possible that the higher concentrations of progesterone already 
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present in pregnant animals alter the response to LPS-induced inflammation through effects on both 
the cardiovascular and immune systems.  
5.1.1 Aims and Objectives 
Progesterone is a commonly used treatment for the prevention of PTL in high-risk women, despite the 
fact that its mechanism of action is largely unknown. Since progesterone alters the maternal immune 
response it is of critical importance to understand whether it may lead to changes the maternal 
response to infection. Consequently, if progesterone were to make women more susceptible to 
developing sepsis or septic shock, not only is this important information for women advised to take 
progesterone, but it may also suggest a potential therapeutic approach in these critically ill women. 
To approach this problem, and to test the hypothesis that increased progesterone levels in pregnant 
mice modulate the haemodynamic response to LPS, the haemodynamics and immune responses of 
pregnant mice treated with supplementary progesterone prior to LPS administration were observed.  
 152 
 
5.2 Results 
5.2.1 The Effect of Progesterone Supplementation on Labour Time and Pup Survival  
To explore the effects of progesterone on maternal haemodynamics and inflammatory pathways, a 
dose-response curve using increasing concentrations of progesterone (P4) administered on E14-E16 
was constructed, in addition to the administration of 10µg LPS on E16.  
Previous work in the group performed by Kaiyu Lei et al., (unpublished data) demonstrated that 
progesterone levels could be elevated 10-fold (from approximately 400nmol/L on E16) by daily 
subcutaneous administration of 10mg P4 in pregnant CD1 mice. This progesterone elevation was 
sufficient to prevent the mice from labouring if daily injections were continued through to E18. In this 
experiment, daily subcutaneous injections on gestational days E14-E16 of peanut oil (PO; vehicle), 
5mg or 10mg P4 were given to raise P4 concentrations for 48 hours prior to LPS administration. 
In initial dose finding experiments, 5mg/day P4 treatment delayed the onset of labour after LPS 
administration on E16 compared to PO treatment (52.92 ± 13.21 hours vs. 22.46 ± 1.47 hours 
respectively), however latency to labour was only significantly increased compared to PO using 
10mg/day P4 (95.33 ± 7.76 hours, p<0.001; Figure 5.1A). Pup survival was increased using 5mg/day 
P4 compared to PO (61.54 ± 31.09 % compared to 0 % respectively) and then fell to 10 ± 10 %  using 
10mg/day P4 (Figure 5.1B). As 10mg/day was able to significantly delay latency to labour this dose 
was chosen for use in all subsequent experiments. 
Latency to labour was recorded throughout the experiments using telemetered mice to monitor blood 
pressure after supplementation with P4 (Figure 5.1C). P4 supplementation reproducibly increased 
latency to labour after LPS (p<0.001, 98 ± 11.8 hours vs. 21.5 ± 2.07 hours). However, in this cohort 
of animals, no pup survival was recorded at labour in either PO or P4 treatment groups (Figure 5.1D). 
Pup survival significantly decreased from 56.9 ± 13.5 % and 50.5 ± 15.8 % for PO and P4 
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respectively at 6 hours, to 6.67 ± 6.67 % and 7.5 ± 7.5 % at 12 hours (p<0.001) . There were no 
significant differences in pup survival after P4 treatment.  
 
Figure 5.1: Dose response to subcutaneous supplementation of progesterone in LPS-treated pregnant 
CD1 mice. Initial dose response studies were carried out using increasing concentrations of P4, administered 
before LPS, where latency to labour (A) and pup survival (B) were observed as outcomes. ***P<0.001 
compared to vehicle, student’s t-test, (PO, n=6; 5mg, n=3; 10mg, n=9). (C) Latency to labour was then recorded 
for all telemetered animals receiving PO or 10mg/day P4 before LPS, ***P<0.001 student’s t-test, (PO, n=4; P4 
n=6). (D) Pup survival was also noted during tissue collections at 6 and 12 hours post-LPS and at labour in 
telemetered animals after PO or 10mg/day P4. ***P<0.001 2-way ANOVA, (6 HRS, n=6; 12 HRS, n=4; 
Labour, n=6). All data are expressed as mean ± SEM. PO- peanut oil; P4- progesterone.      
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5.2.2 The Haemodynamic Response to LPS-induced Inflammation in Mouse Pregnancies 
Supplemented with Progesterone 
Haemodynamic and activity data was collected from telemetered CD1 mice. Mice were given 10mg 
P4 or PO (vehicle control) via the subcutaneous route daily from E14-E16 followed by i.p. LPS on 
E16.  
A decline in MAP was observed in animals treated with PO in the first 12 hours post-LPS (Figure 
5.2A). A nadir was observed at 9 hours post-LPS when MAP dropped to 101.09 ± 9.9 mmHg from a 
pre-LPS baseline of 115.54 ± 6.1 mmHg (Δ-14.5 ± 6.2). P4-treated animals maintained their MAP 
without any hypotensive response (Δ-1.56 ± 4.44 at 9 hours post-LPS).  However, analysis using 2-
way ANOVA did not indicate any significant differences between the treatment groups. Similar 
changes in blood pressure were also reflected in SAP (Figure 5.2B). In PO-treated animals a nadir 
was observed at 11 hours post-LPS when SAP dropped to 118.2 ± 15.7 mmHg from a pre-LPS 
baseline of 131.37 ± 13.9 mmHg (Δ-13.18 ± 7.9). No hypotensive response was seen in P4-treated 
animals (Δ-1.51 ± 4.47 at 11 hours post-LPS). Less marked changes were observed in DAP (Figure 
5.2C). Between 12 hours and 24 hours post-LPS there appeared to be a gradual return to baseline in 
all three parameters in the PO-treated group, however P4-treated animals exhibited a slight trend 
towards hypertension above baseline pre-LPS levels. This was more pronounced in DAP where the 
peak pressure was 89.79 ± 2.8 mmHg compared to pre-LPS baseline of 76.78 ± 2.8 mmHg (Δ13.01 ± 
3.39) at 19 hours post-LPS. No rise above basline was observed in the PO-treated group (99.3 ± 7.4 
mmHg at 19 hours vs. 99.59 ± 1.1 at baseline).   
The peanut oil vehicle itself was not thought to affect the haemodynamic profile of E16 mice as 
similar trends were observed in mice treated with LPS alone.  
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Figure 5.2: The haemodynamic response to LPS-induced inflammation after progesterone 
supplementation. The haemodynamic response in CD1 mice recorded 24 hours after LPS administration 
following either PO or P4 treatment daily from E14. (A) ΔMAP (B) ΔSAP (C) ΔDAP. Data are expressed as 
mean change from pre-LPS baseline (pre) ± SEM (Veh, n=3; P4, n=4). Veh- vehicle, peanut oil; P4- 
progesterone.      
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In the PO-treated group, there was a small reduction in HR, however due to the large variability of 
HR between animals this did not reach significance, therefore there was no signficiant change in heart 
rate in either treatment group after LPS (Figure 5.3). 
Area under the curve (AUC) analyses showed no significant changes between P4- and PO-treated 
animals for either  MAP, SAP, DAP or HR (Figure 5.5A, 5.5D, 5.5G, 5.5H). However, the maximum 
decrease in SAP  was significantly reduced (p<0.05; Figure 5.5E).  
 
 
Figure 5.3: The heart rate response to LPS-induced inflammation after progesterone supplementation. 
Heart rate was recorded in the 24-hours after LPS administration following either PO or P4 treatment daily from 
E14. Data are expressed as a mean change from pre-LPS baseline (pre) ± SEM (Veh, n=3; P4, n=4). Veh- 
vehicle, peanut oil; P4- progesterone.        
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Figure 5.4: The haemodynamic response to LPS-induced inflammation after progesterone 
supplementation as assessed by AUC, maximum decrease and maximum increase. The haemodynamic 
response in CD1 mice recorded 24-hours after LPS administration following either PO (Veh) or P4 treatment 
daily from E14. AUC analysis was perfomed for MAP (A), SAP (D), DAP (G) and HR (J). Maximum decrease 
was calculated for MAP (B), SAP (E), DAP (H) and HR (K). Maximum increase was calculated for MAP (C), 
SAP (F), DAP (I) and HR (L). *P<0.05 student’s t-test. Data are expressed as mean ± SEM (Veh, n=3; P4, n=4). 
Veh- vehicle, peanut oil; P4- progesterone.     
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Figure 5.5: Activity in pregnant CD1 mice treated with LPS after supplementation with progesterone or 
vehicle. The change in activity in CD1 mice was recorded 24-hours after LPS administration following either 
PO or P4 treatment daily from E14. (A) Δ%TSI (B) ΔActivity (C) ΔActivity>0. Data are expressed as a mean 
change from pre-LPS baseline (pre) ± SEM (Veh, n=3; P4, n=4). Veh- vehicle, peanut oil; P4- progesterone.         
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P4-treatment had no significant effect on the %TSI and activity displayed by CD1 mice in the 24 
hours after LPS administration. There was no significant change from baseline observed in either 
treatment group in the %TSI, although there was a slight reduction in the last three hours observed. As 
labour would have occurred in the PO-treated animals, this could account for the increase in activity 
at this point, however, as this was not true of P4-treated animals, it may be that the initial effects of 
LPS wear off with time as the LPS is cleared. These results are also reflected in a slight increase in 
activity at 18-23 hours post-LPS, although not significant. The intestity of activity, as described by 
activity >0, also remained unchanged from baseline despite a sharp and unexplained drop in activity 
>0 of both groups at 3 hours post-LPS. These results idicate that altered activity could not be 
responsible for any differences in blood pressure in P4-treated mice.  
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5.2.3 The Effect of Progesterone Supplementation on LPS-induced Cytokine, Chemokine, Nitric 
Oxide and Asymmetric Dimethylarginine Production in Pregnant Mice 
Absolute concentrations of cytokines and chemokines in maternal serum from PO- or P4-treated mice 
6 and 12 hours after LPS i.p. were measured using the Millipore MAGpix multiplex assay system to 
evaluate any effects of progesterone supplementation on the systemic inflammatory response. 
There were no significant differences in any of the pro- or anti-inflammatory cytokines measured 
between P4-treated and PO controls (Figure 5.6). It can therefore be concluded that P4 
supplementation did not suppress LPS-induced cytokine production in pregnant mice. Of note 
however, is that in PO controls, both IL-1β and TNF-α production significantly decreased between 6 
and 12 hours post-LPS (p<0.05; Figure 5.6A, 5.6C). In P4-treated mice there was a trend towards 
decreased levels of IL-1β and TNF-α but this was not significant.  
Similar results were found for the chemokines measured in these samples. There were no significant 
differences in any of the chemokines measured between P4-treated and PO controls (Figure 5.7). 
However, CCL2 and CXCL1 were significantly decreased between 6 and 12 hours post-LPS in PO 
controls (p<0.05; Figure 5.7A, 5.7C), yet there was no significant reduction in the P4-treated animals 
at 12 hours post-LPS.  
Circulating NO concentrations were not significantly different between P4-treated mice and PO 
controls (Figure 5.8), neither were there any differences in circulating ADMA levels. Absolute 
concentrations were comparable of those measured in LPS-treated mice without PO indicating that 
injections of PO did not provide any additional nitrites. These results indicate that the maintenance of 
MAP in P4-treated animals after LPS was not due to suppressed NO levels.     
  
 161 
 
Figure 5.6: Circulating concentrations of pro- and anti-inflammatory cytokines in the serum of pregnant 
mice treated with LPS after supplementation with progesterone or vehicle. Measurements were made in 
serum samples taken 6 or 12 hours after LPS in PO- or P4-treated mice. (A) IL-1β (B) IL-6 (C) TNF-α (D) IL-4 
(E) IL-10 (F) VEGF. *p<0.05 pairwise t-test comparisons or Mann Whitney U tests were used where 
appropriate. Data shown as mean ± SEM (n=6). PO- vehicle, peanut oil; P4- progesterone.        
 162 
 
Figure 5.7: Circulating concentrations of chemokines in the serum of pregnant mice treated with LPS 
after supplementation with progesterone or vehicle. Measurements were made in serum samples taken 6 or 
12 hours after LPS in PO- or P4-treated mice. (A) CCL2 (B) CCL5 (C) CXCL1 (D) CXCL2. *p<0.05 pairwise 
t-test comparisons or Mann Whitney U tests were used where appropriate. Data shown as mean ± SEM (n=6). 
PO- vehicle, peanut oil; P4- progesterone  
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Figure 5.8: Circulating concentrations of nitric oxide and asymmetric dimethylarginine in the serum of 
pregnant mice treated with LPS after supplementation with progesterone or vehicle. Measurements were 
made in serum samples taken 6 or 12 hours after LPS in PO- or P4-treated mice. (A) Concentration of total 
nitrates and nitrites (NOx) as measured by nitric oxide analyser (B) ADMA as measured by mass spectrometry. 
Data shown as mean ± SEM, or as median ± interquartile range showing minimum and maximum (n=6). PO- 
vehicle, peanut oil; P4- progesterone  
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5.2.4 The Effect of Progesterone Supplementation on the Production of Inflammatory Markers, 
Markers of Cardiac Dysfunction and Apoptotic Markers in Left Ventricular Tissue 
To assess the extent of cardiac sensitivity to LPS after P4 supplementation, the relative expression of 
various markers of inflammation, apoptosis and cardiac dysfunction were assessed in maternal left 
ventricular tissue using RT-PCR. 
Similarly to circulating IL-1β levels, IL-1β mRNA expression in left ventricular tissue was not 
significantly reduced after P4-supplementation. However, in PO controls, IL-1β levels fell between 6 
and 12 hours (p<0.05; Figure 5.9A), there was no change in P4-treated mice. There were no 
differences in IL-6 or IL-10 expression in any treatment group (Figure 5.9B, Figure 5.9D). 
Interestingly, unlike in the circulation, TNF-α was significantly reduced in the left ventricle of P4-
treated mice 6 hours after LPS (p<0.001; Figure 5.9C).  
As recent evidence suggested that upregulation of the LPS-binding protein cysteine-rich secretory 
protein containing LCCL domain 2 (CRISPLD2) protects mice from LPS-induced mortality and is 
also modulated by P4, we looked at CRISPLD2 expression in these samples [364-366]. We found that 
in P4-treated mice 6 hours after LPS, CRISPLD2 expression was significantly reduced compared to 
PO controls (p<0.05; Figure 5.9E). Upregulation of CRISPLD2 in PO controls 6 hours after LPS was 
also significantly reduced by 12 hours (p<0.01) but there was no change between 6 and 12 hours after 
LPS in P4-treated mice, suggesting that changes in CRISPLD2 are not responsible for the improved 
blood pressure responses to LPS induced by P4 supplementation. 
Markers of cardiac dysfunction that were previously found to be altered after LPS administration in 
pregnant mice were also measured (see Chapter 4). The expression of ANP, BNF, c-Troponin I and 
Nkx2.5 were not significantly different after P4 supplementation (Figure 5.10). Similarly, the 
expression of apoptotic markers was unchanged after P4-supplementation (Figure 5.11). Bax 
expression was found to be significantly higher 12 hours after LPS compared to 6 hours, but this was 
true in both P4-treated mice and PO controls (p<0.05; Figure 5.11B).   
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Figure 5.9: mRNA expression of pro- and anti-inflammatory cytokines and inflammatory regulators in 
left ventricular tissue taken from pregnant mice treated with LPS after supplementation with 
progesterone or vehicle. (A) IL-1β (B) IL-6 (C) TNF-α (D) IL-10 (E) CRISPLD2. *p<0.05, **p<0.01, 
***p<0.001, pairwise t-test comparisons or Mann Whitney U tests were used where appropriate. Data shown as 
mean ± SEM (n=6). PO- vehicle, peanut oil; P4- progesterone.  
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Figure 5.10: mRNA expression of markers of cardiac dysfunction in left ventricular tissue taken from 
pregnant mice treated with LPS after supplementation with progesterone or vehicle. (A) ANP (B) BNF 
(C) c-Troponin I (D) Nkx2.5. Data shown as mean ± SEM (n=6). PO- vehicle, peanut oil; P4- progesterone.  
 
 
 
 
 
 
 
Figure 5.11: mRNA expression of markers of apoptosis in left ventricular tissue taken from pregnant 
mice treated with LPS after supplementation with progesterone or vehicle. (A) Bcl-2 (B) Bax (C) Bad. 
*p<0.05 pairwise t-test comparisons or Mann Whitney U tests were used where appropriate.  Data shown as 
mean ± SEM (n=6). PO- vehicle, peanut oil; P4- progesterone.   
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5.3 Summary and Discussion 
Daily supplementation of 10mg P4 was able to significantly delay the onset of labour after LPS 
administration in pregnant CD1 mice, but this did not lead to increased pup survival at intermediate 
time points or labour. After P4 supplementation, the LPS-induced hypotensive response observed in 
control animals was ameliorated and no hypotension was measured in P4-treated mice. P4-treatment 
led to a significantly reduced maximum decrease in SAP. Heart rate and activity levels were not 
affected. There were no significant differences detected in any of the circulating cytokines or 
chemokines measured after P4-treatment. Circulating VEGF, NO and ADMA concentrations were not 
altered by P4 supplementation. In the left ventricle, mRNA expression of TNF-α and CRISPLD2 were 
significantly down regulated after P4-treatment. 
These data suggest that increased progesterone concentrations in pregnant mice do not drive the 
hypotensive response to LPS observed in pregnant animals. Actually, contrary to our hypothesis, that 
P4 may exacerbate the haemodynamic response to LPS, progesterone clearly plays a role in 
haemodynamic adaptation and may provide some protection against LPS-induced hypotension. 
The mechanism of this action is still unclear, as increased progesterone did not exert an anti-
inflammatory effect and decrease the levels of circulating pro-inflammatory cytokines and 
chemokines, nor did it increase the concentrations of anti-inflammatory cytokines such as IL-10. The 
absence of any impact on inflammation is surprising as progesterone plays a key role in the 
differentiation of Th cells and the shift from Th1 to Th2 dominance in pregnancy [367-371], but 
perhaps, as progesterone levels are high in E16 mice, the supplementation of further P4 may not 
induce any further increases in IL-10 or other Th2 cytokines.    
Despite the improved blood pressure response to LPS after P4 supplementation, circulating NO 
concentrations were not altered. This result was unexpected, as Miller et al., showed that P4 
treatement caused both time- and dose-dependent inhibition of NO production in macrophages [372]. 
Further experiments with LPS showed that P4 was able to inhibit the major effector system in 
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activated macrophages, reducing activation of the iNOS gene promotor, iNOS mRNA expression and 
synthesis of NO. However, these experiments were undertaken in macrophage cell lines and mouse 
bone marrow culture-derived macrophages, and NO levels were not measured in the circulation in 
vivo. Furthermore, these macrophages were activated with both LPS and INF-γ and therefore results 
could be an indication of the effects of INF-γ action. 
Evidence from ex vivo vascular tension studies in endothelium-denuded tail artery and aorta helical 
strips showed that P4 blunted vasoconstriction in an NO-independent manner [363]. This work led to 
the suggestion that progesterone acts as a buffer in the vasculature against excessive calcium-
dependent vasoconstrictor responses to a variety of hormonal stimuli. Therefore, progesterone may 
exert its effects on the vasculature via an NO-independent pathway, possibly prostacylin mediated.    
Furthemore, since the discovery of membrane progesterone receptors (PRs) in 2003 [373], it could be 
that progesterone signalling in the vasculature is mediated through membrane PR activation and 
ERK1/2, p38 MAPKs activation, inhibition of cyclic adenosine monophosphate (cAMP) production 
and stimulation of intracellular Ca
2+
 mobilisation [374-378]. However, further work needs to be done 
to establish that this is a relevant pathway.  
Additionally, progesterone metabolites have been shown to act upon the pregnane X receptor (PXR) 
which is known to be expressed in vascular tissue [379-381]. The PXR is a nuclear receptor and is 
important for the regulation of cytochrome P450 enzymes and consequently many aspects of 
xenobiotic metabolism [382]. Pregnancy-induced vascular adapatations were evident in arteries from 
WT but not PXR knockout mice, and these adaptations were exacerbated by treatment with 
exogenous progesterone metabolites [379]. Therefore P4 supplementation may have triggered further 
vascular adaptations via progesterone metabolite action at the PXR.   
Although there were no significant differences in TNF-α measured in the serum, in the left ventricle 
TNF-α mRNA expression was signficantly downregulated in the P4-treated mice 6 hours after LPS 
administration. It has previously been shown that in LPS-stimulated macrophages, P4 downregulates 
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the production of intracellular TNF-α mRNA as well as released TNF-α protein [383], thought to be 
primarily achieved by increasing levels of IBα. Similar results were also seen in BV-2 cells (a 
murine microglia cell line) where pre-treatement with P4 dose-dependently attenuated LPS-induced 
TNF-α secretion [384]. Progesterone also decreased LPS-induced iNOS and Cox-2 expression,  
NF-B activation and p38, c-Jun N-terminal kinase (JNK) and ERK MAPKs phosphorylation in this 
model. The data collected from left ventricular tissue presented in this chapter, add to the emerging 
picture that progesterone exerts anti-inflammatory effects in a diverse range of tissues and cellular 
subsets. However, Jain et al., showed that TNF-α secretion was seen to increase two-fold following 
progesterone treatment in a human pro-monocytic cell line U937, albeit this was seen without LPS 
stimulation [385]. If increasing levels of progesterone can cause an elevation in TNF-α secretion in 
some inflammatory cells, the disparity between TNF-α levels measured in left ventricular tissue and 
the protein levels in the circulation could be explained by a counterbalance effect.  
The expression of CRISPLD2 in P4-treated mice was signficantly decreased compared to in PO 
controls. This result was surprising, as previous experimental evidence had shown that in mice treated 
with P4 for 6 hours CRISPLD2 expression in the uterus was increased [366]. This group also 
demonstrated that P4 regulation of CRISPLD2 is regulated by the PR as CRISPLD2 was signficantly 
increased upon treatment with P4 only in WT mice and not in PR knockouts. However, expression of 
CRISPLD2 may be differently regulated in the heart, or secreted into the circulation leading to 
decreased expression in the tissue. Though this would need to be verified by determined protein levels 
of CRISPLD2. Interestingly, CRISPLD2 measured in the serum of human septic patients was highly 
variable in expression and levels did not correlate with increased sepsis severity, which may suggest 
that lower levels of CRISPLD2 expression indicate increased metabolism or reduced production of 
this protein [365]. An alternative explanation may be that excessive stimulation with P4 leads to a 
reduction in PR levels as well as positive PR chaperone proteins and mPRs in a negative feedback 
loop [386]. There is limited evidence to suggest that the classic nuclear PR (nPR) is downregulated at 
very high concentrations of P4, but tha the mPRα has been shown to undergo endocytosis after P4 
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stimulation via a clathrin-mediated pathway [373, 387]. Further work to define which PR are 
expressed in the heart would help to clarify P4 action on cardiac CRISPLD2 expression.   
Taken together, these results indicate that progesterone plays an important role in the regulation of 
blood pressure in pregnancy, and is not responsible for the fall in blood pressure observed in  pregnant 
animals after LPS challenge. Consequently, progesterone may afford some haemodynamic protection 
to pregnant animals but as these data suggest no overwhelming anti-inflammatory influence, the 
mechanism remains unclear.   
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Chapter 6: The Effect of C-C Chemokine Receptor Type 2 
Deficiency on LPS-induced Hypotension in Pregnancy 
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6.1 Introduction 
Characteristically, CCR2 is expressed in monocytes and in CCR2 deficient mice monocyte 
recruitment to sites of inflammation is impaired [388, 389]. CCR2 has also been found to be 
expressed in macrophages, subpopulations of T cells, basophils and DCs [390-392]. However, the 
chemokine CCL2 (also known as monocyte chemotactic protein-1; MCP-1) and its receptor CCR2 
have been shown to play a crucial role in the inappropriate and excessive recruitment of neutrophils to 
multiple organs, often remote from the site of infection, causing tissue damage and organ dysfunction 
[172]. Additionally, although absent in resting neutrophil populations, chronic inflammation in 
adjuvant-immunised rats has been shown to induce the expression of CCR2 in circulating neutrophils 
[393]. This is thought to be driven by TLR2 and TLR4 signalling through the MyD88/NF-B 
pathway, as neutrophils normally unresponsive to CCR2 chemotaxis acquired strong chemotactic 
responses to CCL2 and CCL7 after LPS administration, which was abolished in MyD88-deficient 
mice. Furthermore, in a mouse model of SIRS induced by cerulean-induced acute pancreatitis, CCL2 
was found to be the key chemokine responsible for the polarised conversion of resident macrophages 
into alternatively activated macrophages (AAMs), which increased SIRS mouse susceptibility to 
CLP-induced sepsis [394]. IL-10 and IL-17 secreted from AAMs were also found to inhibit the 
antibacterial effector macrophages (classically activated macrophages, CAMs) to further perpetuate 
this effect.  
In human pregnancy, chemokine receptors are expressed in both immune and myometrial cells and 
are thought to be important regulators of the inflammatory cell influx into the myometrium and cervix 
at term [395]. CCR2 has been also found in first-trimester decidual tissues, where CCL2 was shown 
to be upregulated by progesterone, oestrogen and hCG. He et al., suggested that this may suggest a 
key role for CCL2 at the maternal-fetal interface [396]. Gomez-Lopez et al., also demonstrated a 
further role of CCL2 in fetal membranes where membrane extracts from women who had experienced 
spontaneous labour exhibited increased CCL2-driven chemotaxis than in those from non-labouring 
women [397], thus amplifying the recruitment of monocytes and macrophages, and alongside CCL3, 
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co-ordinating the recruitment of monocytes into reproductive tissues [398, 399]. However, CCR2 
expression is not required for successful pregnancy and labour [168]. Indeed, it is likely that 
compensatory mechanisms exist, and that CCR2-dependent leukocyte recruitment into the mouse 
uterus is superfluous for the initiation of labour.  
In recent years, there has been a lot of attention paid to the role of inflammatory factors in the 
regulation of blood pressure, endothelial dysfunction and hypertension [400-403]. Chemokines are 
principally chemoattractants, but also thought to play other roles in angiogenesis and the promotion of 
cancer cell growth, haematopoiesis, embryogenesis and the maturation of several immune cells [400]. 
The involvement of chemokines in blood pressure regulation predominantly comes from control of 
inflammation in the vessels and heart, where inflammatory cell infiltration and oxidative stress in the 
vascular walls contributes to an increase in blood pressure [404, 405]. For example, Shen et al., were 
able to show that CCL2 deficiency was able to reduce CCL2-dependent macrophage recruitment and 
consequently reduce tissue inflammation and hypertension in a model of deoxycorticosterone and 
salt-induced hypertension cardiac fibrosis and hypertension [402].    
To explore the role of CCL2/CCR2 signalling in the maternal hypotensive response to LPS, a CCR2 
homozygous knockout mouse (Jackson Laboratories, strain name B6.129S4-Ccr2
tm1Ifc
/J) was used. 
Originally crossed to C57BL/6 mice, the strain was backcrossed to a CD1 background as CD1 mice 
are a particularly fecund strain and typically have much larger litters than C57BL/6. The greater 
robustness and reproduction of the outbred strain was considered to be sufficiently advantageous to 
offset the heterogeneity of the background.   
Preliminary data from our group has shown that in naïve E16 mice, CCR2 deficiency manifests in 
decreased monocyte and macrophage recruitment to various tissues including myometrium, placenta, 
liver and lung. In tissue collected during labour after intrauterine LPS administration, CCR2
 
deficiency did not cause a change in the accumulation of monocyte or macrophage cell densities.  
However, this work has shown that absence of maternal CCR2 reduces the adverse effects of 
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intrauterine administration of LPS, namely preterm labour and pup death, and improves neonatal 
outcome (unpublished data). Pup survival rates were improved from 0% at 7 hours post-LPS in CD1 
dams, to over 90% in CCR2
-/-
 mice which correlated with reduced pro-inflammatory cytokine 
production in CCR2
-/-
 pup brain. These results were also accompanied by the finding that CCR2
-/-
 
placentas showed a reduced inflammatory response to LPS when compared to CD1 mice.  
6.1.1 Aims and Objectives 
As high levels of CCL2 are induced in response to inflammatory stimuli such as IL-1, TNF-α and 
LPS, modulation of CCL2/CCR2 signalling or expression could be beneficial in both treating and 
investigating inflammation in pregnancy. Therefore in this chapter, the role of CCR2 was examined to 
explore the potential effect on the maternal haemodynamic response to LPS. Taken together with the 
group’s previous findings, it was hypothesised that manipulation of CCR2 may be protective in 
systemic LPS-induced inflammation during pregnancy. 
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6.2 Results 
6.2.2 The Haemodynamic Profile of Non-Pregnant CCR2 Knockout Mice 
To determine if there were any basal haemodynamic differences between CD1 (wild-type control) and 
CCR2
-/-
 mice, non-pregnant recordings were taken before timed-mating. There were no differences in 
MAP, SAP or DAP in non-pregnant CCR2
-/-
 mice (Figure 6.1A, 6.1B, 6.1C), however heart rate was 
significantly decreased from 662.1 ± 9.64 bpm in CD1 to 453.2 ± 26.2 bpm in CCR2
-/-
 mice (Figure 
6.1D). Changes in activity were also observed, where %TSI was significantly decreased and activity 
and intensity of activity (activity>0) were significantly increased in CCR2
-/-
 mice (p<0.001; Figure 
6.1E, 6.1F, 6.1G). 
6.2.2 Latency to Labour and Pup Survival Outcomes after LPS administration in CCR2 Knockout 
Mice 
After PBS i.p. on E16, CCR2
-/-
 mice laboured spontaneously at term, approximately 58.0 ± 2.54 hours 
after injection, which was not statistically different from labour time in CD1 controls (48.63 ± 6.18 
hours). Latency to labour after LPS was also not significantly different from CD1 as in both CCR2
-/-
 
and CD1 mice there was a very significant reduction in latency to labour after 10μg LPS 
administration on E16 to 16.99 ± 2.31 hours and 19.31 ± 1.34 hours respectively (p<0.001; Figure 
6.2A).  
There were also no differences between CCR2
-/-
 and CD1 pup survival, with 100% survival after PBS 
and 0% survival at labour after LPS in both CD1 and CCR2
-/-
 (Figure 6.2B, 6.2C).  Surprisingly, after 
i.p. LPS administration we found that CCR2
-/-
 pup survival was typically decreased compared to CD1 
at 6 and 12 hour intermediate time points, although this did not reach statistical significance.   
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Figure 6.1: The haemodynamic and activity profile of non-pregnant CCR2
-/- 
mice. Haemodynamic and 
activity parameters were recorded for 24 hours (prior to mating) in female virgin CD1 and CCR2
-/-
 mice. (A) 
MAP (B) SAP (C) DAP (D) HR (E) %TSI (F) Activity (G) Activity >0. ***p<0.001 student’s t-test or Mann-
Whitney U test as appropriate. Data expressed as mean ± SEM (CCR2
-/-
, n=14; CD1, n=20).    
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Figure 6.2: Latency to labour and pup survival outcomes after LPS administration in CCR2 knockout 
mice. (A) Latency to labour was recorded in telemetered mice (CD1 PBS, n=4; CCR2
-/-
 PBS, n=7; CD1 LPS, 
n=6; CCR2
-/-
 LPS n=5). (B) Pup survival was noted during tissue collections at 6 and 12 hours post-PBS and at 
labour in telemetered animals after PBS (vehicle) and (C) after 10μg LPS administration in CD1 and CCR2-/- 
mice (CD1 6HR, n=6 ; CCR2
-/-
 6HR, n=7; CD1 12 HR, n=6; CCR2
-/-
 12 HR, n=6; CD1 Labour, n=4; CCR2
-/-
 
Labour, n=4). ***P<0.001 compared to PBS control, 2-way ANOVA showing treatment but not genotype was 
significant. Data expressed as mean ± SEM.  
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6.2.3 The Haemodynamic Response to LPS-induced Inflammation in Pregnant CCR2 Knockout Mice 
Experiments to assess the haemodynamic response of pregnant CCR2
-/-
 mice to LPS showed that 
compared with pregnant CD1 controls, MAP was significantly elevated in CCR2
-/-
 mice (p<0.05; 
Figure 6.3A). There was an initial hypertensive response to LPS in CCR2
-/-
 mice when compared to 
CD1 controls which culminated in a peak elevation of Δ28.24 ± 8.5 mmHg at 5 hours post-LPS 
administration (p<0.01; Figure 6.3A). This then gradually declined to reach pre-LPS baseline levels 
by 8 hours. MAP was then maintained at baseline levels which were higher than in CD1 mice. The 
difference in MAP during the last 8 hours measured was also markedly different between CCR2
-/-
 and 
CD1 mice, where at 16, 17, 18 and 23 hours post-LPS there was a significant difference (p<0.05). As 
the Δ MAP above baseline at these time points were not as great as those seen earlier, the significance 
may reflects the gradual decline of MAP in CD1 mice rather than increases in CCR2
-/-
. The nadir in 
MAP of Δ-31.1 ± 7.06 mmHg in CD1 mice was seen at 12 hours post-LPS, but this was then 
maintained and did not resolve.  
These changes were also reflected in SAP and DAP (Figure 6.3B, 6.3C). The general trend in SAP 
was significantly increased in CCR2-/- mice (p<0.05) and SAP at 3, 4, 5, 6, 7, 12, 15, 16, 17 and 23 
hours post-LPS were found to be significantly higher (p<0.05, p<0.01, p<0.001). The peak change in 
pressure at 5 hours post-LPS was Δ35.43 ± 12.6 mmHg (p<0.001). Similarly, DAP was significantly 
elevated in CCR2
-/-
 mice after LPS compared to CD1 (p<0.05) with a peak change in pressure at 5 
hours (Δ36.83 ± 15.94 mmHg, p<0.001).  Interestingly, in CCR2-/- mice DAP remained above 
baseline throughout the 24 hour period in response to LPS. The nadir in DAP observed in CD1 mice 
also came much later than the nadir in MAP, where a Δ-27.91 ± 11.49 mmHg was recorded at 18 
hours post-LPS.  
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Figure 6.3: The haemodynamic response to LPS-induced inflammation in CCR2
-/- 
mice. The 
haemodynamic response in CCR2
-/-
 and CD1 mice was recorded for 24-hours following LPS administration on 
E16. (A) ΔMAP (B) ΔSAP (C) ΔDAP. *p<0.5, **p<0.01, ***p<0.001, trends were compared using 2-way 
ANOVA and individual time points were compared using 2-way ANOVA and Bonferroni post-hoc test. Data 
are expressed as a mean change from pre-LPS baseline (pre) compared to PBS controls ± SEM (CD1, n=7; 
CCR2
-/-
, n=4). 
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Figure 6.4: The heart rate response to LPS-induced inflammation in CCR2
-/- 
mice. Heart rate in CCR2
-/-
 
and CD1 mice was recorded for 24-hours following LPS administration on E16. (A) ΔMAP (B) ΔSAP (C) 
ΔDAP. *p<0.5, **p<0.01, ***p<0.001, trends were compared using 2-way ANOVA and individual time points 
were compared using 2-way ANOVA and Bonferroni post-hoc test. Data are expressed as a mean change from 
pre-LPS baseline (pre) compared to PBS controls ± SEM (CD1, n=7; CCR2
-/-
, n=4).. 
 
HR was seen to decline immediately after LPS in CD1 and CCR2
-/-
 mice. However in CCR2
-/-
 mice 
HR returned to baseline by 7 hours post-LPS, whereas in CD1 mice HR remained significantly 
depressed (p<0.05; Figure 6.4).  
AUC analyses showed that MAP was significantly increased in CCR2
-/-
 mice after LPS (p<0.05; 
Figure 6.5A). The maximum decrease in ΔMAP in CCR2-/- mice was diminished but this did not reach 
statistical significance, and although the maximum increase in ΔMAP was greater in CCR2-/- mice 
this also did not reach statistical significance (Figure 6.5B, 6.5C). Very similar results were observed 
for SAP, where in CCR2
-/- 
mice after LPS AUC was significantly increased (p<0.05; Figure 6.5D), 
maximum decrease in ΔSAP was significantly decreased (p<0.05; Figure 6.5E) and maximum 
increase in ΔSAP was significantly increased (p<0.05; Figure 6.5F). This was also reflected in 
changes in DAP, where AUC was significantly increased in CCR2
-/-
 mice after LPS (p<0.01; Figure 
6.5G) and the maximum increase in ΔDAP was significantly increased (p<0.05; Figure 6,5I). 
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Figure 6.5: The haemodynamic response to LPS-induced inflammation in CCR2-/- mice compared to CD1 
mice as assessed by AUC, maximum decrease and maximum increase. The haemodynamic response in 
CCR2
-/-
 and CD1 mice recorded 24-hours after LPS administration. AUC analysis was perfomed for MAP (A), 
SAP (D), DAP (G) and HR (J). Maximum decrease was calculated for MAP (B), SAP (E), DAP (H) and HR 
(K). Maximum increase was calculated for MAP (C), SAP (F), DAP (I) and HR (L). *p<0.05, **p<0.01 
student’s t-test. Data are expressed as mean ± SEM (CD1, n=7; CCR2-/-, n=4).. 
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 Whilst the maximum decrease in ΔDAP was diminished in CCR2-/- mice after LPS this did not reach 
statistical significance (Figure 6.5H). There were no significant changes between CCR2
-/-
 and CD1 
mice after LPS in the AUC, maximum increase or maximum decrease of HR (Figure 6.5J, 6.5K, 
6.5L).    
There were no statistically significant differences between activity levels in the 24 hours after LPS 
between CCR2
-/-
 and CD1 mice (Figure 6.6A, 6.6B, 6.6C). However, CCR2
-/-
 mice generally had 
much more variable activity levels where the Δ%TSI was initially decreased after LPS and ΔActivity 
was increased in the first 8 hours. It is important to note that where activity in CD1 mice remained at 
baseline throughout the 24 hour period after LPS, activity in CCR2
-/-
 mice did increase above 
baseline, to a peak of Δ60.76 ± 37.07 at 7 hours post-LPS. The highest peak in CD1 mice was Δ0.41 
at 24 hours post-LPS (Figure 6.6B). It should be considered that these initial high levels of activity 
seen in CCR2
-/-
 mice could account for the increased MAP observed at 5 hours post-LPS. However, 
as MAP remained elevated in CCR2
-/-
 compared to CD1 after LPS in the 16 to 23 hour period where 
activity levels had remained at or below baseline, this is unlikely to be the only reason for elevated 
MAP but may be a contributing factor. As observed previously in pregnant animals, the reason for no 
change in activity after LPS administration may be due to overriding nesting behaviours.       
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Figure 6.6: Activity in pregnant CCR2
-/- 
and CD1 mice after LPS administration. Activity levels in CCR2
-/-
 
and CD1 mice were recorded for 24-hours following LPS administration on E16. (A) Δ%TSI (B) ΔActivity (C) 
ΔActivity>0. Data are expressed as a mean change from pre-LPS baseline (pre) compared to PBS controls ± 
SEM (CD1, n=7; CCR2
-/-
, n=4)..   
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6.2.4 The LPS-induced Inflammatory Response in Pregnant CCR2 Knockout Mice 
Absolute concentrations of cytokines and chemokines in maternal serum from CD1 and CCR2
-/-
mice 
6 and 12 hours after LPS i.p. were measured using the Millipore MAGpix multiplex assay system to 
evaluate any effects of CCR2 deficiency on the systemic inflammatory response. 
There were numerous differences between the responses of CD1 and CCR2
-/-
 mice to LPS when 
circulating pro- and anti-inflammatory cytokines were examined. In response to LPS, IL-1β was not 
significantly increased in CD1 or CCR2
-/-
 mice (Figure 6.7A) and IL-6 was significantly increased in 
both strains (p<0.05, p<0.01; Figure 6.7B).  Intriguingly, circulating concentrations of TNF-α were 
only significantly increased in CD1 mice (p<0.01), as at 6 hours post-LPS this increase was 
significantly attenuated in CCR2
-/-
 mice (p<0.001; Figure 6.7C). Also of note, is that in PBS-treated 
CCR2
-/-
 mice there was a trend towards decreased levels of TNF-α in the circulation (15.14 ± 4.3 
pg/mL and 19.69 ± 5.5 pg/mL at 6 and 12 hours respectively in CCR2
-/-
 mice compared to 346.7 ± 
62.4 pg/mL and 502.8 ± 83.4 pg/mL at 6 and 12 hours respectively in CD1 mice), although this did 
not reach statistical significance. Conversely, IL-4 and IL-10 concentrations were significantly 
increased in CCR2
-/-
 but not in CD1 mice. IL-4 was significantly increased after LPS compared to 
PBS control in CCR2
-/-
 mice but only 12 hours post-LPS (p<0.05; Figure 6.7D). Where there was a 
trend towards increased IL-10 levels in CD1 mice in response to LPS, due to high inter-animal 
variability this was not significant; however there were significantly increased concentrations of IL-10 
in CCR2
-/-
 mice 6 hours (p<0.05) and 12 hours (p<0.01) post-LPS (Figure 6.7E).  
There were no differences between the responses of CD1 and CCR2
-/-
 mice to LPS when circulating 
chemokines were measured. CCL2 was increased after LPS administration in CD1 and CCR2
-/-
 mice, 
although only at 6 hours post-LPS in CD1 mice (p<0.05) and at both 6 hours (p<0.001) and 12 hours 
(p<0.01) post-LPS in CCR2
-/-
 mice (Figure 6.8A).  
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Figure 6.7: Circulating concentrations of pro- and anti-inflammatory cytokines in the serum of pregnant 
CD1 and CCR2
-/-
 mice treated with LPS or vehicle. Measurements were made in serum samples taken 6 or 
12 hours after LPS in CD1 and CCR2
-/-
 mice. (A) IL-1β (B) IL-6 (C) TNF-α (D) IL-4 (E) IL-10. *p<0.05, 
**p<0.01, ***p<0.001 pairwise t-test comparisons or Mann Whitney U tests were used where appropriate. Data 
shown as mean ± SEM (CD1, n=7; CCR2
-/-
, n=4). 
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Figure 6.8: Circulating concentrations of chemokines in the serum of pregnant CD1 and CCR2
-/-
 mice 
treated with LPS or vehicle. Measurements were made in serum samples taken 6 or 12 hours after LPS in in 
CD1 and CCR2
-/-
 mice. (A) CCL2 (B) CCL5 (C) CXCL1 (D) CXCL2. *p<0.05, **p<0.01, ***p<0.001 
pairwise t-test comparisons or Mann Whitney U tests were used where appropriate. Data shown as mean ± SEM 
(CD1, n=7; CCR2
-/-
, n=4).   
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Figure 6.9: mRNA expression of pro-inflammatory cytokines in left ventricular tissue taken from 
pregnant CCR2
-/- 
and CD1 mice treated with LPS or vehicle. (A) IL-1β in CD1 mice (B) IL-1β in CCR2-/- 
mice (C) IL-6 in CD1
 
mice (D) IL-6 in CCR2
-/- 
mice (E) TNF-α in CD1 mice (F) TNF-α in CCR2-/- mice. Data 
for CD1 mice is shown in the left panels and CCR2
-/-
 mice in the right panels. CD1 data is taken from Figure 4.6 
showing here only pregnant responses. **p<0.01, ***p<0.001, pairwise t-test comparisons or Mann Whitney U 
tests were used where appropriate. Data are expressed as mean ± SEM (all CD1 groups, n=6; CCR2
-/-
 12HR 
PBS, n=5; all other CCR2
-/-
 groups, n=6).   
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CCL5 was found to be increased in CD1 and CCR2
-/-
 mice in response to LPS but this only reached 
significance in CD1 mice at 6 hours post-LPS (p<0.05; Figure 6.8B). There was no difference in the 
overall trend. Similarly, CXCL1 was increased at 6 hours but not 12 hours after LPS in CD1 and 
CCR2
-/- 
mice (p<0.05; Figure 6.8C). CXCL2 was not found to be increased after LPS in either strain. 
This was surprising, as CXCL2 had previously been found to be significantly increased in pregnant 
CD1 mice in response to LPS (p<0.05; Figure 4.8E). It may be that in this cohort of mice, greater 
inter-animal variability prevented statistical significance from being achieved.  
The inflammatory response to LPS in CCR2
-/-
 mice was also studied in left ventricular tissue, where 
relative mRNA expression levels of pro- and anti-inflammatory cytokines and chemokines were 
measured. No direct comparisons could be made between CD1 and CCR2
-/- 
left ventricles in response 
to LPS, but it was evident that three of the key pro-inflammatory cytokines were supressed in CCR2
-/-
 
mice (Figure 6.9). In CCR2
-/-
 mice IL-1β (Figure 6.9A), IL-6 (Figure 6.9C) and TNF-α (Figure 6.9E) 
were not upregulated 6 or 12 hours after LPS administration. In CD1 mice 6 hours after LPS, IL-1β 
expression was significantly increased (p<0.01; Figure 6.9B) and similarly IL-6 (p<0.01; Figure 6.9D) 
and TNF-α (p<0.001; Figure 6.9F) were also significantly increased. Further to this, in CCR2-/- mice 
LPS caused no upregulation in mRNA expression of any of the markers of inflammation, cardiac 
dysfunction or apoptosis that were measured including Cox-2, ANP, BNF, Bcl-2, Bax and Bad (data 
not shown). 
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6.2.5 Circulating Expression of Vasoactive Factors in Response to LPS in Pregnant CCR2 Knockout 
Mice 
NO and ADMA concentrations in serum from pregnant CD1 or CCR2
-/-
 mice 6 and 12 hours after 
LPS or vehicle control (PBS) were determined using the Seivers nitric oxide analyser and mass 
spectrometry respectively. Absolute concentrations of vasoactive factors in serum were measured 
using the Millipore MAGpix multiplex assay system to evaluate the systemic response.  
Serum NO concentrations were comparable with those seen previously in pregnant mice. Compared 
to CD1 mice, CCR2
-/-
 mice had significantly lower circulating NO, where concentrations were found 
to be 22.88 ± 1.7 μM and 21.66 ± 4.6 μM at 6 and 12 hours post-PBS respectively in CCR2-/- mice 
compared to 44.67 ± 9.9 and 47.6 ± 4.5 μM at 6 and 12 hours post-PBS respectively in CD1 mice 
(p<0.05; Figure 6.10A). At 6 hours post-LPS, NO was significantly increased in CD1 mice to 86.49 ± 
10.8 μM (p<0.05) and although there were increases in NO at 12 hours post-LPS due to high 
variability these were not significant. As well as lower basal NO, CCR2
-/-
 mice also had significantly 
reduced circulating NO 6 hours after LPS compared to CD1 mice (p<0.05) which was not 
significantly increased from PBS controls. At 12 hours after LPS there were increases in NO in 
CCR2
-/-
 mice, but like in CD1 mice this did not reach statistical significance.      
To explore the differences in NO concentrations further, circulating ADMA levels were measured in 
serum of CD1 and CCR2
-/-
 mice. In PBS-treated CCR2
-/-
 mice, significantly reduced ADMA 
concentrations were found compared to those in CD1 mice (p<0.001; Figure 6.10B). No difference in 
ADMA was observed in CD1 mice after LPS treatment at either 6 or 12 hours post-LPS. Likewise, 
LPS did not alter AMDA levels in CCR2
-/-
 mice and thus ADMA was significantly decreased at both 
6 and 12 hours post-LPS compared to CD1 mice (p<0.001).  
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Figure 6.10: Circulating concentrations of nitric oxide and asymmetric dimethylarginine in the serum of 
pregnant CD1 and CCR2
-/-
 mice treated with LPS or vehicle. Measurements were made in serum samples 
taken 6 or 12 hours after LPS or vehicle in CD1 and CCR2
-/-
 mice. (A) Concentration of total nitrates and 
nitrites (NOx) as measured by nitric oxide analyser (B) ADMA as measured by mass spectrometry. *p<0.05, 
**p<0.01, ***p<0.001 compared to PBS control unless otherwise indicated, pairwise t-test comparisons or 
Mann Whitney U tests were used where appropriate.  Data shown as mean ± SEM, or as median ± interquartile 
range showing minimum and maximum (CD1 6 HR PBS, n=7; CD1 12 HR PBS, n=5; CCR2
-/-
 6 HR PBS, n=4; 
CCR2
-/-
 12 HR PBS, n=6; CD1 6 HR LPS, n=4; CD1 12 HR LPS, n=4; CCR2
-/-
 6 HR LPS, n=6; CCR2
-/-
 12 HR 
LPS, n=6) 
VEGF was not altered by CCR2 deficiency or the administration of LPS in these animals (Figure 
6.11A). This was not surprising as previous data had suggested that LPS did not significantly increase 
VEGF in pregnant animals. LPS administration caused PLGF2 to be significantly increased in both 
CD1 mice as previously seen (p<0.05; Figure 6.11B) and in CCR2
-/-
 mice (p<0.01, p<0.05 at 6 and 12 
hours post-LPS respectively). Levels of PLGF2 were diminished in CCR2
-/-
 mice, although this was 
not significant in PBS-treated animals. However, after LPS the increase in PLGF2 was significantly 
diminished in CCR2
-/-
 mice (p<0.05). There were no differences in ET-1 between PBS- treated CD1 
and CCR2
-/-
 mice (Figure 6.11C). Additionally, there were no increases in ET-1 in CD1 mice after 
LPS. However at 6 hours post-LPS, ET-1 was significantly increased in CCR2
-/-
 mice (p<0.05). 
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Figure 6.11: Circulating concentrations of vasoactive factors in serum of pregnant CD1 and CCR2-/- 
mice treated with LPS or vehicle. (A) VEGF (B) PLGF2 (C) Endothelin-1. *p<0.05, **p<0.01, compared to 
vehicle control unless otherwise indicated, pairwise t-test comparisons or Mann Whitney U tests were used 
where appropriate. Data shown as mean ± SEM (CD1, n=7; CCR2
-/-
, n=4). 
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6.2.7 The Haemodynamic Response to LPS-induced Inflammation after Pharmacological CCR2 
Inhibition in Pregnant Mice  
To further explore the effects of CCR2 inhibition on LPS-induced hypotension in pregnancy, the 
CCR2 antagonist RS504393 was used in CD1 mice. RS504393 was chosen for its high specificity to 
CCR2 (approximately 700-fold better binding than at CCR1 with no binding at CXCR1 or CCR3 
[406]) and due to recent evidence that suggested blockade of CCR2 using this receptor antagonist may 
be protective in murine sepsis [172]. Based on the experimental model of Souto et al., and others, 
RS504393 was given 2mg/kg subcutaneously in PBS (5% DMSO in PBS was given as vehicle) 30 
minutes prior to LPS on E16 and every 12 hours thereafter until the onset of labour [172, 407-410].  
Preliminary studies showed that RS504393, given to pregnant mice from E16 onwards, caused no 
maternal morbidity and that animals laboured spontaneously at term and birthed live litters (data not 
shown, n=3). After LPS administration, latency to labour in RS504393-treated mice did not 
significantly differ from vehicle-treated mice, however, labour time was much more variable (32.22 ± 
7.98 hours compared to 28 ± 2.65 in vehicle-treated mice; data not shown, n=4-8). Pup survival was 
improved in RS504393-treated mice (19.79 ± 12.4 % survival, compared to 0% in vehicle-treated; 
data not shown, n=4-8), although again, the data were highly variable.  
Experiments to assess the haemodynamic response of pregnant mice to LPS after pharmacological 
CCR2 inhibition with RS504393 showed that compared with pregnant vehicle (PBS/DMSO) controls, 
MAP was maintained at pre-LPS baseline levels (Figure 6.12A). Vehicle-treated mice exhibited a 
nadir in MAP of Δ-24.23 ± 10.04 mmHg at 19 hours post-LPS and MAP did not return to baseline 
within the 24 hours period, where in RS504393-treated mice MAP dropped to Δ-7.6 ± 5.97 mmHg at 
12 hours post-LPS but this drop below baseline recovered by 14 hours (Δ2.62 ± 2.87 mmHg).  
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Figure 6.12: The haemodynamic response to LPS-induced inflammation in mice pre-treated with CCR2 
inhibitor. The haemodynamic response in mice pre-treated with CCR2 inhibitor RS504393 or vehicle 
(PBS/DMSO) were recorded for 24-hours following LPS administration on E16. (A) ΔMAP (B) ΔSAP (C) 
ΔDAP. Data are expressed as a mean change from pre-LPS baseline (pre) ± SEM (PBS/DMSO, n=2; 
RS504393, n=6).   
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Figure 6.13: The heart rate response to LPS-induced inflammation in mice pre-treated with CCR2 
inhibitor. Heart rate in mice pre-treated with CCR2 inhibitor RS504393 or vehicle (PBS/DMSO) were recorded 
for 24-hours following LPS administration on E16. Data are expressed as a mean change from pre-LPS baseline 
(pre) ± SEM (PBS/DMSO, n=2; RS504393, n=6).  
 
 
There was no statistical significance between treatment groups as assessed by 2-way ANOVA 
followed by Bonferroni correction for multiple tests. Unfortunately there were some time points 
between 8-24 hours at which no data could be collected which led to this statistical test only being 
carried out between pre-LPS baseline and 8 hours post-LPS. This, and the small n number for vehicle 
control, may be the reason for a lack of significance.   
Similar results were obtained for SAP and DAP (Figure 6.12B, 6.12C) where a comparable trend was 
observed. The nadir in SAP in vehicle-treated mice was measured to be Δ-38.6 ± 0 at 15 hours post-
LPS compared to Δ4.25 ± 7.01 mmHg in RS504393-treated mice. A much earlier drop in DAP was 
seen in vehicle-treated mice after LPS where a ΔDAP of Δ-20.3 ± 1.07 mmHg was seen at 3 hours 
post-LPS. DAP then recovered to some extent but dropped to Δ-19.1 ± 1.88 mmHg by 8 hours and 
did not return to baseline levels. Despite these trends, there was no statistical significant difference 
between treatment groups.  
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As seen in previous experiments, HR in the vehicle-treated mice dropped in response to LPS to a 
nadir of Δ-211.02 ± 76.8 bpm by 3 hours (Figure 6.13). There was also an initial drop in HR in 
RS504393-treated mice but of much smaller magnitude (Δ-81.73 ± 44.59 bpm at 3 hours post-LPS). 
HR in RS504393-treated mice then remained at baseline but the HR of vehicle-treated animals did not 
return to baseline within the 24 hour period of recordings. There was no statistical significant 
difference between treatment groups.  
Following a similar trend to the results obtained from CCR2
-/-
 mice, where CCR2 was blocked by 
pharmacological antagonism  AUC analyses showed that MAP was significantly increased after LPS 
compared to vehicle (p<0.05; Figure 6.14A). The maximum decrease in ΔMAP in RS504393-treated 
mice was diminished but this did not reach statistical significance, and although the maximum 
increase in ΔMAP was greater, statistical analysis was not possible (Figure 6.14B, 6.14C). 
Correspondingly, the AUC for SAP was significantly increased in RS504393-treated mice after LPS 
(p<0.05; Figure 6.14D) and the maximum decrease was significantly decreased (p<0.05; Figure 
6.14E). Likely due to the large variability in maximum increase in vehicle-treated mice, there was no 
difference between treatment groups (Figure 6.14F). Unlike the significant differences in DAP 
between CCR2
-/-
 mice and CD1 controls, RS504393 treatment did not cause significant increases in 
the AUC for DAP, nor a significant increase in maximum increase in ΔDAP (Figure 6.14G, 6.14I). 
There was no overall difference in HR as assessed by AUC analysis (Figure 4.16J), however the 
maximum increase in ΔHR was significantly increased in RS504393-treated mice (p<0.05; Figure 
4.16L).  
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Figure 6.14: The haemodynamic response to LPS-induced inflammation in in mice pre-treated with 
CCR2 inhibitor or vehicle control as assessed by AUC, maximum decrease and maximum increase. The 
haemodynamic response in mice pre-treated with CCR2 inhibitor RS504393 or vehicle (PBS/DMSO) were 
recorded 24-hours after LPS administration. AUC analysis was perfomed for MAP (A), SAP (D), DAP (G) and 
HR (J). Maximum decrease was calculated for MAP (B), SAP (E), DAP (H) and HR (K). Maximum increase 
was calculated for MAP (C), SAP (F), DAP (I) and HR (L). *P<0.05 Mann-Whitney U test. Data are expressed 
as mean ± SEM (PBS/DMSO, n=2; RS504393, n=6).   
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To explore the possibility of altered activity levels contributing to changes in haemodynamics 
between treatment groups, activity levels were considered (Figure 6.15). There were no significant 
differences in the Δ%TSI, ΔActivity or ΔActivity>0 after LPS in either the vehicle- or RS504393-
treated groups. However, it is important to note that both groups had an increased %TSI and 
decreased activity after LPS compared to pre-LPS baseline, which was not true of CD1 mice (Figure 
6.6). Therefore the possibility of the DMSO in the vehicle affecting activity should be considered. In 
the design of this experiment, care was taken to reduce DMSO levels to 5% in solution and the 
animals showed no typical signs of DMSO-induced morbidity (piloerection, porphyrin staining and 
hunched posture).      
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Figure 6.15: Activity in pregnant mice pre-treated with CCR2 inhibitor after LPS administration. 
Activity levels in mice pre-treated with CCR2 inhibitor RS504393 or vehicle (PBS/DMSO) were recorded for 
24-hours following LPS administration on E16. (A) Δ%TSI (B) ΔActivity (C) ΔActivity>0. Data are expressed 
as a mean change from pre-LPS baseline (pre) compared to PBS controls ± SEM (PBS/DMSO, n=2; RS504393, 
n=6).   
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6.3 Summary and Discussion 
Non-pregnant CCR2
-/-
 mice did not have significant alterations in blood pressure but HR was 
decreased compared to CD1 mice. Accompanying this, CCR2
-/-
 mice were found to be significantly 
more active. Latency to labour and pup survival after LPS administration (10μg) and vehicle control 
in CCR2
-/-
 mice were not significantly different to CD1 mice. Compared with CD1 controls, the 
haemodynamic response to LPS in CCR2
-/-
 mice was markedly augmented. Compared to the LPS-
induced hypotension in CD1 mice, in CCR2
-/-
 mice MAP was increased to a peak at 5 hours post-LPS 
and then returned to baseline. A very similar pattern was seen in SAP and DAP. There were no 
differences in %TSI which was as expected, as both groups of mice were pregnant and nesting. At 
intermediate time points between LPS administration and labour, circulating concentrations of TNF-α 
were found to be significantly reduced and IL-4 and IL-10 were significantly increased in CCR2
-/-
 
mice compared to CD1. The increase in expression of pro-inflammatory cytokines (IL-1β, IL-6 and 
TNF-α) in CD1 left ventricle at 6 hours post-LPS were not upregulated in CCR2-/- mice. Both 
circulating NO and ADMA concentrations were significantly reduced in CCR2
-/-
 mice both basally 
and after LPS challenge. Additionally PLGF2, but not VEGF, was reduced in CCR2
-/-
 mice at 6 hours 
post-LPS and this was accompanied by a significant increase in ET-1. By administering a CCR2 
antagonist (RS504393) to CD1 mice, CCR2 blockade prevented LPS-induced hypotension; however 
greater numbers may be needed in addition to this preliminary work to potentially achieve statistical 
significance.   
In this study CCR2 deficiency did not alter the timing of LPS-induced PTL. This result has been 
previously observed in our group (intrauterine LPS) and others [168]. The onset of LPS-induced PTL 
is in part, triggered by premature myometrial and decidual activation which cannot be overcome by 
blockade of CCR2 alone. Recently a broad spectrum chemokine inhibitor (BSCI) has been shown to 
delay systemic LPS-induced inflammatory PTL in the mouse [411]. The BSCI was thought to have 
more efficacy as a tocolytic agent as previous therapies targeting specific chemokines failed to mount 
the redundancy of the inflammatory pathway.  
 200 
 
ET-1 was seen to be significantly increased at 6 hours post-LPS in CCR2
-/-
 but not in CD1 mice. A 
potent vasoconstrictor, this may help to explain the significant increase in MAP observed in CCR2
-/-
 5 
hours post-LPS. There is evidence to support an interplay between ET-1 and CCL2/CCR2 signalling, 
as CCL2 can be synthesised in the endothelium, cardiac myocytes and renal cells in response to 
haemodynamic (shear stress and blood flow) and hormonal stimuli (angiotensin II and ET-1) [400]. In 
blood vessels chemokines also play a role in the control of inflammation in blood vessel walls where 
infiltrating inflammatory cells and oxidative stress at the vascular wall can cause hypertension [400, 
412]. Oxidative stress triggers signalling cascades that result in increased wall rigidity and narrowing 
of the vessel lumen [404]; however this mechanism has been contested by Kvist et al., who showed 
that in a model of renal artery stenosis induced-hypertension, removal of the stenosis resulted in 
alleviated hypertension but resistance vessel morphology regressed either slowly or not at all [413].  
In this mouse model, we supposed that a lack of CCL2/CCR2 signalling caused decreased monocyte 
and neutrophil recruitment to off-target sites and thus prevented excessive macrophage infiltration and 
subsequent release of NO and other pro-inflammatory cytokines. This explanation could account for 
the decrease in circulating TNF-α and NO concentrations seen in pregnant CCR2-/- mice after LPS 
challenge. In turn, the reduction in NO could account for the failure of LPS to elicit hypotension in 
these animals. It is likely that the reduced TNF-α levels could also contribute to this effect as TNF is 
known to induce  vasodilation and a loss of vascular permeability [414].  
Previous work has demonstrated that a lack of functional CCR2 receptors may be associated with the 
emergence of hypertension in humans [415, 416]. However, other studies showed that CCR2 
blockade in a L-NAME induced model of hypertension in rats caused a reduction in blood pressure by 
the inhibition of TNF-α and NF-B [417]. Taken together with the findings presented here, these data 
suggest that an attenuation of the excessive pro-inflammatory cytokines can ameliorate subsequent 
effects on blood pressure.   
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At both 6 and 12 hours post-LPS, TNF-α was reduced in the serum of CCR2-/- mice. Likewise, there 
was also an absence of LPS-induced TNF-α mRNA upregulation in CCR2-/- left ventricle. In mice, 
CCR2 is expressed in immature DCs [392]. Peters et al., demonstrated that trafficking of these cells, 
as well as other antigen presenting cells (APCs) is impaired in CCR2 deficient mice [418]. This 
mechanism has been shown to be responsible for diminished INF-γ production and could provide an 
explanation for decreased TNF-α production, possibly from DCs or macrophages, in pregnant CCR2-/- 
mice after LPS exposure.  
Furthermore, CCR2 has been shown to regulate TNF-α/iNOS producing dendritic cell (tipDC) 
emigration into the circulation from bone marrow [419] where CCR2 deficiency prevented tipDC 
trafficking, although this was not seen to correlate with decreased morbidity or mortality after 
influenza virus challenge [420]. This mechanism may also contribute to decreased levels of TNF-α 
and NO measured in the circulation of pregnant CCR2
-/- 
mice after LPS. 
Alongside decreases in TNF-α, the significant increases in circulating IL-4 (at 12 hours post-LPS) and 
IL-10 (at 6 and 12 hours post-LPS) suggest that in these pregnant CCR2
-/- 
mice there is a modulated 
inflammatory response, where the balance between pro- and anti-inflammatory cytokine release is 
dysregulated. Alternatively, another explanation could be that in these mice there is an impaired 
adaptive immune response that is characteristic of dominating Th2 responses, although by 12 hours it 
may be too early to truly determine the involvement of the adaptive immune response. However, aside 
from the role of CCL2/CCR2 signalling in innate immune responses, there are several lines of 
evidence that CCR2 has been shown to be involved in regulating Th1- and Th2-type immunity [167, 
421]. In vitro, CCL2 expression has been shown to enhance secretion of IL-4 by naïve T cells as well 
as Th2-differentiated cells [422]. However in vivo, mice lacking CCR2 are more susceptible to 
infection from pathogens including Leishmania major and Listeria monocytogenes  at least in part due 
to impaired adaptive immune responses by way of an early development of Th2 responses 
demonstrated by high IL-4 levels [419, 423]. Taken together with the CCR2-dependency of tipDCs, 
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these results support the concept that increases in IL-4 and Th2 cytokines are in part caused by the 
paucity of DC migration [423-425].  
It should be taken into consideration that the majority of published data discussed here were collected 
from studies using non-pregnant animals. As it has been established that the immune response is 
already altered in pregnancy, it cannot be disregarded that the actions of systemic CCL2/CCR2 
signalling in pregnancy are also altered. However, our earlier finding that systemic CCL2 levels were 
not altered in pregnancy compared to levels in NP mice (see Chapter 4), would suggest that the effects 
of CCL2 deletion on the response to LPS are not likely to be specific to pregnancy.  
When the CCR2 antagonist RS504393 was administered, the haemodynamic response to LPS 
reflected what had been observed in the knockout mouse, where LPS-induced hypotension was 
ameliorated. After AUC analyses, MAP and SAP were seen to be significantly increased compared to 
vehicle-treated mice, however no hypertension was observed and MAP remained at levels close to 
pre-LPS baseline. These data suggest that although CCR2 inhibition was achieved, it may have been 
only partial antagonism. This could be due to greater doses needing to be administered during 
pregnancy secondary to altered drug metabolism and/or haemodilution, or that a dose regimen should 
have been begun at an earlier time point to achieve maximum drug efficacy. The effects on the 
inflammatory response would need to be studied in greater detail to allow for further comparisons to 
be made to the genetic deletion of CCR2. What this study demonstrates, however, is that the 
compensatory mechanisms and promiscuity of the chemokine pathways are not able to surmount the 
effects of genetic manipulation of CCR2 in this model.   
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Chapter 7: The Effect of Dimethylarginine 
Dimethylaminohydrolase-1 Deficiency in Pregnancy 
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7.1 Introduction 
Currently, methods of targeting NO include the manipulation of NO regulators, including the NO 
synthase enzymes and the DDAH enzymes which hydrolyse ADMA. To try and explore the role of 
NO in LPS-induced hypotension in pregnancy, we employed a mouse model of DDAH1 deficiency.  
Studies that employed genetic eNOS deficiency to investigate the effects of altered NO levels 
demonstrated that the eNOS knockout mouse (eNOS
-/-
) had significantly elevated MAP [426-428]. 
Investigations into the role of eNOS in blood pressure regulation in pregnancy showed that elevated 
blood pressure persisted throughout pregnancy in eNOS
-/-
 mice [429], and continuing from this 
Kusinski et al., demonstrated that in eNOS
-/-
 mice, pregnancy resulted in fetal growth restriction 
(FGR) which was associated with impaired uterine artery function (greater vasoconstriction and 
impaired vasodilatory capacity) that consequently led to placental hypoxia [428]. However, contrary 
to these findings, Shesely et al., had investigated the haemodynamic profile of nNOS
-/-
, eNOS
-/-
, and 
iNOS
-/-
 mice throughout gestation and found that pregnancy did not increase blood pressure in any of 
the three strains of NOS deficiency [430]. Despite that eNOS
-/-
 mice were hypertensive before 
pregnancy, blood pressure reverted to be no different from control during pregnancy.   
Work that examined the role of eNOS in blood pressure regulation in sepsis and inflammation showed 
that in a endotoxaemic model of sepsis, eNOS
-/-
 mice were resistant to LPS-induced hypotension and 
the authors comment that mortality was markedly reduced [427]. Further to this, Connelly et al., saw 
that LPS administration led to a time-dependent increase in the expression of iNOS in multiple 
organs, but in eNOS
-/-
 mice there were significantly lower levels of iNOS protein expression. This led 
the authors to conclude that eNOS derived NO plays a crucial role in facilitating iNOS expression in 
LPS-induced endotoxaemia [427].  
NO inhibition has also been studied by pharmacological inhibition using exogenous L-NMMA or 
L-NAME, inhibitors that target all three NOS isoforms. Several studies have shown that in rodent 
models, L-NMMA and L-NAME were able to significantly elevate blood pressure [431-434] 
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although, Pullamsetti et al., suggested that selective iNOS inhibitors were superior to non-specific 
NOS inhibitors for the treatment of both macro- and microcirculatory abnormalities in septic shock 
[433].  
These data along with the results from genetically targeted NOS depletion suggested that NOS 
inhibition could be beneficial in treating septic shock, but several clinical trials proved unsuccessful 
with the intervention groups showing at best no significant improvement and at worst increased 
mortality [181, 435, 436]. Therefore an alternative approach in the modulation of NO production is to 
target DDAH. Inhibition of DDAH increases the endogenous NOS inhibitor ADMA [437]. 
Furthermore, as DDAH isoforms are tissue-specific [97], this would enable a more controlled 
approach to NOS inhibition, rather than the global effect achieved by exogenous administration of L-
NMMA. 
Pharmacological DDAH1 inhibition using the DDAH1 selective compound L-257 has been shown to 
inhibit LPS-stimulated NO production in aorta but not in macrophages [437]. Additionally, L-257 and 
genetic alteration of DDAH1 by way of a DDAH1 heterozygous mouse (DDAH1
+/-
) led to an increase 
in endogenous ADMA.  Consequently, the haemodynamic changes that occurred in response to LPS 
were attenuated, namely there was a significant improvement in the minimum systolic and diastolic 
blood pressure recorded in the 40 hour period after LPS administration [437]. These data are 
supported by evidence showing that by using gene silencing techniques, disruption of DDAH1 but not 
DDAH2 induced an increase in ADMA levels [98, 438].  
Therefore to study the effects of NO modulation in the response to LPS in pregnancy, and with 
pharmacokinetic/pharmacodynamic data lacking for L-257 in pregnancy, the DDAH1 knockout 
mouse was used.  Initial attempts to generate a global DDAH1
-/-
 mouse through the replacement of 
exon 1 with a neomycin cassette through homologous recombination were unsuccessful and proved to 
be embryonic lethal [249, 439]. However more recently, Hu et al., were able to generate a global 
DDAH1
-/-
 mouse through deletion of DDAH1 in the sperm of male double heterozygote protamine-
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cre/DDAH1
flox/+
 mice to produce homozygous knockout offspring. Further generations could then be 
produced via inbreeding of the heterozygotes [440]. Genomic DNA PCR analysis showed that exon 4 
of the DDAH1 gene was deleted in these mice. In this study, a new global knockout mouse was 
generated in the Leiper laboratory (MRC CSC, Imperial College) where deletion of DDAH1 exon 1 
was driven by actin cre, using the cre/lox P system. 
7.1.1 Aims and Objectives 
As there have been no studies published that have examined haemodynamic data in female DDAH1
-/-
 
mice, it was important to firstly assess whether there were any basal non-pregnant differences to their 
male counterparts.  Secondly, as the DDAH1
-/-
 mice were on a different background to previous 
telemetry experiments undertaken throughout pregnancy in CD1 mice, it was imperative to examine 
both the haemodynamic profile of DDAH1 WT (C57BL/6) and DDAH1
-/-
 mice throughout pregnancy 
and to investigate the cardiovascular changes and adaptations in DDAH1
-/-
 mice compared to WT 
controls throughout pregnancy, labour and the post-partum period. Continuing from this, we aimed to 
examine the effects of LPS-induced inflammation in pregnant DDAH1
-/- 
mice on haemodynamic 
function and NO modulation. 
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7.2 Results 
7.2.1 The Haemodynamic Profile of Non-Pregnant DDAH1 Knockout Mice 
To determine if there were any basal haemodynamic differences between DDAH1 WT and DDAH1
-/-
 
females mice, non-pregnant recordings were taken before timed-mating. MAP was significantly 
elevated from 108.6 ± 0.98 mmHg in DDAH1 WT mice to 116 ± 2.8 mmHg in DDAH1
-/- 
(p<0.05; 
Figure 7.1A) over 24 hours. SAP was significantly elevated from 120.8 ± 1.6 mmHg in DDAH1 WT 
mice to 131.1 ± 2.38 mmHg in DDAH1
-/-
 (p<0.01; Figure 7.1B). DAP was more subtly elevated from 
96.18 ± 1.3 mmHg to 100.5 ± 3.4 mmHg in DDAH1
-/-
 mice, but this was not significant (Figure 
7.1C). Additionally DDAH1
-/-
 mice had a significantly elevated basal heart rate (p<0.05; Figure 7.1D) 
which increased to 605.5 ± 9.79 bpm from 562.1 ± 20.36 bpm in DDAH1 WT mice. There were no 
differences observed between DDAH1 WT and DDAH
-/-
 activity levels including the %TSI or 
intensity of activity (Figure 7.1E, 7.1F, 7.1G).  
7.2.2 The Haemodynamic Profile of Pregnancy in DDAH1 Knockout Mice 
In DDAH1 WT mice, the trend in MAP throughout pregnancy can be described as a decrease in 
pressure from E0 to E9 before returning to baseline by E13, followed by a subsequent decrease in 
pressure at E15 which returned to baseline by E18 (labour) which was followed by a final fall in the 
post-partum period (Figure 7.2A). The trend observed however, was highly variable with large SEM 
and the ΔMAP values may be skewed by a marked increase in MAP from baseline to E0 (Figure 
7.2B). The nadir in MAP of Δ-5.2 ± 9.5 mmHg at the mid-gestational point (E9) was not significantly 
reduced from baseline in these mice, which is in contrast to our previous findings in CD1 mice. The 
increase in MAP at E0 could be explained by heightened stress due to the animal cage being moved 
from the holding room to the recording room following evidence of a copulatory plug. This was also 
seen in CD1 mice, although the increase was not as marked.  
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Figure 7.1: The haemodynamic and activity profile of non-pregnant female DDAH1 WT and DDAH1
-/-
 
mice. Haemodynamic and activity parameters were recorded for 24 hours (prior to mating) in female virgin 
DDAH1 WT and DDAH1
-/-
 mice. (A) MAP (B) SAP (C) DAP (D) HR (E) %TSI (F) Activity (G) Activity >0. 
*p<0.05, **p<0.01 student’s t-test or Mann-Whitney U test as appropriate. Data expressed as mean ± SEM 
(DDAH1 WT, n=9; DDAH1
-/-
, n=11).    
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In DDAH1
-/-
 mice, the trend in MAP throughout pregnancy was not significantly different to WT 
(Figure 7.2). Aside from increased MAP at baseline, there are two main observations that are of note. 
Firstly, there is a subtle increase in MAP in DDAH1
-/-
 mice over the period between E3 and E8 where 
MAP is elevated. At its peak (E5), MAP was 115.14 ± 4.9 mmHg in DDAH1
-/-
 compared to 106.9 ± 
6.49 mmHg in DDAH1 WT. This elevation could be considered to be a conservation of baseline high 
blood pressure, as the ΔMAP did not elevate significantly above baseline. Secondly, MAP fell slightly 
further towards the end of gestation to a nadir at E14 of 99.83 ± 5.9 mmHg in DDAH1
-/-
 compared to 
105.6 ± 7 mmHg in DDAH1 WT mice, but interestingly this was followed by a discernible increase in 
MAP after labour (115.96 ± 4 mmHg on 1DPP, Δ14.2 mmHg from E18).   
Similar trends were observed in SAP and DAP, where again there were no significant statistical 
differences between DDAH1 WT and DDAH1
-/-
 mice (Figure 7.3, 7.4). The trend in SAP between E3 
and E8 was more pronounced than DAP, which may indicate that the MAP on these days is a 
reflection of SAP. However, this is not true for the post-partum rise in pressure.  
There were no significant differences in HR between DDAH1 WT and DDAH1
-/-
 mice over the 
course of gestation. HR in DDAH1
-/-
 mice remained higher than in WTs, (Figure 7.5A) but this was 
not as pronounced as in the non-pregnant state until the post-partum period. Therefore during 
pregnancy, DDAH1 WT and DDAH1
-/-
 mice followed a similar trend. Interestingly, there was a peak 
in HR at approximately E7 in both genotypes (Δ61.15 ± 35.42 bpm and Δ71.8 ± 9.2 bpm in DDAH1 
WT and DDAH1
-/-
 respectively) rising from E5 and returning to baseline on E9-10 (Figure 7.5B). 
This trend was not observed in CD1 mice, although this could be considered reflective of the normal 
increase in cardiac output in early pregnancy that resolves upon placental development.        
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Figure 7.2: Continuous measurement of mean arterial pressure (MAP) throughout pregnancy in DDAH1 
WT and DDAH1
-/-
 mice. (A) MAP in DDAH1 WT and DDAH1
-/-
 mice whilst not pregnant (Baseline), 
throughout gestation, and for 2 days post-partum (1DPP-2DPP) data shown as 24-hour mean average ± SEM 
(n=2-4) (B) ΔMAP from baseline in DDAH1 WT and DDAH1-/- mice. Data shown as 24-hour mean average ± 
SEM (DDAH1 WT, n=4; DDAH1
-/-
, n=4). 
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Figure 7.3: Continuous measurement of systolic arterial pressure (SAP) throughout pregnancy in 
DDAH1 WT and DDAH1
-/-
 mice. (A) SAP in DDAH1 WT and DDAH1
-/-
 mice whilst not pregnant (Baseline), 
throughout gestation, and for 2 days post-partum (1DPP-2DPP) data shown as 24-hour mean average ± SEM 
(n=2-4) (B) ΔSAP from baseline in DDAH1 WT and DDAH1-/- mice. Data shown as 24-hour mean average ± 
SEM (DDAH1 WT, n=4; DDAH1
-/-
, n=4). 
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Figure 7.4: Continuous measurement of diastolic arterial pressure (DAP) throughout pregnancy in 
DDAH1 WT and DDAH
-/-
 mice. (A) DAP in DDAH1 WT and DDAH1
-/-
 mice whilst not pregnant (Baseline), 
throughout gestation, and for 2 days post-partum (1DPP-2DPP) data shown as 24-hour mean average ± SEM 
(n=2-4) (B) ΔDAP from baseline in DDAH1 WT and DDAH1-/- mice. Data shown as 24-hour mean average ± 
SEM (DDAH1 WT, n=4; DDAH1
-/-
, n=4). 
 213 
 
Figure 7.5: Continuous measurement of heart rate (HR) throughout pregnancy in DDAH1 WT and 
DDAH1
-/-
 mice. (A) HR in DDAH1 WT and DDAH1
-/-
 mice whilst not pregnant (Baseline), throughout 
gestation, and for 2 days post-partum (1DPP-2DPP) data shown as 24-hour mean average ± SEM (n=2-4) (B) 
ΔHR from baseline in DDAH1 WT and DDAH1-/- mice. Data shown as 24-hour mean average ± SEM (DDAH1 
WT, n=4; DDAH1
-/-
, n=4).  
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7.2.3 Activity during Pregnancy in CD1 Mice 
There were no significant differences between the activity levels of DDAH1 WT and DDAH1
-/-
mice.  
There was a very similar pattern in %TSI throughout gestation between both DDAH1 WT and 
DDAH1
-/-
 (and CD1 behaviour as documented previously), where the %TSI gradually increased 
towards the time of labour (Figure 7.6). In the post-partum period %TSI decreased, likely due to 
weaning behaviours and reduced size of the mother. %TSI correlated with a decrease in activity and 
in the intensity of activity (activity>0; Figure 7.7, 7.8). The activity of DDAH1 WT mice was seen to 
be greater at baseline than DDAH1
-/-
 mice, although not significantly so. This may explain why the 
ΔActivity in DDAH1 WT was seen to be decreased (Figure 7.7B).     
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Figure 7.6: Continuous measurement of the percentage of time spent inactive (%TSI) throughout 
pregnancy in DDAH1 WT and DDAH1
-/-
 mice. (A) %TSI in DDAH1 WT and DDAH1
-/-
 mice whilst not 
pregnant (Baseline), throughout gestation, and for 2 days post-partum (1DPP-2DPP) data shown as 24-hour 
mean average ± SEM (n=2-4) (B) Δ%TSI from baseline in DDAH1 WT and DDAH1-/- mice. Data shown as 24-
hour mean average ± SEM (DDAH1 WT, n=4; DDAH1
-/-
, n=4). 
 216 
 
Figure 7.7: Continuous measurement of activity throughout pregnancy in DDAH1 WT and DDAH1-/- 
mice. (A) Activity in DDAH1 WT and DDAH1
-/-
 mice whilst not pregnant (Baseline), throughout gestation, and 
for 2 days post-partum (1DPP-2DPP) data shown as 24-hour mean average ± SEM (n=2-4) (B) ΔActivity from 
baseline in DDAH1 WT and DDAH1
-/-
 mice. Data shown as 24-hour mean average ± SEM (DDAH1 WT, n=4; 
DDAH1
-/-
, n=4).  
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Figure 7.8: Continuous measurement of activity >0 throughout pregnancy in DDAH1 WT and DDAH1
-/- 
mice. (A) Activity >0 in DDAH1 WT and DDAH1
-/-
 mice whilst not pregnant (Baseline), throughout gestation, 
and for 2 days post-partum (1DPP-2DPP) data shown as 24-hour mean average ± SEM (n=2-4) (B) ΔActivity>0 
from baseline in DDAH1 WT and DDAH1
-/-
 mice. Data shown as 24-hour mean average ± SEM (DDAH1 WT, 
n=4; DDAH1
-/-
, n=4). 
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7.2.4 Latency to Labour and Pup Survival Outcomes after LPS administration in DDAH1 Knockout 
Mice 
After i.p. PBS on E16, DDAH1 WT and DDAH1
-/-
 mice laboured at term, at 58.6 ± 12.26 hours and 
55.4 ± 4.61 hours respectively and birthed live litters (Figure 7.9A, 7.9B). 10μg LPS i.p on E16 
significantly reduced latency to labour to 22.56 ± 2.5 hours in DDAH1 WT and 21.8 ± 2.12 hours in 
DDAH1
-/-
 mice (p<0.001; Figure 7.9A). There were no significant differences from the effects of LPS 
between WT and knockout. In contrast to previous findings in CD1 mice, 10μg LPS did not lead to 
100% pup death in DDAH1 WT or DDAH1
-/-
 mice, where by the time of labour 10-25% of pups 
survived for at least 3 days post-partum. This could be accounted for by strain differences as these 
mice are on an inbred C57BL/6 background. Furthermore, there were no significant differences 
between pup survival at 6 and 12 hours and at labour between DDAH1 WT and DDAH1
-/-
, although 
there was a strong trend towards decreasing pup survival over time in both strains. This could be 
accounted for by high variability. 
During the process of timed-mating, it was observed that many of the animals that were plugged and 
had pregnancy confirmed by palpation on E8, were no longer pregnant on what would have been E15. 
Upon analysis, only 50% of DDAH1
-/-
 pregnancies resulted in success. Initial thoughts were that as 
DDAH1 has been previously shown to be important in mammalian development and that DDAH1 
null embryos (deletion of DDAH1 exon 1) could be generated at much lower frequency than DDAH2 
null (and could not progress through embryonic development), that these DDAH1
-/-
 mice could be 
resorbing pregnancies at a higher frequency due to developmental defects. However, it was 
determined that DDAH1 WT mice had equally as many ‘failed’ pregnancies (Figure 7.10A). 
Therefore, this phenomenon was likely to be due to inbred strain differences compared to the outbred 
CD1 strain used in previous experiments.  
Subsequently, because of the number of failed pregnancies and the consequent difficulty in timed-
mating these strains, the n numbers for the longitudinal study (where haemodynamics throughout 
gestation were studied) were much lower than those used to determine non-pregnant baseline.  
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Therefore because of the finite number of instrumented animals, this meant that no haemodynamic 
data could be collected in mice after LPS injection on E16 and it was not possible to study the 
haemodynamic response to LPS in DDAH1
-/-
 animals.  
 
 
Figure 7.9: Latency to labour and pup survival outcomes after LPS administration in DDAH1 WT and 
DDAH1
-/-
 mice. Latency to labour (A), pup survival after PBS (vehicle) (B) and pup survival after 10μg LPS 
administration were observed as outcomes after in DDAH1 WT and DDAH1
-/-
 mice. Latency to labour was 
assessed in telemetered mice ***P<0.001 compared to PBS control, 2-way ANOVA showing treatment but not 
genotype was significant. Data expressed as mean ± SEM (PBS groups, n=4; LPS groups, n=5).  (B) and (C) 
Pup survival was noted during tissue collections at 6 and 12 hours post-LPS and at labour in telemetered 
animals. Data expressed as mean ± SEM (DDAH1 WT 6 HR, 12HR and Labour, n=4; DDAH1
-/-
 6 HR, 12HR 
and Labour, n=5).  
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Figure 7.10: The extent of failed pregnancies and average litter sizes in DDAH1 WT and DDAH1
-/-
 mice. 
(A) Failed pregnancies were counted in DDAH1 WT and DDAH1
-/-
 mice. After plug detection on E0 and 
confirmation of pregnancy by embryo/placenta palpation on E8, failed pregnancies were then counted if the 
mouse was no longer gravid on what would be E15. Data are expressed as a percentage of the total pregnancies 
counted (n=11-13). (B) Litter sizes were recorded from litters born to telemetered animals as well as at the time 
of tissue collections (6 or 12 hours after PBS/LPS i.p.; DDAH1 WT, n=29; DDAH1
-/-
. n=34).  
 
 
Further to this, it was noticed that DDAH1
-/-
 litters seemed to be smaller. The numbers of pups in each 
litter were counted after labour in telemetered animals, and also after opening the abdomen and uterus 
during 6 and 12 hour time point tissue collections. Whilst there was a slight trend towards smaller 
litter sizes in the DDAH1
-/-
 mice, this was not found to be significant (Figure 7.10B). The numbers 
noted (mean litter size of 7.2 ± 0.4 and 6.5 ± 0.5 for DDAH1 WT and DDAH1
-/-
 respectively) were 
consistent with previous reports in the literature [441, 442] and Jackson Laboratories state that 
C57BL/6 average litter sizes are typically 6-8.  
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7.2.5 Circulating Expression of Vasoactive Factors in Response to LPS in Pregnant DDAH1 
Knockout Mice 
NO and ADMA concentrations in serum from pregnant DDAH1 WT and DDAH1
-/-
 mice 6 and 12 
hours after LPS or vehicle control (PBS) were determined using the Seivers nitric oxide analyser and 
mass spectrometry respectively. Absolute concentrations of vasoactive factors in serum were 
measured using the Millipore MAGpix multiplex assay system to evaluate the systemic response.  
There were no significant differences in circulating NO concentrations on E16 after PBS injections 
between DDAH1 WT and DDAH1
-/-
 mice (Figure 7.11A). In DDAH1 WT mice, NO concentrations 
were significantly increased after LPS injection at 6 hours (from 7.39 ± 0.15 μM to 59.6 ±12.22 μM, 
p<0.01) and at 12 hours (from 17.65 ± 3.5 to 107.6 ± 37.72, p<0.05). However, whilst LPS increased 
NO concentration in DDAH1
-/-
 mice this was only significant at 12 hours (from 19.97 ± 2.24 μM to 
50.35 ± 8.01 μM after LPS, p<0.05).  
As there were no differences between circulating NO concentrations in DDAH1 WT and DDAH1
-/-
 
on E16 12 hours after LPS, circulating ADMA concentrations were measured (Figure 7.11B). ADMA 
levels were not changed after LPS administration, but DDAH1
-/-
 mice had significantly higher ADMA 
concentrations than DDAH1 WT mice at both time points (p<0.05). In PBS controls (at 6 hours), 
ADMA was elevated in DDAH1
-/-
 mice to 119.4 ± 15.06 pmoles compared to 64.75 ± 5.1 pmoles in 
DDAH1 WT mice. Similar results were seen in LPS-treated mice where in DDAH1
-/-
 ADMA 
measured 89.65 ± 9.5 pmoles compared to 65.27 ± 4.58 pmoles in DDAH1 WT mice. It therefore 
appeared that in pregnant DDAH1
-/-
 mice, NO levels were not affected by the increase in ADMA 
brought about by deletion of DDAH1. 
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Figure 7.11: Circulating concentrations of nitric oxide and asymmetric dimethylarginine in the serum of 
pregnant DDAH1 WT and DDAH1
-/-
 mice treated with LPS or vehicle. Measurements were made in serum 
samples taken 6 or 12 hours after LPS or vehicle in DDAH1 WT and DDAH1
-/-
 mice. (A) Concentration of total 
nitrates and nitrites (NOx) as measured by nitric oxide analyser (B) ADMA as measured by mass spectrometry. 
*p<0.05, **p<0.01, compared to PBS control unless otherwise indicated, pairwise t-test comparisons or Mann 
Whitney U tests were used where appropriate.  Data shown as mean ± SEM, or as median ± interquartile range 
showing minimum and maximum (DDAH1 WT 6HR PBS, n=4; DDAH1 WT 12HR PBS, n=6; DDAH1
-/-
 6HR 
PBS, n=6; DDAH1
-/-
 12HR PBS, n=5; DDAH1 WT 6HR LPS, n=8; DDAH1 WT 12HR LPS, n=6; DDAH1
-/-
 
6HR LPS, n=5; DDAH1
-/-
 12HR LPS, n=4). 
VEGF was not altered by DDAH1 deficiency or the administration of LPS in these animals (Figure 
7.12A). The isoform VEGF-D was not altered by DDAH1 deficiency; however compared to PBS 
control VEGF-D was both reduced at 6 hours post-LPS and increased 12 hours post-LPS in DDAH1 
WT mice (p<0.05; Figure 7.12B). There was no change in VEGF-D after LPS administration in 
DDAH1
-/-
 mice. PLGF2 was significantly increased after LPS (p<0.01), but only at 12 hours post-LPS 
in DDAH1 WT and DDAH1
-/-
 mice (Figure 7.12C). PLGF2 levels were elevated to 83.05 ± 25.01 
pg/mL and 98.39 ± 36.17 pg/mL in DDAH1 WT and DDAH1
-/-
 respectively from 12 hours post-PBS 
controls which were measured to be 5.94 ± 2.02 and 6.77 ± 2.4 pg/mL. ET-1 was not significantly 
different between DDAH1 WT and DDAH1
-/-
 mice in PBS controls (Figure 7.12D). There were also 
no differences in ET-1 levels after LPS administration in DDAH1 WT mice, however in DDAH
-/-
 
mice, ET-1 was significantly increased to 38.87 ± 4.8 pg/mL 6 hours post-LPS compared to 21.85 ± 
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3.17 pg/mL 6 hours post-PBS (p<0.05). This elevation was attenuated by 12 hours post-LPS. 
Although significantly different from PBS controls, this elevation was not significantly different from 
LPS-treated DDAH1 WT mice at 6 hours.  
 
 
Figure 7.12: Circulating concentrations of vasoactive factors in serum of pregnant DDAH1 WT and 
DDAH1
-/-
 mice treated with LPS or vehicle. (A) VEGF (B) VEGF-D (C) PLGF2 (D) Endothelin-1. *p<0.05, 
**p<0.01, compared to vehicle control unless otherwise indicated, pairwise t-test comparisons or Mann Whitney 
U tests were used where appropriate. Data shown as mean ± SEM (n numbers as for Figure 7.11).  
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7.2.6 The Production of Inflammatory Markers, Markers of Cardiac Dysfunction and Apoptotic 
Markers in Left Ventricular Tissue in Response to LPS in Pregnant DDAH1 Knockout Mice 
To assess the extent of cardiac sensitivity, the relative expression of various markers of inflammation, 
cardiac dysfunction and apoptosis were assessed in maternal left ventricular tissue using RT-PCR. 
In the left ventricle, IL-1β mRNA expression was not altered by DDAH1 deficiency or by LPS 
administration in these mice (Figure 7.13A). IL-6 expression was increased at 6 hours post-LPS in 
DDAH1 WT mice, but not significantly when compared to PBS control (Figure 7.13B). In DDAH1
-/-
 
mice, IL-6 expression was significantly increased compared to PBS control (p<0.01) which was then 
significantly ameliorated by 12 hours post-LPS (p<0.05). The pro-inflammatory cytokine TNF-α was 
increased in DDAH1 WT and DDAH1
-/-
 mice (p<0.01 12 hours post-LPS in DDAH1 WT, p<0.05 6 
and 12 hours post-LPS in DDAH1
-/-
; Figure 7.13C). High variability in the DDAH1 WT at 6 hours 
post-LPS and in the PBS control is the likely reason for a lack of significance at 6 hours post-LPS. 
There were also significant increases in Cox-2 (6 hours post-LPS only, p<0.01; Figure 7.13E), and the 
chemokines CXCL1 (at 6 and 12 hours post-LPS, p<0.05 and p<0.01; Figure 7.13F) and CXCL2 (at 6 
and 12 hours post-LPS; Figure 7.13G). There were no changes in the anti-inflammatory cytokine IL-
10 (Figure 7.13D).  
Interestingly, 6 hours after LPS administration, iNOS mRNA expression in the left ventricle was 
significantly reduced in DDAH1 WT (p<0.001) and DDAH1
-/-
 mice (p<0.01; Figure 7.14A). There 
was no change in iNOS expression due to DDAH1 deficiency. Similarly, there was no change in 
eNOS expression due to DDAH1 deficiency in left ventricle (Figure 7.14B). However, 6 hours after 
LPS eNOS expression was significantly decreased in DDAH1
-/-
 (p<0.001) and not in the DDAH1 WT 
(p<0.01 compared to DDAH1
-/-
). There were no changes in ANP (Figure 7.14C), but BNF was 
significantly increased 6 hours post-LPS in DDAH1 WT (p<0.01) and DDAH1
-/-
 mice (p<0.01; 
Figure 7.14D). Interestingly, the increase in BNF was greater in DDAH1
-/-
 (p<0.05 compared to 
DDAH1 WT 6 hours post-LPS; Figure 7.14D). There were no changes in αMHC, βMHC or SERCA 
expression (Figure 7.14E, 7.14F, 7.14G). ET-1 expression in the left ventricle was increased 6 hours 
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after LPS, but this was only significant in DDAH1
-/-
 mice (p<0.05), likely due to high variability in 
DDAH1 WT response (Figure 7.14H). Surprisingly, VEGF was found to be significantly decreased 
after LPS, but only in the DDAH1 WT mice at 12 hours (p<0.01 compared to PBS control). It must be 
considered that VEGF expression, although decreased from PBS control, was not significantly 
different from DDAH1 WT 6 hours post-LPS or from DDAH1
-/-
 12 hours post-LPS, and therefore 
may just be a reflection of an increase in VEGF 12 hours post-PBS in DDAH1 WT mice.  
In the left ventricle, Bcl-2 mRNA expression was decreased 6 and 12 hours after LPS, although this 
effect was only able to reach significance in the DDAH1
-/-
 mice (p<0.05; Figure 7.15A). This is likely 
to be due to high variability in Bcl-2 expression in the PBS controls in DDAH1 WT mice. There were 
no differences between DDAH1 WT and DDAH1
-/-
 mice, indicating that DDAH1 deficiency did not 
alter Bcl-2. Bad expression was not altered in PBS controls between DDAH1 WT and DDAH
-/-
 mice 
(Figure 7.15B).  
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Figure 7.13: mRNA expression of pro- and anti-inflammatory cytokines, inflammatory regulators and 
chemokines in left ventricular tissue taken from DDAH1 WT and DDAH1
-/-
 mice treated with LPS or 
vehicle. (A) IL-1β (B) IL-6 (C) TNF-α (D) IL-10 (E) Cox-2 (F) CXCL1 (G) CXCL2. *p<0.05, **p<0.01 
compared to PBS control unless otherwise indicated, pairwise t-test comparisons or Mann Whitney U tests were 
used where appropriate. Data are expressed as mean ± SEM (DDAH
-/-
 12HR PBS, n=5; DDAH1
-/-
 6HR LPS, 
n=5; DDAH1
-/-
 12HR LPS, n=4; all other groups n=6).  
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Figure 7.14: mRNA expression of markers of cardiac dysfunction in left ventricular tissue taken from 
DDAH1 WT or DDAH1
-/-
 mice treated with LPS or vehicle. (A) iNOS (B) eNOS (C) ANP (D) BNF (E) 
αMHC (F) βMHC (G) SERCA (H) Endothelin-1 (I) VEGF. *p<0.05, **p<0.01, ***p<0.001 compared to PBS 
control unless otherwise indicated, pairwise t-test comparisons or Mann Whitney U tests were used where 
appropriate. Data are expressed as mean ± SEM (DDAH
-/-
 12HR PBS, n=5; DDAH1
-/-
 6HR LPS, n=5; DDAH1
-
/-
 12HR LPS, n=4; all other groups n=6). 
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Figure 7.15: mRNA expression of markers of apoptosis in left ventricular tissue taken from DDAH1 WT 
or DDAH1
-/-
 mice treated with LPS or vehicle. (A) Bcl-2 (B) Bax (C) Bad. *p<0.05, compared to PBS control 
unless otherwise indicated, pairwise t-test comparisons or Mann Whitney U tests were used where appropriate. 
Data are expressed as mean ± SEM (DDAH
-/-
 12HR PBS, n=5; DDAH1
-/-
 6HR LPS, n=5; DDAH1
-/-
 12HR LPS, 
n=4; all other groups n=6).   
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7.2.7 The Production of Vasoactive Factors in DDAH1 Knockout Mouse Placenta 
Placental tissue taken 6 or 12 hours after PBS i.p from DDAH1 WT and DDAH1
-/- 
mice were 
analysed to investigate vasoactive factors that could influence maternal haemodynamics. As there 
were no significant differences between any of the factors measured between 6 and 12 hours post-PBS 
these tissues were pooled and referred to as DDAH1 WT or DDAH1
-/-
 only. 
Placental tissue from DDAH1
-/-
 mice had significantly higher concentrations of ADMA compared to 
WT (14.51 ± 1.18 vs. 8.22 ± 0.68 pmol/mg tissue; Figure 7.16A). In accordance with this finding, 
placentas from DDAH1
-/-
 mice had significantly lower concentrations of L-arginine (1.42 ± 0.09 
pmol/mg tissue) compared to WT (1.90 ± 0.12 pmol/mg tissue; Figure 7.16B). Similar to circulating 
concentrations (Figure 7.11A) placental NO concentrations were not significantly different in 
DDAH1 deficient mice (Figure 7.16C).  
sFlt-1 is the soluble form of the VEGF/PLGF receptor Flt-1 (also known as sVEGFR1) which has 
been shown to act as a VEGF and PLGF antagonist [443, 444]. sFlt-1 produced by the placenta in 
response to hypoxia is released into the maternal circulation and can both antagonise the angiogenic 
effects of VEGF and PLGF as well as sensitise endothelial cells to the effects of pro-inflammatory 
cytokines [444, 445]. sFlt-1 concentration did not significantly differ between DDAH1 WT and 
placental tissue from DDAH1
-/-
 mice
 
(Figure 7.16D). Placentas from DDAH1
-/-
 mice overall exhibited 
higher concentrations of sFlt-1 with a mean concentration of 11.1 ± 0.47 ng/μg tissue vs. 9.86 ± 0.51 
ng/μg tissue in DDAH1 WT placenta but this did not reach significance.  
Placental tissue from DDAH1
-/- 
mice had significantly lower mRNA expression of iNOS (p<0.05; 
Figure 7.16E) and VEGF-B (p<0.05; Figure 7.16H) compared to DDAH1 WT mice. There was no 
significant difference in expression of eNOS, VEGF, ET-1 or Hsp70 (Figure 7.16F, 7.16G, 7.16I, 
7.16J) between DDAH1 WT and placental tissue from DDAH1
-/- 
mice. In addition, expression of 
PPAR-γ, PGC1-α, VEGF-C and VEGF-D did not significantly differ between DDAH1-/- and DDAH1 
WT placenta (data not shown). Interestingly, 4 of the 11 placentas from DDAH1
-/-
 mice exhibited a 
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mean mRNA expression of Hsp70 that was 40-fold higher than the mean expression of Hsp70 in 
DDAH1 WT placentae and 2.5-fold higher than the 7 other placenta from DDAH1
-/-
 mice. 
Placental tissue from DDAH1
-/-
 mice exhibited lower protein expression of DDAH1 compared to 
DDAH1 WT mice (Figure 7.17A, 7.17B). DDAH-1 expression is still observed in these placentas, as 
homozygous female DDAH1
-/-
 mice were mated with CD1 (DDAH1
+/+
) stud males, therefore the 
resulting placentas, which consist of tissue of both maternal and fetal origin, display heterozygous 
expression of DDAH1. Densitometry analysis which calculated the ratio of DDAH1 to GAPDH 
(loading control) confirmed this observation (p<0.001; Figure 7.17B). There was no significant 
difference in the protein expression of DDAH2 between DDAH1 WT and placentas from DDAH1
-/-
 
mice (Figure 7.17A, 7.17C). 
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Figure 7.16: Placental concentrations of vasoactive factors in DDAH1 WT and DDAH1
-/-
 mice. (A) ADMA 
concentations in the placenta as measured by mass spectrometry. ***p<0.001, student’s t-test (B) L-Arginine 
concentrations in the placenta as measured by mass spectrometry. **<0.01, student’s t-test (C) Concentration of 
total nitrates and nitrites (NOx) as measured by nitric oxide analyser (D) Concentration of sFlt-1 as measured by 
ELISA, normalised to protein content. Data expressed as mean ± SEM (n=11-12). mRNA expression of (E) 
iNOS (F) eNOS (G) VEGF (H) VEGF-B (I) ET-1 (F) Hsp70, *p<0.01, student’s t-test or Mann Whitney U test 
as appropriate. Data shown as median ± interquartile range showing minimum and maximum (DDAH1 WT, 
n=11; DDAH1
-/-
, n=12). 
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Figure 7.17: Expression of DDAH1 and DDAH2 in placental tissue taken from DDAH1 WT and DDAH1
-/-
 
mice. (A) Representative western blots showing DDAH1 and DDAH2 expression in DDAH1 WT and 
DDAH1
-/-
 mice including GAPDH loading controls. Densitometry analysis was performed with ImageQuant 
software using GAPDH as loading control for DDAH1 (B) and DDAH2 (C). ***p<0.001 student’s t-test 
(DDAH1 WT, n=11; DDAH1
-/-
, n=12). Cal- calibrator, PC- positive control. 
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7.3 Summary and Discussion 
Non-pregnant female DDAH1
-/-
 mice had significantly elevated MAP, SAP and HR compared to 
DDAH1 WT. There was an increase in DAP but this was not significant. There were no significant 
changes in activity level between DDAH1 WT and DDAH1
-/-
. In pregnant mice the haemodynamic 
profile of DDAH1 WT (C57BL/6) did not follow the same pattern as seen in the CD1 mice. There 
was a drop in MAP at mid-gestation but this was not significantly different from non-pregnant 
baseline. Similar patterns were observed in SAP and DAP. HR was increased at the post-implantation 
stage and peaked at E7 before returning to baseline. Surprisingly, DDAH1
-/-
 mice exhibited a very 
similar haemodynamic profile throughout pregnancy and there were no significant differences 
between DDAH1
-/-
 and DDAH1 WT mice for MAP, SAP or DAP. Likewise, although HR was 
consistently higher in DDAH1
-/-
 mice, a very similar pattern to DDAH1 WT was observed throughout 
the course of gestation. One interesting observation was that DDAH1
-/-
 mice had elevated MAP and 
SAP during the first trimester which was not different from their hypertensive baseline measurements. 
This may have implications in placental development and implantation. Additionally, another finding 
of note was that after labour and during the post-partum period, MAP, SAP and DAP all increased in 
DDAH1
-/-
 mice to baseline levels or higher, demonstrating that the hypertensive phenotype of the 
non-pregnant DDAH1
-/-
 mouse was quickly re-established after expulsion of the fetuses and placentas. 
There were no significant differences in activity levels between DDAH1 WT and DDAH1
-/-
 mice 
during pregnancy or the post-partum period.  
Latency to labour and pup survival after LPS administration (10μg) and vehicle control in DDAH1-/- 
mice were not significantly different to WT mice. The number of failed pregnancies and average litter 
sizes were also not different between DDAH1 WT and DDAH1
-/-
 mice. Circulating NO levels were 
significantly increased after LPS in both strains compared to vehicle control. In contrast, ADMA 
levels were significantly increased in DDAH1
-/-
 mice compared to DDAH1 WT in both LPS- and 
vehicle-treated mice and LPS was not seen to affect ADMA levels. There were no significant 
differences in VEGF or PLGF2 levels between DDAH1 WT and DDAH1
-/-
, but 6 hours after LPS 
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administration, ET-1 was significantly increased in DDAH1
-/-
 and not in DDAH1 WT. 
Cytokine/chemokine expression in response to LPS in left ventricular tissue was not altered in 
DDAH1
-/-
 mice, however eNOS mRNA expression was significantly downregulated after LPS 
compared to vehicle, which did not occur in DDAH1 WT mice. BNF was also altered in DDAH1
-/-
 
mice, where in response to LPS BNF elevation was significantly greater.  
In placental tissue, ADMA concentrations were significantly increased and L-arginine levels were 
correspondingly decreased in DDAH1
-/-
 compared to DDAH1 WT. There were no changes in NO 
concentrations or sFlt-1. mRNA expression of iNOS, but not eNOS, was significantly decreased in 
placenta from DDAH1
-/-
 mice and VEGF-B expression was also downregulated. Not surprisingly, 
DDAH1 protein expression was significantly reduced in placentas from DDAH1
-/-
 mice compared to 
DDAH1 WT. The presence of low DDAH1 expression is likely due to the fetal component of the 
placenta, as fetal genotype was DDAH1 heterozygous. There was no change in DDAH2 levels.     
The non-pregnant female DDAH1
-/-
 mice displayed a hypertensive phenotype that was consistent with 
previous work done using male DDAH1
-/-
 mice both in our group and others [437, 440]. When the 
haemodynamic profiles of both DDAH1
-/-
 and DDAH1 WT were examined during pregnancy, there 
was some discrepancy between the data presented here and that previously seen in outbred CD1 mice, 
where DDAH1 WT mice did not display the same characteristic decline in MAP to mid-gestation 
which then recovered before labour (Chapter 3). It is possible that in C57BL/6 mice the 
cardiovascular adaptations that occur during pregnancy are dysregulated, however this would 
contradict several reports in the literature. Several studies have used C57BL/6 mice to look at 
haemodynamics in pregnancy and have been able to replicate the general trend of a mid-gestational 
nadir in MAP [250, 429, 446]. Therefore it is more likely that due to the low n numbers in this study, 
there is an erroneous finding that may have skewed the results.    
The finding that there was no significant difference between DDAH1 WT and DDAH1
-/-
 mice 
throughout pregnancy, and that the basal hypertension seen in DDAH1
-/-
 females before pregnancy 
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did not persist, indicates that the cardiovascular adaptations that occur during pregnancy can override 
the contribution of DDAH/ADMA in the regulation of vascular tone. Whilst in pregnant DDAH1
-/-
 
mice (on E16) ADMA was found to be significantly increased compared to DDAH1 WT, this did not 
impact on the circulating levels of NO. Furthermore, the administration of LPS did not elicit a 
differential effect in DDAH1
-/-
 compared to DDAH1 WT as there was an LPS-induced increase in NO 
in both strains. These results did not mirror the effect of DDAH deficiency in male mice, where Hu et 
al., reported that relative urinary NO content and plasma NO concentration were decreased in 
DDAH1
-/-
 mice [440]. The authors suggested that DDAH1 was therefore responsible for maintaining 
both tissue and systemic NO bioavailability. In the DDAH1 transgenic mouse where DDAH1 is 
globally overexpressed, NO production in explanted heart tissue was found to be increased 
accordingly [447].  In concordance with these results, pharmacological inhibition of DDAH1 using 
the selective inhibitor L-257 was able to significantly attenuate NO production in male mice in 
response to experimental model of polymicrobial sepsis [448].  
It is still unclear as to the underlying mechanism that would override the initial hypertensive 
phenotype of the DDAH1
-/-
 mouse in pregnancy and result in similar levels of NO to DDAH1 WT 
control despite elevated ADMA concentrations. An important investigation to try and elicit the effect 
of DDAH1 deficiency on haemodynamics in pregnancy would be to measure blood pressure 
following LPS administration in pregnant DDAH1
-/-
 mice. It may be that as the endogenous 
vasoconstrictor ET-1 was seen to be increased in DDAH1
-/-
 and not in DDAH1 WT 6 hours after LPS, 
that in pregnancy DDAH1
 
deficiency would confer a protective phenotype against LPS-induced 
hypotension.  
One possible explanation may be that LPS has been seen to elevate ADMA concentrations and reduce 
DDAH activity in human umbilical cord endothelial cells (hUVECs) [449]. Therefore, after LPS 
challenge, DDAH activity could be diminished to levels similar to those seen in DDAH1
-/-
 mice. 
However, in this model, ADMA levels were not elevated further after LPS treatment so this is 
unlikely. Conversely, there have been reports that found arterial plasma concentrations of ADMA to 
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be lower after LPS infusion in rats [450]. Nijveldt et al., suggested that this finding could be due to an 
increased uptake by cells having the cationic amino acid transporter of system y
+
. The expression of 
this transporter is known to be upregulated by LPS in several organs resulting in increased transport 
capacity. However, this transporter has also been shown to be abundantly expressed independent of 
LPS treatment [450]. It is important to consider whilst comparing these systems that changes in 
plasma ADMA levels may not be accurately reflected in cellular models, as changes in cellular 
ADMA concentrations may be not be evident in the plasma pool due to the effects of haemodilution.  
Furthermore in the study presented in this chapter, a relatively mild dose of LPS was used, which was 
evident when examining the expression of cytokines and chemokines present in left ventricular tissue. 
Only CXCL1 and CXCL2 were upregulated in all groups that had been treated with LPS and IL-1β 
was not upregulated at all. Furthermore, iNOS mRNA expression was not elevated in the left ventricle 
after LPS and was actually seen to be downregulated 6 hours post-LPS. In a study that used LPS to 
model acute lung injury (ALI), 28 cytokines were found to be upregulated in BAL fluid, of which 13 
of these were attenuated after DDAH2 overexpression [451]. This could suggest that DDAH 
deficiency could exacerbate the cytokine cascade after LPS and potentiate inflammation. This notion 
would be supported by in vitro evidence that CCL2 and IL-8 secretion was augmented after 
exogenous ADMA treatment in hUVECs and that DDAH2-transfected fibroblast-like synoviocytes 
upon stimulation with TNF-α produced significantly less IL-1β and IL-6 [452, 453]. However this 
may be reflective of only DDAH2 manipulation as we know that DDAH2 is the only isoform found in 
immune cells [97]. 
BNF mRNA expression was found to be upregulated after LPS in both DDAH1 WT and DDAH1
-/-
, 
but interestingly the effect in DDAH1
-/-
 mice was significantly greater. BNF has been seen to be 
significantly elevated both in animal models of LPS-induced endotoxaemia and in humans with 
endotoxic shock [153, 454].  Witthaut et al., were able to conclude from their clinical study in patients 
with sepsis that although ANP and BNF were increased in patients with septic shock, BNF reflected 
left ventricular dysfunction and ANP was related to IL-6 production rather than to cardiovascular 
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dysfunction [153]. Therefore the greater increase in BNF after LPS in DDAH1
-/-
 mice may reflect 
increased sensitivity to LPS-induced ventricular dysfunction.  
An important factor to consider would be that in this study, only circulating NO and ADMA 
concentrations were measured in DDAH1 WT and DDAH1
-/-
 mice after LPS. Nijveldt et al., showed 
the capacity for alternative handling of ADMA in different tissues and it could therefore be 
hypothesised that as NO and ADMA were not measured in the heart that the serum levels cannot be 
taken as indicative of the levels in the left ventricle [450]. This notion would be supported by other 
findings that showed despite a 3-4 fold ADMA increase measured in restenotic lesions and the 
ischemia-reperfused myocardium, this was not associated with increased plasma ADMA and would 
therefore not be expected to contribute to systemic vascular pathology [90, 91, 455]. It may be then 
that elevated circulating ADMA would not be an indication of increased endothelial ADMA.  
Similar to the finding in the circulation, NO was not decreased in the placenta despite increased 
ADMA. Additionally in placenta iNOS was found to be significantly downregulated, this would be 
expected to have an effect on overall NO production. This finding, in part, supports the work of Pope 
et al., where DDAH1 knockdown let to a modest reduction in NO bioavailability but a 48% reduction 
in L-arginine/ADMA ratio, whereas DDAH2 knockdown led to a 57% reduction in NO 
bioavailability and had no effect in L-arginine/ADMA ratio [91]. This led the authors to suggest that 
DDAH1 may exert its effects via an ADMA-dependent pathway and DDAH2 through an ADMA-
independent pathway. Heterozygous expression of DDAH1 in the placentas of DDAH1
-/-
 mice 
resulted in elevated placental ADMA which did not affect NO production, further supported by the 
finding that DDAH2 levels were not changed in the placentas of these mice.  
Therefore, alongside the finding that female DDAH-1
-/-
 mice have significantly higher mean arterial 
BP basally, and that there may be an effect of persistent hypertension throughout the first trimester of 
pregnancy; the reduction in placental iNOS expression, increased placental and serum concentrations 
of ADMA and no change in circulating or placental NO production in this study suggests that 
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DDAH1 functions to regulate ADMA levels which has a subsequent impact on haemodynamic 
regulation, possibly independent of NO.  
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Chapter 8: General Discussion 
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8.1 Summary of Main Findings 
Sepsis is now the leading cause of direct maternal mortality in the UK and work conducted in the 
USA has shown that the rates of severe maternal sepsis and the risk of sepsis-related death has 
doubled since 2003 [227, 228, 235, 236]. The susceptibility to and severity of infections during 
pregnancy has been shown to be increased, where, for example, during the 2009 H1N1 influenza 
pandemic, over a third of all pregnant women diagnosed were hospitalised, and accounted for 5-7% of 
all deaths, hospitalisations and ICU admissions despite accounting for less than 1% of the population 
[110]. However, the mechanisms behind this increased morbidity and mortality during pregnancy are 
not fully understood. 
The work described in this thesis was performed to address the two main hypotheses:  
 The haemodynamic response to infection and inflammation is altered in pregnancy. 
 Agents targeting the chemokine and NO signaling pathways given in pregnancy could alter 
the maternal response to infection and inflammation. 
To explore these hypotheses, first, a telemetric method of measuring haemodynamic parameters 
during murine pregnancy in conscious mice was established. Telemetry recordings throughout 
gestation showed that MAP, DAP and SAP significantly decreased to a mid-gestational nadir at E8-
E9 before returning to baseline by E16 accompanied by no change in HR. This fall in MAP is likely a 
consequence of peripheral vasodilation driven by early maternal hormonal changes. Over the course 
of gestation it was observed that activity decreased, although the time spent inactive decreased just 
before labour which continued post-partum. This was likely due to overwhelming nesting and 
weaning behaviours. These data were comparable with previously published data examining 
haemodynamic parameters during pregnancy in other mouse strains such as B6 and Balb/c [2].  
The telemetric method established then allowed for the investigation of the cardiovascular response to 
inflammation in pregnancy. A non-invasive route to induce non-fatal endotoxaemia during pregnancy 
was established. A dose of 10μg LPS resulted in no maternal mortality and reproducible PTL with 
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delivery at a mean of approximately 20 hours post-injection. Pup survival was approximately 10% in 
these animals. Endotoxaemia in pregnancy led to significantly reduced MAP in pregnant compared to 
non-pregnant CD1 mice. Contrary to our hypothesis however, this was accompanied by a very similar 
systemic cytokine reaction suggesting that the response of the maternal innate immune system is 
neither impaired nor excessive. Although several cytokines and chemokines were elevated after LPS 
administration, there were no significant differences observed between pregnant and non-pregnant 
responses. These data suggest that during pregnancy the cardiovascular system is more sensitive to 
inflammation and potentially for this reason is less able to maintain blood pressure in the face of an 
inflammatory stimulus. Therefore the hypotensive response and any bearing this may have on 
maternal susceptibility to infection are not due to greater increases in cytokine and chemokines in 
pregnant animals. Levels of both NO and VEGF were significantly increased in non-pregnant mice 
after LPS, but this response was attenuated in pregnant mice. These results suggest that LPS-induced 
vasodilation (and consequently hypotension) should be more pronounced in non-pregnant mice, 
which is opposite to what was actually observed. Potentially, a pregnancy-induced increased 
sensitivity to the vasodilator action of VEGF and NO could account for these results but the vessels 
taken from pregnant animals did not respond differently to the NO donor, SNP. The most marked 
difference between the two groups was in the infiltration of the lungs, where pregnant animals had 
decreased neutrophils and increased monocytes. If greater monocytic infiltration were to lead to 
impaired arteriolar function as a result of an increase in inflammation and release of locally active 
vasoactive factors, this might contribute to the marked hypotension observed in pregnant animals. 
The role of progesterone in LPS-induced haemodynamic alterations in pregnancy was investigated 
using progesterone supplementation. 10mg P4 was given daily between E14 and 16 and 10μg of LPS 
was administered i.p. on E16. P4 administration led to a reproducible extended latency to labour but 
there were no differences in pup survival compared to vehicle control (0% survival). After P4 
supplementation, the LPS-induced hypotensive response observed in control animals was ameliorated. 
As circulating pro-inflammatory cytokines and chemokines as well as VEGF, NO and ADMA 
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concentrations were not altered by P4 supplementation, the underlying mechanism behind this result 
is unclear. The action of P4 in this circumstance is likely to be through an NO-independent pathway, 
potentially via membrane PRs or prostacyclin. Together, these data suggest that increased 
progesterone concentrations in pregnant mice do not drive the hypotensive response to LPS observed 
in pregnant animals. This finding was surprising as the initial hypothesis was that P4 would cause a 
further drop in MAP, implicating progesterone responsible for the different response observed in 
pregnancy. 
To try and understand the involvement of chemokines, specifically signalling via CCL2/CCR2, in the 
inflammation-induced haemodynamic and immune responses in pregnancy, a CCR2-deficient mouse 
model and a CCR2 antagonist were used. Female non-pregnant CCR2
-/-
 mice did not display 
significant alterations in blood pressure. Latency to labour and pup survival after LPS administration 
in CCR2
-/-
 mice was not significantly different to CD1 mice. After LPS administration in CCR2
-/-
 
mice, there was no hypotension observed, in fact MAP increased to a peak at 5 hours post-LPS (which 
corresponded with elevated ET-1 at 6 hours) and then returned to baseline. At intermediate time 
points between LPS administration and labour, circulating concentrations of TNF-α were significantly 
reduced and IL-4 and IL-10 were significantly increased in CCR2
-/-
 mice compared to CD1. 
Circulating NO and ADMA concentrations were significantly reduced in CCR2
-/-
 mice both basally 
and after LPS challenge which is likely to be due to a lack of CCL2-induced monocyte (and 
neutrophil) recruitment to off-target sites, thus reducing excessive macrophage infiltration and NO 
release. This conclusion may also explain the reduced concentration of TNF-α in serum. Taken 
together, these data suggest a blockade of CCR2 results in the attenuation of an exacerbated innate 
immune response. Whilst this seems to contradict the conclusions drawn from previous observations 
in WT mice, where it was suggested that LPS administered in pregnancy does not elicit an excessive 
cytokine response over and above that in non-pregnant mice, it may be that manipulation of 
CCL2/CCR2 signalling is able to alter the Th1/Th2 balance. It may be however, that the results 
observed here at 12 hours post-LPS injection are unlikely to reflect the more long-term changes that 
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reflect a modulated adaptive immune response. The CCR2 antagonist RS504393 was able to 
reproduce the majority of the effects observed in the CCR2 knockout mouse. Whilst it was promising 
to be able to recreate the effects of CCR2 knockout with the CCR2 antagonist on LPS-induced 
haemodynamic changes, to be able to draw further conclusions from these data increased numbers of 
animals would be necessary. 
Finally, to try and understand the contribution of NO signalling to the altered haemodynamic 
responses in pregnancy, the upstream endogenous ADMA inhibitor DDAH was targeted. In pregnant 
mice the haemodynamic profile of DDAH1 WT (C57BL/6) did not follow the same pattern as seen in 
the CD1 mice. There was a decrease in MAP at the mid-gestational point but this was not 
significantly different from non-pregnant baseline. HR was increased at the post-implantation stage 
and peaked at E7 before returning to baseline. Surprisingly, DDAH1
-/-
 mice exhibited a very similar 
haemodynamic profile throughout pregnancy and there were no significant differences in the overall 
gestational MAP profile between DDAH1
-/-
 and DDAH1 WT mice. One interesting observation was 
that DDAH1
-/-
 mice exhibit a persistent hypertension during the first trimester that was not different 
from their hypertensive baseline measurements, which may have implications in placental 
development and implantation. This may be due to increased ET-1 which was only observed in 
DDAH1
-/-
 and not in WT littermates. Or potentially, the lack of DDAH could lead to raised local 
ADMA preventing local NO production and thus the expected fall in MAP. Additionally, another 
finding of note was that after labour and during the post-partum period, MAP increased in DDAH1
-/-
 
mice to baseline levels or higher, demonstrating that the hypertensive phenotype of the non-pregnant 
DDAH1
-/-
 mouse was quickly re-established after expulsion of the fetuses and placentas. Upon 
investigation, the placentae from these animals (genetically heterozygous for DDAH1) had reduced 
iNOS expression, increased ADMA concentrations and no change in NO levels when compared to 
WT littermates. These data suggest that the effect of DDAH1 on ADMA has a subsequent impact on 
haemodynamic regulation, but this may be independent of NO.  
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In summary, it has been shown here for the first time that a telemetric murine model of infection in 
pregnancy can be utilised in studying the effects of inflammation on maternal haemodynamics and the 
effects this may have on several outcomes in pregnancy. This model has been used to demonstrate 
that low levels of inflammation in pregnancy can lead to hypotension. Additionally, the increased 
levels of progesterone characteristic of pregnancy were shown not to be responsible for this 
hypotension. Manipulation of CCL2 signalling was able to reverse inflammation-induced hypotension 
in pregnancy, both by genetic knockout and pharmacological inhibition. DDAH1 knockout, whilst 
conferring initial hypertension, did not significantly impact the gestational haemodynamic profile.   
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8.2 Limitations of Study 
Here we show that by using telemetric technique in combination with endotoxin to model maternal 
sepsis, it is possible to study the potential mechanisms behind the effects of inflammation during 
pregnancy. Clearly, it would be extremely difficult to conduct such investigations in human 
pregnancy with regards to ethical concerns and to the lack of tools to explore the underlying 
mechanisms (e.g. genetically modified mouse models). Despite this, there are several limitations, both 
experimental and technical, that should be considered when interpreting these results. 
8.2.1 Experimental Limitations 
There are several experimental limitations that should be taken into account when interpreting the 
results described in this thesis.  The first of these is the consideration of the choice of experimental 
time points. In this thesis the time points of 6 and 12 hours were chosen to evaluate the cytokine 
profile after LPS or vehicle in non-pregnant and pregnant mice. The 12 hour time point was chosen to 
allow for the further investigation of the haemodynamic data where the nadir in blood pressure 
elicited by LPS in pregnant mice was at 12 hours post LPS injection. The time point of 6 hours was 
chosen as an intermediate. Several laboratories have noted that the induction of the main pro-
inflammatory cytokines reach peak levels at approximately 1-2.5 hours post-LPS (IL-1β, IL-6 and 
TNF-α), regardless of the route of administration [456, 457]. Although, the temporal profile of IL-1β 
release is less well-defined, as others have found peak concentrations of plasma IL-1β to be much 
later, at around 6 hours, similar to the temporal profile of IFN-γ [458]. Consequently, the employment 
of a 6 hour time point may have led to the peak concentrations of some circulating cytokines being 
missed; however the emphasis in this study was not on the determination of the cytokine profile 
evoked by LPS, but to allow for the comparison of haemodynamic responses between non-pregnant 
and pregnant mice. Equally, the majority of serum cytokines examined were significantly elevated 
after LPS at the 6 hour time point when compared to vehicle control.  
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Secondly, only a subset of the cytokines that might be affected by pregnancy-induced immune system 
adaptations was studied. For example, despite the understanding that G-CSF is increased during 
pregnancy, and both G-CSF and GM-CSF have been shown to be elevated after LPS administration, 
neither were examined in the chapters of this thesis [80, 459]. In fact, whilst ‘fingerprinting’ the 
murine TLR4-induced inflammatory response, Bosmann et al., showed that amongst others IL-1α, IL-
2, IL-3, IL-5, IL-9, IL-12(p40), IL-13, CCL11, G-CSF and GM-CSF were observed to have elevated 
plasma concentrations between 3 and 24 hours post-LPS administration [459], none of which were 
examined here. This was due to several technical and financial restrictions including, but not limited 
to, the unavailability of some of these cytokines on the multiplex cytokine panel.  
8.2.2 Technical Limitations 
When using a mouse model to investigate the changes that are conferred during pregnancy, it is 
important to consider the differences between mouse and human pregnancies. Aside from the 
dissimilarities in gestational length, and the number of fetuses carried in mouse pregnancy, there are 
also some important anatomical and endocrine differences. One critical difference is the withdrawal 
of progesterone to initiate labour. In most mammalian species, including the mouse, the levels of 
progesterone fall and oestrogen rises at the end of pregnancy to induce parturition. In humans, 
parturition occurs without this fall in progesterone and thus the initiation of labour is said to occur 
after a ‘functional’ withdrawal of progesterone, likely through diminished target tissue responsiveness 
facilitated by altered progesterone receptor expression [460].    
Anatomically, both the uterus and placenta are very different when comparing the mouse and human. 
The rodent uterus has a bicornuate shape with two distinct uterine horns and a discrete 
longitudinal/circular muscle arrangement. Also, the differences in placentation, endocrine function 
and morphogenesis of the placenta can be considered to be of critical importance. During the first 
trimester of human pregnancy, extravillous trophoblast cells breach maternal spiral arteries and 
replace the residual endothelial cells leading to the remodelling of the spiral arteries and arterial 
vasodilation. In mice, trophoblast invasion into the maternal vasculature is negligible and the 
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exchange of nutrients occurs in the placental labyrinth region. The vascular remodelling that occurs 
does so independently of trophoblast cells invasion [461]. Consequently the immunological 
adaptations that occur particularly at the fetomaternal interface are potentially very different between 
mice and humans, therefore affecting the maternal immune response to infection. With respect to 
endocrine function, the principal difference between mice and humans is the mechanism controlling 
transition of the cyclic corpus luteum into a gestational corpus luteum, allowing the maintenance of 
progesterone secretion [274]. In mice, the corpus luteum has to produce progesterone throughout 
gestation. The consequent production of progesterone, and to some extent oestrogen, is much greater 
in humans than in other mammals.  
Many researchers have suggested the guinea pig as a potentially much better model than other species 
(rodents, pigs and sheep) due to the relative similarity of placental structure and function to humans as 
well as a similar ‘functional’ withdrawal of progesterone before labour. Guinea pig placenta shares 
both the haemochorial placental type and the process of trophoblast invasion [462]. However, there 
are still obvious differences including the labyrinthine (rather than villous) placentation and further 
complicated lobular structure. Furthermore, there is not currently the capability to use genetic 
manipulation in the guinea pig to probe the pathways and mechanisms that lie behind the responses to 
inflammation and infection in pregnancy.    
Along with considerations for the use of animal models in pregnancy research, there must be 
consideration of the technical limitations of the animal models used to study inflammation and sepsis. 
For example, the inhibition of inflammatory markers that has proven to be beneficial in endotoxin 
models, has not translated into an effective therapy in clinical trials [463]. Both TNF-α and IL-1 have 
been shown to be fundamental mediators of inflammation after LPS administration and have therefore 
attracted attention as potential targets in sepsis research. Promising results from TNF-α blockade in 
LPS animal studies led to several clinical trials for TNF-α antibodies or soluble receptors (TNF-SR 
p55, or p75), all of which showed either no improvement or actually led to increased mortality [464]. 
The limitations of TNF-α blockade likely includes the difficulty of the identification of the subset of 
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sepsis patients that would benefit. Similarly, blockade of IL-1 by IL-1 receptor antagonist (IL-1RA) 
was also shown to be ineffective in large clinical trials [465]; where only those patients identified as 
being most at risk of sepsis-induced mortality were seen to benefit from IL-1RA administration [466]. 
In fact, between 1981 and 2014 there has been at least 15 studies that have shown selected sepsis 
drugs that improved survival in animal models (including LPS and bacterial inoculation) but that had 
no beneficial effect in humans (or this effect was too small to achieve statistical significance) [467].  
Given the lack of efficacy of these human clinical trials based on targets identified in the endotoxin 
studies, the endotoxin sepsis model has been called into question [213]. Several review articles have 
discussed and highlighted a number of putative differences between animal models of sepsis and what 
is presented in the clinic. Firstly, the systemic administration of LPS to model inflammation and 
sepsis relies on the assumption that the onset of sepsis is caused by the host-response and not the 
intact pathogen [214]. Undoubtedly, LPS administered via several different routes can bring about 
sepsis-like pathophysiological responses in these models, inducing increases in many circulating 
cytokines; however the contemporaneous nature of cytokine release has been shown to be very 
different between LPS models (in both animals and humans) and human sepsis, where in LPS models 
TNF-α, IL-6 and CXC chemokines were shown to peak much earlier and in far greater quantities 
[468, 469]. Secondly, the discrepancy of several orders of magnitude in the sensitivity of mice and 
humans to LPS in vivo has recently been shown to not be present when researchers looked at the 
response of macrophages from the two species in vitro [470]. This is unlike the responses to LPS of 
other cells taken from both species and grown in culture under identical conditions. Warren at el., 
showed that proteins present in mouse serum were able to markedly supress the induction of pro-
inflammatory cytokines compared to in human serum. To the author’s knowledge the specific proteins 
present in mouse, but not human, serum that exerted this immunosuppressant effect have not been 
identified. Thirdly, there should be consideration of the vast differences in the administration of 
endotoxin between studies: dose, bolus vs infusion, serotype and route of administration are extremely 
variable. Not only does that make it more difficult to compare results between studies, but leads to the 
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production of quite different models. For example, models that use sub-lethal doses of LPS have been 
shown to produce a hyperdynamic cardiovascular response compared to the hypodynamic response 
that accompanies larger typically lethal doses [215].   
Mouse models to study inflammation and the immune system are improving though, and since the 
earlier 2000s, immunodeficient mice appropriate for generating “humanized mice” have been 
successfully developed.  These mice were established by introducing the mutant IL2ra gene into 
severe combined immunodeficiency (SCID) or RAG1/2
-/-
 mice to produce NOD/SCID/γc-/- and 
Rag1/2
-/-γc-/- mice respectively. These mice exhibit manifold immunodeficiencies including defects on 
T, B and NK cells as well as reduced macrophages and dendritic cell function. This means that due to 
the high human engraftment rates it is possible to generate mice that retain human immune cells to 
facilitate the analysis of the mechanisms behind the human immune responses in sepsis [471, 472]. 
There has been several studies examining the mechanisms behind sepsis (using LPS and CLP models) 
and viruses in ‘humanized mice’, but the use of these mice have not yet been explored in maternal 
infection research [473, 474].  
Fink et al., commented that even though most animal models of human sepsis are flawed and the 
results from preclinical studies cannot be directly extrapolated to the problem of human sepsis, 
experiments using these models remain central to the development of new agents for the 
pharmacological treatment severe sepsis [475]. It is important to recognise the limitations of each 
model for them to be able to provide relevant information for application to humans. 
One important technical limitation that affected the design of this study was the concern of pairing 
two surgical techniques: that of insertion of the telemetry probe, and CLP. This was dictated by the 
limitations of the PPL that this work was conducted under that did not permit multiple invasive 
surgeries on the same animal (such as the implantation of the telemetry device coupled with CLP). As 
discussed previously, the CLP model is considered to more closely resemble the polymicrobial 
characteristics of human sepsis than a bolus injection of endotoxin, producing a more representative 
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host response and appropriately timed cytokine release. Going forward, the combination of these 
techniques would provide further insight into the mechanisms behind maternal sepsis and the 
differences between the immune response in the non-pregnant state and during pregnancy.  
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8.3 Further Research 
The results described in this thesis contribute towards our understanding of the maternal 
cardiovascular and immune response to inflammation. However, further work would complement and 
build upon the work presented here. For example, as there was no evidence to suggest excessive 
activation of the innate immune system by way of a resulting cytokine/chemokine storm in pregnant 
animals, the differences in cardiovascular response are likely to be perpetuated by different 
mechanisms. The greatest difference between pregnant and non-pregnant animals was observed in the 
immune cell infiltration of the lungs, where pregnant animals had fewer neutrophils and more 
monocytes. As previously stated, if greater monocytic infiltration can lead to impaired arteriolar 
function as a result of an increase in inflammation and release of locally active vasoactive factors, this 
could contribute to the marked hypotension observed. To investigate this further, it would be 
beneficial to explore the composition of these infiltrating cells into the lung and other tissues in 
greater detail by differentiating between the monocytic populations (that is, resident and infiltrating, 
or ‘patrolling’ monocytes) in the aim of assessing the dynamics of leukocyte trafficking following 
LPS challenge [476]. Other studies have suggested it is the failure of neutrophil migration that has the 
most deleterious effect on survival outcomes [477]. Therefore, further study of neutrophil trafficking 
is warranted as if there is impaired neutrophil migration in pregnant animals, this dysregulation would 
indicate impaired clearance of the infectious insult, reduced production of reactive oxygen species and 
decrease recruitment to infected sites.  
Further to this, because of the difference observed in vasoactive factors such as VEGF in the maternal 
response to inflammation, it would be interesting to explore the effects of VEGF on vessel function 
using wire myography. In this thesis, VEGF was significantly elevated in response to LPS in non-
pregnant but not pregnant animals. This was surprising as VEGF has been previously found to be 
increased in maternal serum and thought to contribute to vasodilation of the uterine and uteroplacental 
vasculature [478, 479]. A comparison of the vessel responses to VEGF taken from pregnant and non-
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pregnant animals pre-treated with LPS or vehicle may lead to a greater understanding of the role of 
the VEGF in the cardiovascular response to inflammation in pregnancy.  
In CCR2
-/-
  mice we supposed that a lack of CCL2/CCR2 signalling was able to infer decreased 
monocyte and neutrophil recruitment to off-target sites and thus prevent excessive macrophage 
infiltration and subsequent release of NO and other pro-inflammatory cytokines. This explanation 
could account for the decrease in circulating TNF-α and NO concentrations also seen in pregnant 
CCR2
-/-
 mice after LPS challenge. In turn, the reduction in NO could account for the failure of LPS to 
elicit hypotension in these animals. These data are of particular note as the manipulation of this 
pathway seems a promising avenue for the potential attenuation of inflammation-induced hypotension 
and warrants further investigation. The pharmacological blockade of CCR2 also led to promising 
results where LPS-induced hypotension was reversed, however although inhibition was achieved it 
may have only been partial antagonism. Experiments designed to define a more appropriate dose and 
dosing regimen may lead to maximum drug efficacy. Equally, with more time greater numbers of 
animals in each experimental group would strengthen the conclusions drawn from these data as it 
would minimise error and increase statistical power. Further to this, it would be interesting to compare 
these results with the effects of a BSCI, which has previously been shown to be an effective tocolytic 
agent in models of LPS-induced PTL [411].  
Work presented in this thesis showed that DDAH1
-/-
 mice exhibited a very similar haemodynamic 
profile throughout pregnancy to DDAH1 WT mice. This was a surprising result and it remains unclear 
as to the underlying mechanism that would override the initial hypertensive phenotype of the 
DDAH1
-/-
 mouse in pregnancy and result in similar levels of NO to DDAH1 WT control despite 
elevated ADMA concentrations. Due to time constraints it was not possible to administer LPS to 
pregnant DDAH1
-/-
 mice as intended to try and establish the role of this pathway during infectious 
insult and inflammation. Advancing the work presented in this thesis would unquestionably involve 
the exploration of the cardiovascular response of DDAH1
-/-
 mice to LPS. The measurement of blood 
pressure in pregnant DDAH1
-/-
 mice would enable the further investigation of the ET-1 response and 
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determine whether DDAH1 deficiency confers a protective phenotype against LPS-induced 
hypotension. 
Similar to the premise behind introducing a pharmacological antagonist to target the CCL2/CCR2 
signalling pathway, namely to determine if the same results can be observed when compensatory 
pathways are removed, it would be beneficial to test a DDAH inhibitor to confirm the effects of 
DDAH blockade. To date, the only compounds that show selectivity for DDAH over NOS are the 
guanidine substituted arginines NG-(2-methoxyethyl)-L-arginine (L-257) and NG-(2-methoxyethyl)-
L-arginine methylester (L-291) [480]. Inhibition of NO by L-257, which binds to the active site of 
DDAH1, would result in increased levels of ADMA which as an endogenous NO inhibitor, may have 
the potential to improve the inflammation-induced hypotension observed after LPS challenge in 
pregnant animals. Previous research has shown that haemodynamic performance, including the degree 
of tachycardia and microvascular perfusion, in rat model of septic shock (induced by LPS or faecal 
slurry) could be preserved by treating with L-257. Importantly, L-257 was shown to prolong survival 
in these models [448].  
8.3.1 Future Directions 
To address some of the limitations of using LPS to induce inflammation, the combination of telemetry 
and CLP could provide further insight into the mechanisms behind maternal sepsis and the differences 
between the immune response in the non-pregnant state and during pregnancy. After a surgical 
procedure for conducting CLP in pregnancy is established and survival studies completed, this model 
could be used in conjunction with telemetry to monitor maternal cardiovascular responses to 
polymicrobial sepsis. In a similar fashion to the experiments described in this thesis, the 
haemodynamic data gathered could be understood in greater detail by taking tissues and maternal 
blood at several time points between the induction of sepsis by CLP and defined humane endpoints. 
These tissues could then be used to explore any differences in leukocyte densities, dysregulated 
leukocyte trafficking, the induction of cytokine/chemokines and the role of NO. The use of a 
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polymicrobial model would allow for the consideration of the effects of combination therapies (such 
as a combination of CCR2 antagonist or DDAH antagonist with broad spectrum antibiotics). The 
advantage of this approach would be to use a more representative model of sepsis, allowing for 
potentially more relevant conclusions to be drawn.  
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8.4 Conclusions 
These data demonstrate that pregnant mice exhibit a marked hypotensive response to LPS and that 
this is associated with evidence of cardiac compromise, but normal vascular function. The 
administration of progesterone did not lead to a worsened hypotensive outcome, thus suggesting it is 
not progesterone that is responsible for the increased response to LPS in pregnancy. Conversely, 
although is it unlikely that pregnancy-induced immune adaptations in CCL2/CCR2 signalling are 
solely responsible for the altered response to inflammation during pregnancy, blockade of this 
pathway resulted in a reversal of LPS-induced hypotension in pregnancy. The marked fall in blood 
pressure in response to LPS may help to explain the greater ‘susceptibility’ of pregnant women to 
sepsis. Further research is necessary to understand the mechanisms responsible to allow for the 
development of a specifically targeted therapeutic response and an improvement in the management 
of severe infection in pregnant women. 
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Statistical Analysis Using Mixed Effects Modelling 
This work was done by Dr Fabiana Gordon at Imperial College Statistical Advice Service. 
The methodology used to compare pregnant and non-pregnant haemodynamic responses to LPS was 
Mixed Models for longitudinal data. To capture change over time a quadratic trend was fitted, which 
meant that missing data points were accounted for. These fitted trends were then compared back to the 
original data to ensure a good fit.  
In some of the outcome measures it was necessary to adjust for before-after treatment (baseline 
values) to get a better fit. In all outcome measures it was found there was an interaction effect 
between time (hours) and treatment group. This meant that the trajectory of the outcome measure 
varies across groups. It also meant that the comparisons between groups were dependent on time. 
Therefore overall comparisons were done in conjunction with individual time-point analysis.  
Activity was assessed using the outcome of logarithm of activity, to correct for skewness and 
heterogeneity of variances across groups. Furthermore, the ‘TSI’ parameter (time spent inactive) 
outcome measure had to be adjusted for whether there was activity or not (activity binary) to account 
for the 100 % values. In other words, there was a discontinuity in the data which may mean that p-
values are less robust. 
Lastly, as comparisons of interest were made on multiple outcomes which were measured from the 
same animal simultaneously, an adjustment for p-value significance should be considered. The level 
of significance becomes 0.0125 after adjusting for multiple comparisons.  
SPSS 22 and Stata 13 were used to obtain the estimated effects. 
The overall trends for each parameter measured are shown in the figures below (Figure A1.1 to A1.7).   
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Figure A1.1: Mean arterial pressure (MAP) values from mice in each treatment group were plotted as mmHg 
over time (24 hours post-i.p. injection). 0 hours represents the baseline (pre-i.p.) time-point. A quadratic trend 
was fitted and used to calculate statistical significance using mixed effects modelling. n=4-5. E16LPS- pregnant 
LPS-treated, E16PBS- pregnant PBS-treated, NPLPS- non-pregnant LPS-treated, NPPBS- non-pregnant PBS-
treated.  
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Figure A1.2: Systolic arterial pressure (SAP) values from mice in each treatment group were plotted as mmHg 
over time (24 hours post-i.p. injection). 0 hours represents the baseline (pre-i.p.) time-point. A quadratic trend 
was fitted and used to calculate statistical significance using mixed effects modelling. n=4-5. E16LPS- pregnant 
LPS-treated, E16PBS- pregnant PBS-treated, NPLPS- non-pregnant LPS-treated, NPPBS- non-pregnant PBS-
treated. 
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Figure A1.3: Diastolic arterial pressure (DAP) values from mice in each treatment group were plotted as mmHg 
over time (24 hours post-i.p. injection). 0 hours represents the baseline (pre-i.p.) time-point. A quadratic trend 
was fitted and used to calculate statistical significance using mixed effects modelling. n=4-5. E16LPS- pregnant 
LPS-treated, E16PBS- pregnant PBS-treated, NPLPS- non-pregnant LPS-treated, NPPBS- non-pregnant PBS-
treated. 
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Figure A1.4: Heart rate (HR) values from mice in each treatment group were plotted as beats per minute (bpm) 
over time (24 hours post-i.p. injection). 0 hours represents the baseline (pre-i.p.) time-point. A quadratic trend 
was fitted and used to calculate statistical significance using mixed effects modelling. n=4-5. E16LPS- pregnant 
LPS-treated, E16PBS- pregnant PBS-treated, NPLPS- non-pregnant LPS-treated, NPPBS- non-pregnant PBS-
treated. 
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Figure A1.5: Time spent inactive (TSI) values from mice in each treatment group were plotted as percentage 
(%) over time (24 hours post-i.p. injection). 0 hours represents the baseline (pre-i.p.) time-point. A quadratic 
trend was fitted and used to calculate statistical significance using mixed effects modelling. n=4-5. E16LPS- 
pregnant LPS-treated, E16PBS- pregnant PBS-treated, NPLPS- non-pregnant LPS-treated, NPPBS- non-
pregnant PBS-treated. 
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Figure A1.6: Activity (arbitrary units) values from mice in each treatment group were plotted over time (24 
hours post-i.p. injection). 0 hours represents the baseline (pre-i.p.) time-point. A quadratic trend was fitted and 
used to calculate statistical significance using mixed effects modelling. n=4-5. E16LPS- pregnant LPS-treated, 
E16PBS- pregnant PBS-treated, NPLPS- non-pregnant LPS-treated, NPPBS- non-pregnant PBS-treated. 
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Figure A1.7: Activity >0, or positive activity (arbitrary units) values from mice in each treatment group were 
plotted over time (24 hours post-i.p. injection). 0 hours represents the baseline (pre-i.p.) time-point. A quadratic 
trend was fitted and used to calculate statistical significance using mixed effects modelling. n=4-5. E16LPS- 
pregnant LPS-treated, E16PBS- pregnant PBS-treated, NPLPS- non-pregnant LPS-treated, NPPBS- non-
pregnant PBS-treated. 
 
 
